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The	 N-methyl-D-aspartate	 (NMDA)	 receptors	 (NMDAR)	 are	 a	 subtype	 of	 ionotropic	
glutamate	receptors	that	are	highly	expressed	in	the	central	nervous	system	(CNS)	and	
are	 involved	 in	 the	 excitatory	 synaptic	 transmission	 and	 synaptic	 plasticity	 that	
underpin	 many	 critical	 CNS	 functions.	 NMDAR	 dysfunction	 has	 been	 implicated	 in	
Alzheimer’s	disease,	neuropathic	pain,	 schizophrenia,	 and	depression,	 among	others.	
Most	non-selective	NMDAR	antagonists	 (e.g.	ketamine)	have	undesirable	side-effects	
that	 restrict	 their	 clinical	 utility	 for	 relieving	 symptoms	 of	 neuropathic	 pain	 and	
treatment-resistant	depression,	but	indirect	modulators	of	NMDAR	function	offer	the	
potential	 to	 have	 reduced	 side-effects	 relative	 to	 non-selective	 antagonists.	 One	
approach	 is	 to	 inhibit	 the	 production	 of	 the	 NMDAR	 co-agonist,	 D-serine,	 which	 is	





degree	 of	 purity	 (>	90%).	 The	 crystal	 structure	 of	 SR	 was	 solved	 in-house	 using	 the	




light.	 Assay	 parameters	 such	 as	 Km	 and	 IC50	were	 determined,	 and	 following	 further	
optimisation	 to	 enable	medium-throughput	 screening,	 a	 single-point	 screen	 of	 3000	
fragments	 was	 performed	 to	 identify	 novel	 inhibitory	 hit	 matter.	 A	 final	 list	 of	 61	
specific	hits	was	collated	of	 fragments	 that	did	not	exhibit	nonspecific	 inhibition	 in	a	
DAO	counter	screen,	and	demonstrated	IC50	values	against	SR	approximately	1	mM	or	
below.	These	specific	hits	were	characterised	with	biophysical	methods	adapted	for	SR	








































































































































































































































































































































































































































































































































































































presence	 of	 neurons,	 which	 are	 distinguished	 from	 other	 cells	 by	 their	 ability	 to	
communicate	 with	 neighbouring	 cells	 via	 synapses	—	specialized	 contacts	 between	
neuronal	 membranes.	 The	 arrival	 of	 an	 action	 potential	 to	 the	 presynaptic	 neuron	
triggers	an	 influx	of	Ca
2+
	 ions	and	consequent	 fusion	of	vesicles	with	 the	membrane,	
causing	 the	neurotransmitter	within	 the	vesicle	 to	be	 released	 into	 the	synapse.	The	
neurotransmitter	binds	to	and	activates	receptors	on	the	postsynaptic	neuron	to	cause	
an	excitatory	or	inhibitory	response,	which	can	be	either	a	rapid,	transient	action	or	a	
slower,	modulatory	 response	 (Purves	 et	 al.,	 2001).	Glutamate,	 an	 amino	 acid,	 is	 the	





The	 role	 of	 glutamate	 as	 an	 excitatory	 neurotransmitter	 is	 well	 established,	 with	
studies	 first	 identifying	 this	particular	action	 in	 the	1950s	 (Hayashi,	1952).	Nowadays	
glutamate	is	generally	accepted	to	be	the	principle	excitatory	neurotransmitter	in	the	
vertebrate	 nervous	 system,	 with	 the	 ability	 to	 act	 postsynaptically,	 and	 to	 a	 lesser	
extent	 presynaptically,	 on	 two	 types	 of	 glutamate	 receptors:	 metabotropic	 and	
ionotropic	 (Vyklicky	 et	 al.,	 2014).	 The	 ionotropic	 glutamate	 receptors	 can	be	 further	
categorized	into	three	families	named	according	to	their	preferred	agonists;	N-methyl-
D-aspartate	 (NMDA),	 α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic	 acid	 (AMPA)	
and	 2-carboxy-3-carboxymethyl-4-isopropenylpyrrolidine	 (kainate).	 In	 addition	 to	 its	
excitatory	 function,	 glutamate	 can	 also	 be	 used	 by	 the	 brain	 to	 synthesise	 γ-



















Glutamate	 receptors	 are	 primarily	 found	 on	 the	 dendrites	 of	 postsynaptic	 neurons,	
where	 they	 bind	 glutamate	 released	 into	 the	 synaptic	 cleft	 from	 the	 presynaptic	






	 channels	 (Meldrum,	 2000).	 In	 general,	 neurotransmitter	
release	 is	 stimulated	 by	 Ca
2+
	 influx	 through	 P/Q-	 (Cav2.1)	 or	 N-type	 Ca
2+
	 channels	
(Cav2.2)	 and	 to	 a	much	 lesser	 extent	 by	 R-	 (Cav2.3)	 and	 distantly	 related	 I-type	 Ca
2+
	
channels	 (Cav1	 family;	 Sudhof,	 2004).	 Glutamate	 release	 can	 occur	 in	 two	 phases	
following	Ca
2+
	 influx:	 the	 initial	 rapid,	synchronous	component	within	50	µs	of	a	Ca
2+
	
current	 (Sabatini	 and	 Regehr,	 1996),	 and	 the	 slower,	 asynchronous	 component	
continuing	 for	 over	 1	s	 after	 the	 action	 potential	 owing	 to	 increased	 spontaneous	





synapse,	 glutamate	 may	 diffuse	 away	 from	 the	 synaptic	 cleft	 and	 interact	 with	
			 3	
metabotropic	 glutamate	 receptors	 along	 the	 spine	 and	 nerve	 terminal	 membranes,	
and	 this	 synaptic	 “overspill”	 may	 also	 reach	 glial	 glutamate	 transporters	 (Danbolt,	
2001).	 	 The	 glutamate	 receptors	 and	 transporters	 may	 differ	 in	 their	 affinities	 for	
glutamate,	 their	 opening	 and	 inactivation	 times	 (receptors)	 and	 their	 transport	








in	 order	 to	 prevent	 prolonged	 excitation,	 glutamate	 transporters	 remove	 glutamate	
from	 the	 synaptic	 cleft	 into	 the	 neuroglia	 and	 neurons.	 This	 reuptake	 ensures	
glutamate	 levels	 are	 kept	 low	 in	 the	 synapse	 after	 an	 action	 potential,	 and	 so	
terminates	 synaptic	 transmission.	 Without	 this	 process,	 glutamate	 levels	 would	





maintain	a	high	signal-to-noise	 (background)	 ratio	 in	both	synaptic	and	extrasynaptic	
transmission,	and	to	conserve	the	glutamate	released	for	reuse.		
	
The	 mammalian	 genome	 contains	 five	 genes	 (SLCA1A1–3,	 6	 and	 7)	 encoding	 the	















SLC17A8)	 encode	 the	 vesicular	 glutamate	 transporters	 (VGLUTs	 1–3),	 which	 pack	




The	 expression	 of	 EAAT1–5	 show	 distinct	 neuroanatomical	 distributions,	 as	
demonstrated	using	either	in	situ	hybridization	or	immunohistochemistry	and	western	
blot	 analyses.	 In	 general,	 EAAT1–3	 are	 mostly	 abundant	 in	 the	 CNS	 but	 have	 been	
detected	 in	 some	 peripheral	 tissues	 such	 as	 the	 heart,	 liver,	 kidney,	 and	 intestines	
(Gegelashvili	 and	 Schousboe,	 1998).	 EAAT1	 and	 EAAT2	 are	 found	 in	 glial	 cell	
membranes,	although	small	amounts	of	EAAT2	can	be	found	on	neurones	(Petr	et	al.,	
2015).	 EAAT1	 is	predominantly	expressed	 in	 the	 cerebellum,	and	EAAT2	 in	 the	brain	
and	spinal	cord	with	highest	 levels	 in	the	neocortex	and	hippocampus,	where	5–10%	
EAAT2	is	neuronal	(Danbolt,	2001).	EAAT2	is	considered	to	mediate	most	(90%)	of	the	
glutamate	 uptake	 in	 the	 adult	 brain	 (Holmseth	 et	 al.,	 2009).	 EAAT3	 and	 EAAT4	 are	
exclusively	neuronal,	with	EAAT3	expressed	throughout	the	forebrain	and	spinal	cord,	
particularly	 in	 the	 hippocampus,	 basal	 ganglia,	 and	 cortical	 structures,	 and	 EAAT4	
predominantly	 expressed	 in	 the	 cerebellum	 localised	 to	 Purkinje	 cells	 (Furuta	 et	 al.,	




disease	 states	 using	 knockout	 mice	 of	 glutamate	 transporter	 proteins.	 Homozygous	
EAAT2	knockout	mice	became	spontaneously	epileptic	at	around	three	weeks	of	age	
and	died	shortly	after	(Tanaka	et	al.,	1997).	The	same	effect	was	seen	with	knockout	of	
astroglial	 EAAT2	 but	 not	 neuronal	 EAAT2	 (Petr	 et	 al.,	 2015),	 suggesting	 astroglial	
EAAT2	 is	 the	main	 protector	 against	 excitotoxicity.	 EAAT4	 knockout	mice	 are	 viable	
and	 appear	 normal	 despite	 lacking	 glutamate	 transporter	 currents	 at	 Purkinje	 cell	
synapses	 (Huang	 et	 al.,	 2004b),	 therefore	 its	 role	 is	 probably	 not	 critical.	 Targeted	
deletion	 of	 VGLUT1	 in	mice	 caused	 lethality	 three	weeks	 after	 birth,	 and	 drastically	
reduced	glutamatergic	neurotransmission	 (Wojcik	 et	 al.,	 2004)	whereas	homozygous	
VGLUT2	 knockout	mice	were	 not	 viable	 at	 birth	 (Moechars	 et	 al.,	 2006),	 implicating	
distinct	developmental	roles	for	VGLUT1	and	VGLUT2.	Heterozygous	VGLUT2	knockout	
mice,	 which	 were	 viable,	 have	 been	 used	 to	 link	 VGLUT2-dependent	 glutamatergic	






Glutamine	 (Gln)	 is	 converted	 to	 glutamate	 (Glu;	 blue	 circles)	 by	 glutaminase.	 Glutamate	 can	 bind	 to	
metabotropic	 type	 2/3	 (mGlu2/3)	 and	 type	 5	 (mGlu5)	 receptors	 to	 modulate	 glutamate	











can	 diffuse	 into	 the	 post-synaptic	 terminal.	 NMDARs	 can	 be	 inhibited	 by	 the	 open	 channel	 blocker	
ketamine	(KET).	Membrane-spanning	receptors	such	as	mGluR5	and	ErbB4	indirectly	influence	NMDAR	
function	by	interacting	with	the	post-synaptic	density	(PSD).	D-serine	is	produced	from	L-serine	in	glial	
cells	 by	 serine	 racemase,	 shuttled	 into	 the	 synaptic	 cleft,	 then	 eventually	 degraded	 by	 D-amino	 acid	










and	mechanism	 of	 action.	 Hence,	 when	 activated	 by	 glutamate,	 iGluRs	 form	 an	 ion	
channel	pore	whereas	mGluRs	are	G-protein	coupled	receptors	(GPCRs)	that	rely	on	a	
signaling	 cascade	 involving	G-proteins.	 The	 functional	 role	 and	 pharmacology	 of	 the	







their	 sequence	 homology,	 second	messenger	 effects	 and/or	 pharmacology:	 Group	 I	
(mGlu1	 and	mGlu5),	 group	 II	 (mGlu2	 and	mGlu3),	 and	 group	 III	 (mGlu4,	mGlu6,	mGlu7	





inositol	 1,4,5-trisphosphate	 (IP3)	 and	 diacylglycerol	 (DAG;	Willard	 and	 Koochekpour,	
2013).	 Groups	 II	 and	 III	 mGluRs	 are	 linked	 to	 Gi/Go	 and	 couple	 to	 the	 inhibition	 of	
adenylyl	 cyclase,	 the	enzyme	 that	 catalyses	 the	 conversion	of	ATP	 to	 cAMP,	 thereby	
leading	to	a	decrease	in	intracellular	cAMP	levels	(Kew	and	Kemp,	2005).		
	












selectively	 target	 individual	 mGluR	 subtypes	 that	 modulate	 specific	 cellular	 and	
neuronal	 functions.	 There	 is	 evidence	 to	 suggest	 targeting	mGluRs	 in	 this	way	has	 a	
potential	 to	 treat	 several	 CNS	 disorders,	 such	 as	 depression,	 anxiety	 disorder,	
schizophrenia,	 pain	 disorders,	 epilepsy,	 Alzheimer’s	 disease	 and	 Parkinson’s	 disease	




2002).	 For	 instance,	when	 Eli	 Lilly	 synthesised	 the	 first	 orally	 active	mGlu2/3	 agonist,	
LY354740,	it	was	found	to	possess	anticonvulsant	and	anxiolytic	effects	in	rats	(Monn	
et	al.,	 1997).	 Further	 tests	 in	animals	 corroborated	 the	anxiolytic	effect	of	 LY354740	
(Helton	et	al.,	1998,	Schoepp	et	al.,	2003),	and	demonstrated	 its	ability	 to	attenuate	
disruptions	 in	 cognition	 and	 locomotion	 in	 a	 PCP	 rat	 model	 of	 schizophrenia	
(Moghaddam	and	Adams,	1998,	Cartmell	et	al.,	1999),	inhibited	withdrawal	symptoms	
in	 morphine	 dependent	 mice	 (Klodzinska	 et	 al.,	 1999),	 and	 reduced	 pain-induced	
behaviours	in	a	rat	model	of	neuropathic	pain	(Simmons	et	al.,	2002).		
	









LY-404039,	 for	 the	 oral	 treatment	 of	 schizophrenia.	 The	 drug	 demonstrated	
			 8	
antipsychotic	 efficacy	 in	 a	 randomised,	 placebo-controlled,	 phase	 II	 clinical	 trial	 in	
patients	 with	 schizophrenia	 without	 eliciting	 side	 effects	 commonly	 observed	 with	
current	antipsychotics,	but	unfortunately	the	results	could	not	be	replicated	(Mezler	et	
al.,	 2010).	 A	 following	 phase	 II	 clinical	 trial	was	 inconclusive,	 as	 LY-2140023	was	 no	
more	 efficacious	 than	 placebo,	 but	 the	 active	 control	 (olanzapine)	 did	 not	 separate	
from	 placebo	 either	 (Kinon	 et	 al.,	 2011).	 Subsequently,	 LY-2140023	 did	 not	
demonstrate	 any	 efficacy	 in	 patients	 with	 acute	 exacerbation	 of	 schizophrenia	 in	 a	
double	blind,	placebo	controlled	phase	II	clinical	trial	(Downing	et	al.,	2014),	nor	as	an	
adjunctive	treatment	in	schizophrenic	patients	being	treated	with	a	second-generation	
antipsychotic	 (Stauffer	 et	al.,	 2013).	Despite	 these	disappointing	 results,	 there	 is	 still	















as	 can	 the	 kainate	 receptor	 subunits	 GluK1–GluK3,	 while	 GluK4	 and	 GluK5	must	 be	
coexpressed	with	GluK1,	GluK2,	 or	GluK3	 to	 form	 functional	 receptors.	NMDARs	 are	
only	functional	in	heteromeric	configurations,	requiring	two	obligatory	GluN1	subunits	
to	 assemble	with	 either	 two	GluN2	 subunits,	 or	 a	 combination	 of	 GluN2	 and	GluN3	
subunits.	In	addition,	NMDARs	have	been	observed	forming	triheteromeric	structures,	
in	 which	 the	 GluN1	 subunits	 assemble	 with	 two	 different	 GluN2	 subunits	—	for	
			 9	
example,	 GluN1/GluN2A/GluN2B	—	which	 creates	 the	 variation	 necessary	 to	 form	
NMDARs	with	 specific	 functions	 and	distribution	profiles	 in	 the	brain,	 although	 little	
progress	 has	 been	 made	 elucidating	 the	 exact	 functions	 of	 these	 triheteromeric	
structures.	
	
Different	 subunit	 compositions	 create	 diversity	 in	 receptor	 properties,	 allowing	
receptors	to	 fulfil	a	broader	set	of	 functions.	For	NMDARs	 in	particular,	 the	different	
compositions	 influence	 the	 kinetics	 and	 gating	 properties	 of	 the	 resulting	 NMDAR	
subtypes.	 For	 example,	 heteromeric	 NMDARs	 containing	 GluN2A	 or	 GluN2B	 have	 a	
higher	 conductance	 and	 sensitivity	 to	 Mg
2+





a	 higher	 open	 probability,	 lower	 sensitivity	 to	 glutamate	 and	 glycine,	 and	 faster	
deactivation	 kinetics	 compared	 to	 GluN1/GluN2C	 and	 GluN1/GluN2D	 receptors	











































































































































































































ACPA,	 (R,S)-2-amino-3-(3-carboxy-5-methyl-4-isoxazolyl)proprionic	 acid;	 ACPC,	 1-aminocyclopropane-1-carboxylic	
acid;	AP4,	L-2-amino-4-phosphonobutyric	acid;	APDC,	 (2R,4R)-4-aminopyrrolidine-2,4-carboxylate;	CNQX,	6-cyano-
7-nitroquinoxaline-2,3-dione;	DCKA,	5,7-dichlorokynurenic	acid;	DHPG,	 (S)-3,5-dihydroxyphenylglycine;	EGLU,	 (2S)-
α-ethylglutamic	 acid;	 HIBO,	 (R,S)-4-(chloro/bromo)-homoibotenic	 acid;	 JNJ16259685,	 (3,4-dihydro-2H-pyrano[2,3-
b]quinolin-7-yl)-cis-4-methoxycyclohexyl)-methanone;	MPEP,	2-methyl-6-(phenylethynyl)pyridine;	MPPG,	α-methyl-
4-phosphonophenylglycine;	 NBQX,	 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione;	 NS102,	 5-
















iGluRs	 are	 all	 ligand	 (glutamate)-gated	 ion	 channels	 that	 upon	 activation	 permit	 an	
influx	 of	 cations	—	either	 sodium,	 potassium,	 and/or	 calcium	 ions	 (Traynelis	 et	 al.,	




firing	 of	 an	 action	 potential	—	the	 primary	 type	 of	 excitatory	 synaptic	 transmission	
throughout	 the	 CNS	 and	 PNS.	 The	 properties	 of	 this	 transmission,	 such	 as	 the	





Kainate	 receptors	 are	 prevalent	 in	 the	 CNS	 grey	 matter,	 with	 a	 higher	 density	
expressed	 in	 the	 telencephalic	 structures	 and	 cerebellum	 (Monaghan	 and	 Cotman,	
1982)	 and	 have	 roles	 at	 both	 pre-	 and	 postsynaptic	 sites.	 They	 have	 been	
demonstrated	 to	 have	 a	 role	 in	mediating	 slow	 synaptic	 transmission	 at	 developing	
thalamocortical	 synapses,	 which	 then	 decreases	 as	 AMPA-mediated	 transmission	
increases,	 demonstrating	 a	 developmental	 form	 of	 LTP	 (Kidd	 and	 Isaac,	 1999).	
Activation	of	kainate	receptors	 is	associated	with	short	bursts	of	presynaptic	activity,	
and	 in	 other	 cortical	 circuits	 they	 are	 largely	 expressed	 on	 inhibitory	 interneurons	
(Traynelis	 et	 al.,	 2010).	Additionally,	 kainate	 receptors	 are	 able	 to	downregulate	 the	
release	 of	 GABA	 in	 the	 hippocampus	 by	 signalling	 via	 G-protein-coupled	 second	
messenger	cascades	to	downstream	effectors	(Rodríguez-Moreno	and	Lerma,	1998).		
	






Wenthold,	 2009).	 The	 GluN1b	 isoforms	 contain	 an	 insert	 of	 21	 amino	 acids	 in	 the	
amino-terminal	 domain,	 which	 affects	 the	 receptor	 kinetics,	 open	 probability,	 and	





The	 structure	 of	 iGluRs	 differs	 significantly	 from	 the	 typical	 arrangement	 of	 seven	
transmembrane	 domains	 seen	 in	 mGluRs	 and	 other	 GPCRs.	 Instead,	 they	 are	
composed	of	four	subunits	that	form	the	channel,	with	each	subunit	sharing	four	well-






NMDAR	 subunits,	 as	 in	 other	 glutamate	 receptors,	 have	 a	 modular	 structure	 comprising:	 two	 large	
extracellular	 domains,	 the	 amino-terminal	 domain	 (ATD)	 and	 ligand-binding	 domain	 (LBD);	 a	
transmembrane	 domain	 (TMD)	 that	 forms	 part	 of	 the	 ion	 channel	 pore;	 and	 an	 intracellular	
carboxyterminal	domain	(C).	The	LBD	is	defined	by	two	segments	of	amino	acids,	S1	and	S2.	The	TMD	is	




important	 role	 in	 neuronal	 function	 as	 well	 as	 CNS	 disorders	 such	 as	 depression,	
schizophrenia,	 stroke	 and	 Alzheimer’s	 disease,	 among	 others.	 This	 structural	
determination	began	with	the	 individual	domains	such	as	the	water	soluble	ATD	and	
LBD,	with	X-ray	crystallography	being	used	to	solve	the	structures	of	these	domains	for	
various	 iGluR	 subunits	 in	 complex	 with	 agonist,	 antagonists,	 partial	 agonists	 and	
modulators	 (Karakas	 et	al.,	 2015).	The	 first	 fully-intact	 structure	 for	an	 iGluR	—	a	 rat	
homotetrameric	GluA2	receptor	in	complex	with	antagonist	—	was	not	solved	until	ten	
years	after	that	of	the	first	LBD	(Armstrong	et	al.,	1998,	Sobolevsky	et	al.,	2009).	Since	
then,	 several	 iGluR	 structures	have	been	published	describing	 the	GluA2	 receptor	 in	
different	 functional	 states,	 the	 GluK2	 kainate	 receptor,	 and	 most	 excitingly,	 two	
recently	published	structures	for	the	NMDA	receptor.	
	
The	 crystallographic	 studies	 of	 the	 rat	 GluA2	 receptor,	 as	 solved	 by	 Sobolovsky	 and	
colleagues,	has	determined	that	the	ATDs	and	LBDs	are	organized	as	a	dimer	of	dimers	
with	 twofold	 symmetry	 perpendicular	 to	 the	 membrane	 plane,	 and	 the	 TMDs	 are	
arranged	 as	 a	 tetramer	with	 fourfold	 rotational	 symmetry	 (Sobolevsky	 et	 al.,	 2009).	
The	 extracellular	 ATD	 and	 LBD	 domains,	 as	 well	 as	 the	 TMDs,	 exhibit	 symmetry	
mismatch,	 which	 is	 due	 to	 the	 AMPA	 receptor	 containing	 two	 conformationally-
distinct	 subunits	—	A/C	 and	 B/D	 subunits	—	which	 couple	 differently	 at	 the	 ion	




Further,	 they	determined	 the	AMPA	receptor	TMD	consists	of	 three	 transmembrane	






Structural	 studies	 of	 NMDAR	 ATDs	 have	 indicated	 distinct	 architecture	 and	 subunit	
arrangement	 from	 those	 of	 other	 iGluRs.	 The	 NMDAR	 ATDs	 are	 structurally	 distinct	
from	the	ATD	of	other	iGluR	subunits	with	which	they	share	relatively	little	sequence	
			 14	
identity.	Moreover,	 the	NMDAR	ATDs	are	functionally	distinct	 from	other	 iGluR	ATDs	
since	 they	 can	 accommodate	 allosteric	 modulator	 compounds	 and	 control	 gating	
properties	 (Furukawa,	 2012).	 Combined	 with	 the	 extensive	 research	 carried	 out	 on	
NMDAR	 LBDs	 (Furukawa	 and	 Gouaux,	 2003,	 Yao	 et	 al.,	 2008,	 Vance	 et	 al.,	 2011),	
predictions	were	made	on	the	architecture	of	the	NMDAR	(Salussolia	et	al.,	2011,	Riou	
et	al.,	2012),	which	were	confirmed	when	the	structures	of	 the	 rat	 (Fig.	1.3;	Karakas	














packing	of	 the	ATD	and	LBD	 in	 the	GluN1a/GluN2B	NMDAR,	whereas	 these	domains	
interact	minimally	in	GluA2	AMPARs,	which	is	a	reflection	of	the	low	sequence	identity	
and	 divergent	 pattern	 of	 dimeric	 arrangement	 between	 NMDAR	 and	 AMPAR	 ATDs	
(Karakas	 and	 Furukawa,	 2014).	 Given	 that	 the	 ATD	 is	 known	 to	 regulate	 channel	
activity,	such	as	channel	open	probability,	in	NMDARs	(Yuan	et	al.,	2009)	but	not	other	
iGluRs	 (Möykkynen	 et	 al.,	 2014),	 the	 tight	 packing	 of	 LBDs	 and	 ATDs	 in	 NMDARs	 is	
consistent	with	this	functional	characteristic.	At	the	TMD,	the	subunits	exhibit	pseudo-
fourfold	 symmetry	 between	 the	 central	M3	 helices,	 and	 between	 the	M4	 helices	 of	
one	subunit	and	M1	and	M3	helices	of	the	adjacent	subunit,	again	similar	to	the	GluA2	
AMPAR	 and	 reminiscent	 of	 a	 K
+
















shown	 as	 green	 sticks.	 Both	 the	 NMDAR	 and	 AMPAR	 are	 assembled	 as	 a	 dimer-of-dimers	 at	 the	
extracellular	 region.	 The	 key	difference	 in	 the	overall	 structures	of	 the	 two	 receptors	 arises	 from	 the	
















NMDA	 receptors	 are	 unique	 in	 that	 unlike	 other	 iGluRs,	 they	 are	 both	 voltage-
dependent	and	 ligand-gated.	Moreover,	activation	requires	the	simultaneous	binding	
of	 two	different	 agonists:	 glutamate,	which	binds	 to	GluN2,	 and	 glycine	or	D-serine,	
which	 binds	 to	 GluN1	 (Kleckner	 and	 Dingledine,	 1988).	 There	 are	 several	 other	
molecules	that	can	activate	NMDARs	as	co-agonists	—	although	to	a	 lower	degree	of	
specificity	 than	 glycine	 or	 D-serine	—	such	 as	 L-serine,	 D-alanine	 and	 L-alanine	
(Vyklicky	et	al.,	2014).	 	 Studies	have	 indicated	 that	D-serine	 is	 the	main	coagonist	at	
synapses	while	glycine	 is	the	coagonist	at	extrasynaptic	NMDARs,	which	 is	supported	
by	 the	 differences	 in	 distribution	 between	 the	 two	 coagonists,	 as	 well	 as	 the	
preferential	 affinity	 of	 synaptic	NMDARs	 for	D-serine	 and	extrasynaptic	NMDARs	 for	
glycine	(Papouin	et	al.,	2012).	
			
In	 addition	 to	 their	 novel,	 co-agonist	 mechanism	 of	 activation,	 NMDARs	 exhibit	 a	
channel	 block	 by	 divalent	 cations	 such	 as	Mg
2+
,	 which	 is	 responsible	 for	 its	 voltage	
dependence.	This	 is	different	 to	 the	 typical	 voltage	dependence	seen	 in	 the	voltage-










The	 combination	 of	 ligand-gating	 and	 voltage	 dependence	 contribute	 to	 the	 unique	
integrative	 functions	 of	 NMDARs	 and	 understandably	 has	 broad	 implications	 for	
various	 physiological	 and	 pathological	 processes	 reliant	 upon	 NMDAR	 activation,	
including	neuronal	development,	cognition,	behaviour,	and	nervous	system	pathology.	
Moreover,	 the	 fact	 that	 NMDARs	 require	 two	 forms	 of	 activation	 creates	 more	





Long-term	potentiation	 (LTP)	 is	an	enduring	enhancement	 in	 signal	 transmission	and	
synaptic	 strength	 resulting	 from	high	 frequency	stimulation	of	a	 synapse.	 It	was	 first	
described	 in	 detail	 by	 Terje	 Lømo,	 who	 studied	 signalling	 between	 the	 medial	




synaptic	 plasticity	 thought	 to	 underlie	 learning	 and	 memory.	 LTP	 has	 since	 been	
observed	 in	 a	 variety	 of	 neural	 structures,	 including	 the	 cerebral	 cortex,	 cerebellum	
and	amygdala	(Clugnet	and	LeDoux,	1990).	Long-term	depression	(LTD),	conversely,	is	
an	activity-dependent	reduction	in	the	efficacy	of	neural	synapses,	involving	selective	




Both	 LTP	 and	 LTD	 (Fig.	 1.4)	 are	 generally	 considered	 to	 be	 processes	mostly	 reliant	
upon	the	activity	of	NMDARs,	although	a	unique	form	of	developmental	LTP	has	been	
described	where	synaptic	transmission	is	initially	mediated	by	slow	kainate	receptors,	






LTP	 is	 induced	when	a	 train	of	 action	potentials	 induces	glutamate	 release	 from	 the	
presynaptic	 nerve	 terminal,	 causing	 an	 AMPAR-mediated	 depolarisation	 of	 the	
postsynaptic	 membrane	 that	 results	 in	 a	 displacement	 of	 the	 Mg
2+












(Malenka,	 1994).	 The	 induction	 of	 LTP	 or	 LTD	 by	 presynaptically-released	 glutamate	
ensures	that	only	synapses	 involved	in	the	signal	transmission	will	undergo	plasticity,	
allowing	for	a	level	of	specificity	in	which	neural	pathways	are	strengthened.	NMDARs	
are	 an	 abundant	 component	 of	 the	 postsynaptic	 density	 (PSD),	 a	 postsynaptic	
specialisation	 containing	 glutamate	 receptors	 and	 associated	 cytoskeletal	 signalling	









instigated	 a	 conversion	 of	 these	 silent	 synapses	 into	 functional	 synapses,	 resulting	
from	the	insertion	of	AMPARs	into	the	postsynaptic	membrane	(Isaac	et	al.,	1995,	Liao	
et	 al.,	 1995).	 Therefore,	 it	 is	 thought	 that	 while	 LTP	 is	 associated	 with	 increased	
movement	of	AMPARs	from	perisynaptic	to	synaptic	sites,	LTD	involves	the	removal	of	




The	 involvement	 of	NMDARs,	 AMPARs,	 and	 their	 associated	 proteins	 in	 this	 type	 of	
plasticity	means	that	a	number	of	different	disease	states	are	thought	to	be	linked	to	















synaptic	 stimulation	 causes	 Ca
2+















Schizophrenia	 is	 a	 severe	 mental	 disorder	 characterised	 by	 positive	 (or	 psychotic)	
symptoms	comprising	delusions	and	hallucinations,	negative	symptoms	such	as	social	
withdrawal,	 anhedonia,	 and	 lack	 of	 motivation,	 and	 cognitive	 symptoms	 including	





underlying	 pathophysiology	 of	 the	 disease	 remains	 unknown,	 there	 is	 considerable	
pharmacological	 evidence	 for	 the	 dysfunction	 of	 both	 dopamine	 and	 glutamate	
neurotransmitters.	 Although	 the	 dopaminergic	 hyperfunction	 hypothesis,	 which	 is	
based	upon	the	well	described	clinical	efficacy	of	dopamine	D2	receptor	antagonists	in	




The	 involvement	 of	 glutamate	 signalling	 in	 schizophrenia	 dates	 as	 far	 back	 as	 1949	
with	reports	of	catatonic	schizophrenic	patients	showing	improved	motor	activity	after	








al.,	 2001).	 The	wealth	 of	 supporting	 literature	 has	 led	 to	 NMDAR	 antagonists	 being	
used	as	 a	 rodent	model	 system	of	 schizophrenia.	 Subsequently,	 rodent	 studies	have	
demonstrated	 that	 administration	 of	 NMDAR	 antagonists	 are	 capable	 of	 producing	
neurochemical	effects	 that	 reflect	brain	changes	seen	 in	schizophrenia.	For	example,	
studies	 using	 sub-chronic	 PCP	 treatment	 have	 resulted	 in	 parvalbumin-
immunoreactive	neuronal	deficits	 in	 the	hippocampus	and	prefrontal	 cortex	of	adult	
rats,	 as	 well	 as	 neurobiological	 deficits	 such	 as	 hypofrontality,	 a	 reduction	 in	 blood	
flow	 that	 is	 symptomatic	 of	 schizophrenia	 in	 humans	 (Neill	 et	 al.,	 2014).	 Further,	
NMDAR	 antagonists	 have	 been	 used	 to	 elicit	 behavioural	 analogues	 of	 emotional	
blunting	in	mice	(Noda	et	al.,	1995),	and	anhedonia	and	social	withdrawal	in	rats	(Baird	
et	al.,	2008,	Neill	et	al.,	2010).	It	 is	thought	that	the	effects	of	NMDAR	antagonists	in	
animal	 studies	are	due	 to	 inhibition	of	NMDARs	 located	on	GABAergic	 interneurons,	
which	 are	 involved	 in	 regulating	 feedback	 inhibition	 on	 pyramidal	 glutamatergic	
neurons,	 leading	 to	 disinhibition	 of	 this	 feedback	 and	 an	 increase	 in	 hippocampal	
pyramidal	cell	firing	(Lisman	et	al.,	2008).	
	
The	 glutamate	 hypothesis	 of	 schizophrenia	 has	 been	 somewhat	 supported	 by	 post-
mortem	studies,	which	have	identified	reduced	GluN1	subunit	expression	in	the	brain,	
but	 this	 may	 be	 due	 to	 impairments	 in	 receptor	 localisation,	 trafficking	 and	
downstream	activation	rather	than	a	general	deficit	in	receptor	expression	(Howes	et	
al.,	 2015).	 Recent	 genetic	 studies	 have	 identified	 several	 genes	 associated	 with	
schizophrenia	 that	 are	 involved	 in	 glutamatergic	 neurotransmission,	 most	 notably	
GRIN2A	gene	(which	encodes	for	an	NMDA	receptor	subunit)	as	well	as	the	GRM3	and	











since	 schizophrenia	 is	 likely	 the	 result	 of	 the	 integrated	 effect	 of	 both	 altered	
dopaminergic	 and	 glutamatergic	 neurotransmission	 on	 the	 different	 symptom	
domains	of	schizophrenia.	Nonetheless,	the	emergence	of	the	role	of	glutamate	in	this	





Neuropathic	pain	has	been	defined	by	 the	 International	Association	 for	 the	Study	of	
Pain	(IASP)	as	‘pain	caused	by	a	lesion	or	disease	of	the	somatosensory	system’	(Jensen	
et	 al.,	 2011).	 It	 is	 characterised	 by	 spontaneous	 on-going	 or	 shooting	 pain	 and	




2011).	 Inflammatory	pain	typically	 improves	as	a	 function	of	 the	healing	process	and	
responds	positively	to	NSAIDs	and	opiates,	where	by	contrast,	neuropathic	pain	cannot	
generally	be	alleviated	by	typical	analgesics	such	as	paracetamol	(Gilron	and	Dickenson,	
2014).	With	 a	 limited	 choice	 of	 effective	 treatments,	 there	 is	 a	 continuing	 need	 to	
better	 understand	 the	 mechanisms	 that	 underpin	 neuropathic	 pain	 and	 develop	
improved	therapies	that	are	able	to	target	this	group	of	devastating	conditions.	
	
The	 symptoms	 of	 neuropathic	 pain	 have	 been	 linked	 to	 various	 factors,	 including	
inflammatory	 cytokines	 released	 from	 immune	 cells	 that	 may	 target	 the	 peripheral	
nerves,	dorsal	root	ganglia	and	spinal	cord	(Marchand	et	al.,	2005,	Watkins	and	Maier,	
2005),	disinhibition	of	GABAergic	 transmission	at	 inhibitory	dorsal	horn	 interneurons	
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(Thompson	et	al.,	1993),	and	plastic	changes	in	the	spinal	cord,	possibly	as	a	result	of	
peripheral	 nerve	 injury	 (Costigan	 et	 al.,	 2009).	 In	 addition	 to	 these,	 there	 is	 a	
considerable	amount	of	evidence	to	suggest	that	NMDAR	activation	is	involved	in	pain	
associated	with	peripheral	tissue	or	nerve	injury.	There	is	also	accumulating	evidence	
that	 peripheral	 as	 well	 as	 central	 NMDARs	 contribute	 to	 nociception,	 therefore	
providing	two	potential	levels	of	pharmacological	intervention	(Petrenko	et	al.,	2003).	
	
It	 is	 generally	 thought	 that	 central	 NMDARs	 play	 a	 pivotal	 role	 in	 establishing	 the	
characteristics	 of	 neuropathic	 pain.	 The	 precise	 mechanism	 is	 central	 sensitisation,	
wherein	 the	dorsal	horn	excitability	 increases	and	 thus	becomes	more	 responsive	 to	
sensory	 input.	 This	 results	 in	 a	 state	 where	 a	 low-intensity,	 ordinarily	 non-harmful	
stimulus	 generates	 pain	 (allodynia)	 and	 noxious	 stimuli	 result	 in	 a	more	 painful	 and	
prolonged	 pain	 response	 (hyperalgesia;	 Petrenko	 et	 al.,	 2003).	 Sensitisation	 of	 the	
dorsal	 horn	 is	 likely	 caused	 by	 a	 process	 called	 ‘wind-up’,	 which	 is	 a	 frequency-
dependent	 increase	 in	 the	 excitability	 of	 spinal	 cord	 neurons	 evoked	 by	 electrical	
stimulation	of	C-fibre	primary	afferent	nerves	(Zhou	et	al.,	2011).	This	process	of	wind-
up	and	 the	 subsequent	 sensitisation	of	dorsal	horn	neurons	have	been	 shown	 to	be	
reduced	 by	 blocking	 NMDARs	 with	 antagonists	 including	 ketamine,	 memantine	 and	
MK-801	 in	 rat	models	of	neuropathy	 in	which	a	 selective	 ligation	of	 the	L5/L6	spinal	
nerves	 is	used	to	produce	a	partial	denervation	of	 the	hindpaw	(Suzuki	et	al.,	2001).	
Further,	 in	a	rat	model	of	neuropathic	pain,	GluN2B	subunit	specific	antagonists	such	
as	 ifenprodil	 were	 found	 to	 decrease	 the	 amplitude	 of	 NMDAR-mediated	 excitatory	
postsynaptic	currents	(EPSCs)	recorded	from	dorsal	horn	neurons	(Iwata	et	al.,	2007).		
In	the	same	rat	model,	the	GluN2B-selective	antagonist	Ro	25-6981	resulted	in	a	dose-
dependent	 anti-allodynic	 effect	 by	 inhibiting	 the	 C-fibre	 responses	 in	 dorsal	 horn	
neurons,	 and	 also	 inhibited	 LTP	 in	 these	 neurons	 when	 induced	 by	 high-frequency	
stimulation	 (Qu	 et	 al.,	 2009).	 Together,	 these	 results	 implicate	 a	 role	 for	 GluN2B	
NMDARs	 in	nociceptive	transmission,	dorsal	horn	sensitisation,	and	the	development	












However,	 despite	 the	 strong	 preclinical	 data,	 the	 efficacy	 of	 NMDAR	 antagonists	 in	
preclinical	 models	 of	 neuropathic	 pain	 has	 generally	 failed	 to	 translate	 into	 clinical	
efficacy	 in	humans.	For	example,	while	GV196771	is	effective	 in	rat	neuropathic	pain	
models,	 it	does	not	reduce	the	 intensity	of	evoked	pain	 in	patients	with	neuropathic	
pain	 disorders	 (Wallace	 et	 al.,	 2002).	 Similarly,	 another	GluN2B-selective	 antagonist,	
radiprodil,	was	 found	 to	 have	 no	 significant	 effect	 on	 the	mean	daily	 pain	 scores	 of	
patients	compared	to	placebo	in	a	2010	Phase	II	randomised,	double-blind	clinical	trial.	
On	 the	 other	 hand,	 the	 administration	 of	 ketamine	 in	 the	 treatment	 of	 neuropathic	






middle	 or,	 more	 commonly,	 old	 age,	 and	 is	 the	 most	 common	 cause	 of	 dementia,	
being	 responsible	 for	 60–80%	 of	 cases	 (Hebert	 et	 al.,	 2003).	 AD	 is	 characterised	
clinically	by	three	groups	of	symptoms:	cognitive	dysfunction,	which	includes	memory	
loss	 and	 language	 difficulties;	 psychiatric	 symptoms,	 which	 includes	 depression,	
hallucinations	 and	delusions;	 and	 impairments	 to	normal	daily	 living,	 such	as	driving	
and	 dressing	 (Burns	 and	 Iliffe,	 2009).	 Pathologically,	 there	 are	 two	 microscopic	
hallmarks	of	AD;	the	 intracellular	neurofibrillary	tangles	and	the	extracellular	neuritic	








hyperphosphorylated	tau	proteins	 that	cause	the	 formation	of	neurofibrillary	 tangles	
inside	 neuronal	 cell	 bodies	 (Goedert	 et	 al.,	 1991),	 ultimately	 leading	 to	 cell	 death	
(Chun	and	Johnson,	2007).	
	








within	 the	 CNS	 (Puzzo	 et	 al.,	 2011)	 but	when	 present	 in	 excess	 has	 been	 shown	 to	
enhance	neurotransmitter	 release	probability	at	 the	 synapse,	which	may	 lead	 to	 the	
compensatory	 synapse	 loss	 observed	 in	 AD	 (Abramov	 et	 al.,	 2009).	 Pathologically	
elevated	 levels	 of	 large	 Aβ	 oligomers	 may	 block	 neuronal	 glutamate	 uptake	 at	 the	
synaptic	 cleft,	 leading	 to	 elevated	 glutamate	 levels,	 and	 consequently	 increased	
activation	 of	 synaptic	 NMDARs	 (Esposito	 et	 al.,	 2013)	 and	 extra-synaptic	 NMDARs	
(Rammes	 et	 al.,	 2011).	 Aβ	 oligomers	 can	 also	 directly	 activate	NMDARs,	 particularly	
those	 with	 the	 GluN2A	 subunit	 (Texido	 et	 al.,	 2011).	 Together,	 increased	 synaptic	
glutamate	 with	 additional	 activation	 of	 NMDARs	 by	 Aβ	 can	 lead	 to	 Ca
2+
-mediated	
excitotoxity,	 oxidative	 stress,	 mitochondrial	 damage	 and	 ultimately	 neuronal	 death	
(Alberdi	et	al.,	2010).		
	













NMDAR	 activity,	 such	 as	 ketamine,	 are	 accompanied	 with	 various	 severe	 CNS	 side	
effects	 such	 as	 hallucinations,	 anxiety,	 nausea,	 vomiting,	 and	 memory	 impairment	
(Muir	and	Lees,	1995).	The	only	NMDAR	antagonist	approved	for	the	clinical	treatment	
of	AD	 is	memantine,	a	 low	affinity	channel	blocker	that	preferentially	blocks	NMDAR	
activity	 without	 disrupting	 normal	 activity,	 by	 entering	 the	 channel	 when	 it	 is	
excessively	open	and	dissociating	quickly	to	avoid	it	accumulating	and	interfering	with	
normal	synaptic	transmission	(Lipton,	2004).	Memantine	has	also	been	demonstrated	
to	 reduce	 the	 levels	of	APPα	 (the	secreted	cleavage	product	of	APP	generated	by	α-
secretase)	and	release	of	Aβ	(Ray	et	al.,	2010),	as	well	as	protect	against	mitochondrial	
toxins	 and	 hypoxia	 (Volbracht	 et	 al.,	 2006),	 and	 protect	 cholinergic	 neurones	 from	
inflammatory	processes	(Willard	et	al.,	2000).		
	
Memantine	 represents	 an	 interesting	 paradigm	 shift	 away	 from	 other	 AD	 drugs	 in	
terms	of	 its	mechanism	of	action.	 It	 is	only	one	of	 four	approved	pharmacotherapies	
for	 AD,	 the	 other	 three	 (donepezil,	 rivastigmine,	 galantamine)	 being	 cholinesterase	
inhibitors,	which	 raise	 the	 level	 of	 acetylcholine	 (ACh)	by	 inhibiting	 the	enzyme	 that	
degrades	 it	 (Burns	 and	 Iliffe,	 2009).	 Although	 memantine	 has	 been	 found	 in	 some	
clinical	 trials	 to	 improve	 cognitive	 impairment	 in	 people	with	moderately	 severe	AD	







subunit-selective	 antagonist	 ifenprodil	 inhibits	 steady-state	 NMDAR	 currents	 evoked	
by	 polyamines	 (Kew	 and	 Kemp,	 1998)	 and	 lacks	 the	 severe	 side	 effects	 seen	 with	
classical	non-selective	NMDAR	blockers	(Chenard	et	al.,	1995).	Derivatives	of	ifenprodil,	
such	as	Ro	25-6981,	have	been	studied	as	lead	compounds	in	the	development	of	new	
drugs	 for	neurodegenerative	disorders,	and	have	 led	to	the	 identification	of	GluN2B-
selective	antagonists	 such	as	CERC-301	and	EVT-101	 (Mony	 et	al.,	 2009)	 currently	 in	





Major	 depressive	 disorder	 (MDD)	 is	 one	 of	 the	most	 common	 psychiatric	 disorders,	
characterised	 by	 persistent	 low	mood,	 often	 experienced	 with	 low	 self-esteem	 and	
inability	to	experience	pleasure	(anhedonia).	MDD	is	associated	with	severe	reductions	
in	 quality	 of	 life,	 impaired	 work	 productivity,	 reduced	 social	 functioning,	 and	 poor	
physical	 health	 (Katona	 and	 Katona,	 2014).	 It	 is	 also	 accompanied	 by	 substantial	
economic	costs,	and	is	listed	as	the	leading	cause	of	disability	worldwide	in	the	WHO’s	
Global	Burden	of	Disease	project	 (Whiteford	et	al.,	2013).	Current	treatment	options	
are	 limited	 for	 acutely	 suicidal	 or	 severely	 depressed	 patients,	 with	 conventional	
treatments	 including	 cognitive	 behavioural	 therapy	 (Brown	 et	 al.,	 2005),	




are	moderately	effective	and	slow	 to	act,	 requiring	6–8	weeks	of	 therapy	 to	achieve	
relief	 from	 depression,	 as	 defined	 by	 a	 50%	 reduction	 in	 depressive	 symptomology	
(Thase	et	al.,	2001).		A	twofold	problem	is	created	with	SSRI	treatment:	patients	suffer	
residual	 symptoms	 that	 increase	 their	 risk	 of	 relapse;	 and	 they	 are	 also	discouraged	
from	 adhering	 to	 the	 treatment	 program	by	 side	 effects	 that	 often	manifest	 before	
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clinical	benefit,	including	weight	gain,	sexual	dysfunction,	nausea,	headache,	and	sleep	
disturbances	 (Rosenzweig-Lipson	 et	 al.,	 2007).	Only	 30–40%	of	 SSRI-treated	 patients	
achieve	a	full	remission	after	a	single	course	of	antidepressants,	and	in	addition	to	this,	
approximately	 one-third	 of	 patients	 with	 MDD	 suffer	 from	 treatment-resistant	
depression,	 which	 is	 characterised	 by	 an	 inadequate	 response	 to	 at	 least	 one	







However,	 recent	 efforts	 to	 further	 understand	 the	 pathophysiology	 of	 depressive	
disorders	 have	 revealed	 a	 role	 of	 glutamate	 and	 its	 receptors	 in	 MDD,	 opening	 an	
avenue	 for	 next-generation	 treatments.	 For	 example,	 there	 have	 been	 numerous	
studies	 reporting	 changes	 in	glutamate	 levels	 in	 the	blood	and	cerebrospinal	 fluid	 in	
patients	 with	 MDD.	 In	 general,	 it	 has	 been	 observed	 that	 glutamate	 levels	 are	






glutamate	 in	 MDD,	 it	 should	 be	 acknowledged	 that	 peripheral	 glutamate	 does	 not	
necessarily	reflect	CNS	neurotransmitter	levels	(Tremolizzo	et	al.,	2012).	
	
Various	 post-mortem	 and	 in	 vivo	 studies	 on	 the	 brain	 have	 also	 indicated	 a	 link	
between	 glutamate	 signalling	 and	 the	 pathophysiology	 of	 MDD.	 For	 example,	 an	
examination	 of	 post-mortem	 brains	 from	 patients	 with	 MDD	 and	 bipolar	 disorder	
found	an	increased	concentration	of	glutamate	as	well	as	D-serine	in	the	frontal	cortex	
(Hashimoto	 et	 al.,	 2007).	 However,	 in	 vivo	magnetic	 resonance	 spectroscopy	 (MRS)	
studies	are	somewhat	conflicting	in	that	on	the	one	hand	glutamate	levels	have	been	
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reported	 to	be	significantly	 increased	 in	 the	occipital	 cortex,	while	GABA	 levels	were	
significantly	 decreased	 (Sanacora	 et	 al.,	 2004)	 whereas	 groups	 using	 the	 same	
methods	 reported	 a	 reduction	 in	 glutamate/glutamine	 and	GABA	 in	 prefrontal	 brain	
regions	(Hasler	et	al.,	2007),	 the	anterior	cingulate	cortex	(Auer	et	al.,	2000)	and	the	
left	 amygdala	 (Michael	 et	 al.,	 2003).	 It	 seems	 that	 while	 the	 exact	mechanisms	 are	




Several	 reports	 have	 investigated	 the	 potential	 genetic	 link	 between	 glutamate	
signalling	and	MDD.	For	example,	in	a	microarray	analysis	of	post-mortem	mRNA	from	
the	 cerebral	 cortex	 of	 MDD	 patients	 there	 was	 a	 downregulation	 of	 SLC1A2	 and	
SLC1A3,	 genes	 that	 encode	 for	 EAAT2	 and	 1,	 respectively	 (Choudary	 et	 al.,	 2005)	 as	
well	 as	 glutamate-ammonia	 ligase,	 the	 enzyme	 that	 catalyses	 the	 synthesis	 of	
glutamine	from	glutamate	(Choudary	et	al.,	2005,	Bernard	et	al.,	2011),	all	of	which	are	
critical	 in	 synaptic	 glutamate	 clearance.	 Moreover,	 the	 mRNA	 of	 four	 glutamate	
receptor	 proteins	was	upregulated	 (GRIA1,	GRIK1,	GRM1,	GRM5),	 as	was	VGLUT2	 in	
post-mortem	MDD	 and	 bipolar	 brains	 compared	 to	 healthy	 controls	 (Bernard	 et	 al.,	
2011).	In	a	large-scale	study	on	polymorphisms	of	GRIN2B	(the	gene	encoding	GluN2B),	
involving	 patients	 with	 (n=178)	 and	 without	 (n=612)	 treatment-resistant	 depression	
(TRD),	 as	well	 as	 779	 healthy	 controls,	 it	was	 found	 that	GRIN2B	 contained	 a	 single	






The	dissociative	anaesthetic	ketamine	was	 first	synthesised	 in	 the	1960s	 for	use	as	a	
general	 anaesthetic	 as	 a	 safer,	 better	 tolerated	 alternative	 to	 phencyclidine	 (PCP;	




(Schüttler	 et	 al.,	 1987).	 Its	 rapid	 effects	 are	 reflected	 in	 its	 pharmacodynamics	 after	





,	 and	 an	 elimination	 half-life	 of	 2–3	h	 (Niesters	 et	 al.,	 2014).	 The	












several	 other	 groups	 have	 demonstrated	NMDAR	 antagonists	 can	 be	 as	 effective	 as	




using	 behavioural	 tests	 on	 mice	 models	 of	 depression	 that	 (R)-ketamine	 elicited	 a	
longer-lasting	and	more	potent	antidepressant	effect	compared	 to	 (S)-ketamine,	and	
may	possibly	be	free	of	the	psychotomimetic	effects	typically	associated	with	ketamine	
(Zhang	 et	 al.,	 2014b,	 Yang	 et	 al.,	 2015).	 There	 has	 been	 particular	 interest	 in	 (S)-
ketamine	 (esketamine)	 by	 the	 pharmaceutical	 company	 Janssen,	 who	 are	 currently	
investigating	its	antidepressant	potential	in	humans	(section	1.5.2)	
	
Several	 rodent	 models	 of	 neuropathic	 pain	 have	 been	 developed,	 usually	 involving	
ligation	 of	 certain	 nerves	 or	 inducing	 human	 disease	 phenotypes,	 such	 as	 diabetic	




and	 this	 effect	 is	 attenuated	 when	 NMDAR	 antagonists	 such	 as	 ketamine	 and	
dizocilpine	are	administered	peripherally	 (Jackson	et	al.,	1995).	 In	a	similar	study	but	
using	 a	 rat	 neuropathic	 partial	 nerve	 transection	 model,	 daily	 administration	 of	
ketamine	led	to	a	significantly	decreased	paw	withdrawal	response,	as	did	nimodipine	
(calcium	 channel	 blocker)	 and	 imipramine	 (tricyclic	 antidepressant),	 indicating	 that	
several	 mechanisms	 contribute	 to	 the	 pathology	 of	 neuropathic	 pain	 (Hota	 et	 al.,	
2007).	Several	studies	of	rodents	that	were	administered	intrathecal	ketamine	before	
undergoing	nerve	 ligation	have	 all	 demonstrated	 similar	 results,	 including	decreased	
allodynia	 and	 decreased	 on-going	 pain	 for	 at	 least	 two	 weeks	 after	 ketamine	
administration	 and	 ligation	 (Burton	 et	 al.,	 1999)	 and	 a	 relief	 of	 depression-like	
behaviours	 associated	with	 induced	 neuropathic	 pain	 (Wang	 et	 al.,	 2011).	 Ketamine	
also	 potentiated	 anti-allodynic	 effect	 when	 used	 in	 combination	 with	 spinal	 cord	
stimulation	(Truin	et	al.,	2011)	and	 in	combination	with	electroacupuncture,	which	 is	
known	to	stimulate	the	endogenous	opioid	system	(Huang	et	al.,	2004a).	Interestingly,	
ketamine	 may	 also	 exert	 its	 effects	 via	 µ-opioid	 receptors,	 as	 indicated	 in	 a	 study	




has	been	 reported	 that	Aβ	deposition	was	 significantly	 reduced	 in	 the	 frontal	 cortex	
after	 repeated	 exposure	 to	 ketamine	 in	 the	 Tg2576	 amyloid-overexpression	 mouse	
model	 of	 AD	 compared	 to	 control	 mice,	 indicating	 it	 may	 have	 a	 protective	 role	
(Quiroga	et	al.,	2014).	In	contrast,	long-term	ketamine	administration	has	been	shown	
to	 increase	hyperphosphorylated	tau	protein	 in	mice	and	monkeys,	a	hallmark	of	AD	
(Yeung	 et	 al.,	 2010).	 The	 effects	 of	 IP	 infusion	 of	 subanaesthetic	 doses	 of	 ketamine	
(<	100	mg/kg)	 have	 been	 well	 documented	 in	 healthy	 rats,	 and	 include	 cognitive	






subjects,	 triggering	 a	 relapse	 in	 those	with	 schizophrenia	 (Lahti	 et	 al.,	 2001)	 and	 as	
such	 is	often	used	 in	generating	animal	models	of	 schizophrenia	 (Kotermanski	 et	al.,	
2013).	The	schizophrenic-like	effects	induced	by	ketamine	inhibition	of	NMDARs	might	
implicate	 NMDAR	 hypofunction	 as	 the	 source	 of	 glutamate	 neurotransmission	
dysfunction	 in	 schizophrenia.	 However,	 in	 recent	 years,	 there	 has	 been	 increasing	
evidence	 to	 suggest	 glutamatergic	 hyperfunction	 is	 actually	 critical	 in	 schizophrenia,	
and	 that	 developing	 treatments	 should	 focus	 on	 reducing	 rather	 than	 increasing	
presynaptic	glutamate	levels	(Moghaddam,	2003).	For	example,	systemic	injections	of	
NMDAR	antagonists	such	as	ketamine	into	conscious	rats	at	subanaesthetic	doses	that	
impaired	 cognitive/PFC	 function	were	 found	 to	 increase	 glutamate	 efflux	 in	 the	 PFC	
(Moghaddam	et	al.,	1997,	Lorrain	et	al.,	2003),	 leading	to	abnormally	high	glutamate	
neurotransmission	at	non-NMDARs,	particularly	AMPARs	(Moghaddam	et	al.,	1997).	In	
addition,	neuronal	activity	 in	 the	PFC	was	 found	 to	be	generally	 increased	 in	human	
fMRI	 studies	 of	 NMDAR	 antagonists	 (ketamine	 and	 PCP)	 that	 measured	 metabolic	
activation	in	PFC	regions	(Breier	et	al.,	1997,	Vollenweider	et	al.,	1997).	The	most	likely	
explanation	 for	 the	 paradoxical	 increase	 of	 cortical	 excitation	 caused	 by	 NMDAR	
antagonists	 such	 as	 ketamine	 is	 that	 inhibition	 of	NMDARs	 decreases	 the	 activity	 of	
GABA	 interneurons,	 and	 ultimately	 increases	 the	 firing	 rate	 of	 pyramidal	 neurons	
(Homayoun	 and	 Moghaddam,	 2007).	 Thus,	 NMDARs,	 which	 have	 a	 higher	 open	







Berman	 and	 colleagues,	 who	 discovered	 that	 that	 a	 single	 subanaesthetic	 dose	
(0.5	mg/kg)	 of	 ketamine	 administered	 by	 intravenous	 (IV)	 infusion	 over	 a	 40-minute	
period	produced	a	significant	improvement	within	two	hours	compared	to	placebo,	as	
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measured	 by	 the	 Hamilton	 Depression	 Rating	 Scale	 (HAM-D;	 Berman	 et	 al.,	 2000).	
These	effects	have	since	been	reproduced	in	larger	trials	of	patients	with	TRD	following	
a	single	(Zarate	et	al.,	2006,	Murrough	et	al.,	2013)	and	repeated-dose	(aan	het	Rot	et	
al.,	2010,	Messer	et	al.,	2010)	 IV	 infusion	of	ketamine,	each	reporting	a	 reduction	 in	
depression	 symptoms	 as	 measured	 by	 the	 Montgomery-Åsberg	 Depression	 Rating	
Scale	 (MADRS)	or	HAM-D	 rating	 scale.	As	well	 as	eliciting	a	profound	antidepressant	





30	 patients	 were	 randomly	 assigned	 to	 receive	 placebo,	 or	 a	 lower	 (0.2	mg/kg)	 or	
higher	 (0.4	mg/kg)	 dose	 of	 esketamine.	 Two	 IV	 doses	were	 administered	 during	 the	
double-blind	 phase,	 followed	 by	 a	 two-week	 follow-up	 wherein	 the	 patients	 could	
receive	up	 to	 four	additional	open-label	doses.	The	earliest	antidepressant	effect,	 as	
measured	 by	 change	 in	 MADRS,	 occurred	 two	 hours	 post-infusion,	 and	 both	 dose	
groups	 showed	 significant	 improvement	 in	 depressive	 effects	 over	 placebo	 within	
three	 days.	 Adverse	 effects	 did	 also	 occur,	with	 the	most	 common	 being	 headache,	
nausea,	 and	 temporary	 dissociation.	 The	 considerable	 evidence	 from	 clinical	 studies	
that	 support	 the	 efficacy	 of	 ketamine	 prompted	 Janssen	 to	 develop	 intranasal	
esketamine,	which	 is	currently	 in	phase	 III	clinical	 trials	 to	assess	 its	efficacy,	optimal	
dosing	and	safety	profile	in	the	treatment	of	TRD	(Janssen,	2017).		
	
A	preceding	 study	of	 (R)-	 and	 (S)-ketamine	administered	by	 IV	 to	healthy	 volunteers	
found	that	(R)-ketamine	produced	a	state	of	relaxation	and	elation	with	no	psychotic	
effects,	 as	 opposed	 to	 (S)-ketamine	 which	 produces	 psychotomimetic	 effects.	
Therefore,	it	may	be	possible	NMDARs	do	not	have	a	major	role	in	the	antidepressant	
effects	 of	 ketamine,	 which	 may	 be	 due	 to	 the	 potency	 of	 the	 isomers	 at	 different	
receptor	systems	(Zhang	et	al.,	2014b).	Interestingly,	this	did	seem	to	be	the	case	with	
(R)-ketamine	 appearing	 to	 be	 more	 biologically	 active	 than	 (S)-ketamine,	 and	
moreover,	 the	 antidepressant	 activity	 associated	 with	 (R)-ketamine	 may	 have	 been	
mediated	 by	 its	 active	 metabolite	 (2R,6R)-hydroxynorketamine	 (HNK)	 via	 AMPARs	
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of	 unmetabolised	 pharmacologically-active	 ketamine	 with	 the	 attenuated	 ketamine	
metabolites,	there	was	a	reduction	of	antidepressant	effect	and	of	metabolites	in	the	
brain,	suggesting	the	antidepressant	action	of	ketamine	is	mediated	by	its	metabolites.	
Administration	 of	 the	 metabolites	 alone	 revealed	 that	 (2R,6R)-HNK	 had	 greater	
efficacy	 than	 (2S,6S)-HNK	 in	 the	mouse	 learned	helplessness	 paradigm,	 and	was	not	
self-administered,	 indicating	a	 low	drug	abuse	potential.	The	key	finding	of	the	study	
was	that	(2R,6R)-HNK	did	not	affect	NMDA-induced	currents	in	a	rat	hippocampal	slice	
model,	 but	 actually	 increased	 AMPA-mediated	 excitatory	 postsynaptic	 currents.	





also	 been	 explored	 in	 the	 clinic.	 Ketamine	 administered	 by	 IV	 infusion	 has	
demonstrated	efficacy	at	relieving	pain	in	those	suffering	from	complex	regional	pain	




NMDAR	 antagonists,	 such	 as	 amantadine	 and	 dextromethorphan,	 have	 also	
demonstrated	a	reduction	in	neuropathic	pain	 in	postsurgical	cancer	patients	(Pud	et	
al.,	 1998)	 and	 diabetic	 neuropathy	 (Nelson	 et	 al.,	 1997),	 respectively.	 When	
administered	 peripherally	 by	 subcutaneous	 infusion,	 ketamine	 enhanced	 the	 local	
anaesthetic	 and	 analgesic	 effects	 of	 bupivacaine	 (a	 local	 anaesthetic)	 when	
administered	 postoperatively	 (Tverskoy	 et	 al.,	 1996)	 and	 also	 demonstrated	 a	 dose-
dependent	 decrease	 in	 hyperalgesia	 in	 neuropathic	 patients,	 as	 did	 the	 µ-opioid	
agonist	alfentanil	(Leung	et	al.,	2001).	However,	due	to	the	differences	in	methods	of	
administration	and	dosages,	 there	has	been	 little	 consistency	 in	 the	 longevity	of	 the	
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analgesic	 effect,	 lasting	 anywhere	 from	45	minutes	 to	 three	months	 (Niesters	 et	 al.,	
2014).	Of	the	few	studies	that	examined	the	long-term	effects	of	intravenous	ketamine	
infusion	 for	CRPS	and	spinal	cord	 injury,	 the	dosing	ranged	 from	daily	 IV	 infusion	 for	
4	h	(25	mg/h)	over	ten	days	(Schwartzman	et	al.,	2009),	to	a	100	h	IV	infusion	of	low-
dose	 (20–30	mg/h)	 ketamine	 (Sigtermans	 et	 al.,	 2009b)	 to	 a	 daily	 IV	 infusion	 of	








As	 previously	 mentioned,	 the	 most	 common	 CNS	 side	 effects	 of	 ketamine	 are	
psychotomimetic,	often	present	at	the	doses	used	to	treat	chronic	pain	(20–30	mg/h,	
80–100	mg	 total)	 and	 include	 perceptual	 alterations,	 delusions,	 paranoia,	 anxiety,	
disordered	thinking,	and	a	 feeling	of	 intoxication	(Pomarol-Clotet	et	al.,	2006).	Other	
CNS	 side	 effects	 include	 nausea/vomiting,	 blurred	 vision,	 dizziness,	 impaired	 motor	
function	and	memory	deficits	(Niesters	et	al.,	2014).	There	is	also	a	risk	that	ketamine	
can	indirectly	stimulate	the	cardiovascular	system,	causing	tachycardia,	hypertension,	




CNS	 side	 effects,	 physical	 harm,	 psychological	 dependence	 and	 tolerance,	 and	
urological	 disorders	 (Kalsi	 et	 al.,	 2011).	 Considering	 these	 potential	 side	 effects,	 and	
the	 fact	 that	 repeated	 in-patient	admission	 for	 IV	administration	 is	often	 required	 in	






















D-cycloserine	and	other	cyclic	analogues	of	glycine	 (Hood	 et	al.,	1989,	Sheinin	 et	al.,	
2001,	Dravid	 et	al.,	 2010).	Agonists	of	GluN2	 include,	naturally,	NMDA	—	a	 synthetic	





NMDAR	 activity	 over	 other	 glutamate	 receptors	 by	 administering	 its	 co-agonists	
glycine	 and	 D-serine,	 particularly	 in	 disorders	 such	 as	 schizophrenia	 that	 have	 been	
associated	with	NMDAR	hypofunction	(Coyle	and	Tsai,	2004).	In	general,	almost	all	of	






and	 even	 suggest	 that	 high-dose	 glycine	 can	 improve	 cognitive	 symptoms	 (Heresco-
Levy	et	al.,	1999)	and	to	some	extent,	positive	symptoms	when	added	to	antipsychotic	
drug	 therapy	 (Heresco-Levy	and	 Javitt,	 2004).	Conversely,	when	 the	effect	of	 glycine	
was	 examined	 in	 a	 larger	 patient	 population	 in	 the	 CONSIST1	trial,	 there	 were	 no	
significant	improvements	for	either	cognitive	or	negative	symptoms	(Buchanan	et	al.,	





was	 a	 significant	 improvement	 in	 negative	 and	 positive	 symptoms	 and	 general	
psychopathology	in	patients	with	treatment-resistant	schizophrenia	(Tsai	et	al.,	2006).	
The	conclusions	of	these	studies	were	promising	but	were	not	without	caveats,	such	as	
the	 very	 high	 dose	 required	 to	 observe	 significant	 effects,	 relatively	 poor	 brain	






glycine-binding	 site.	 In	 rat	 studies,	 GLYX-13	was	 able	 to	 act	 as	 a	 cognitive	 enhancer	
when	tested	with	the	Morris	water	maze	and	alternating	T-maze	tasks	(Burgdorf	et	al.,	
2011b)	 and	 produced	 antidepressant-like	 effects	 in	 several	 animal	 models	 of	
depression,	without	psychotomimetic	side-effects	(Burgdorf	et	al.,	2013).	In	a	Phase	II	
clinical	trial	of	GLYX-13	on	patients	with	MDD	who	had	not	responded	to	at	least	one	
other	 antidepressant	 treatment,	 a	 single	 IV	 dose	 (1–30	mg/kg)	 over	 3–15	min	
improved	 depression	 scores	 within	 hours	 and	 lasted	 seven	 days	 on	 average.	 The	









to	 GLYX-13	 in	 preclinical	 trials	 but	 is	 considerably	more	 potent	 and	 orally	 active.	 In	
2015,	 a	 Phase	 II	 clinical	 trial	 was	 completed	 for	 an	 IV	 formulation	 of	 NRX-1074	 in	
patients	with	MDD	(NCT02067793)	while	a	Phase	I	trial	for	an	oral	formulation	has	also	




synthesised	 GLYX-13	 used	 a	 radiolabeled	 form	 ([
3
H]	 GLYX-13)	 to	 determine	 the	
compound	 readily	 crossed	 the	 blood-brain	 barrier	 in	 rats,	 and	 found	 via	
electrophysiological	experiments	in	frog	oocytes	that	GLYX-13	could	act	as	a	co-agonist	
of	NMDARs	 in	 the	absence	of	 glycine,	 an	effect	 that	was	blocked	by	 the	glycine	 site	
selective	antagonist	7-chlorokynurenic	acid	 (Moskal	 et	al.,	 2005).	 In	 rat	hippocampal	
slices,	GLYX-13	reduced	NMDAR-mediated	synaptic	currents	in	CA1	pyramidal	neurons	
evoked	 by	 low	 frequency	 Schaffer	 collateral	 stimulation,	 but	 enhanced	 NMDAR	
currents	 during	 high	 frequency	 bursts	 of	 activity,	 corresponding	 to	 a	 respective	
suppression	of	 LTD	and	enhancement	of	 LTP	 (Zhang	 et	al.,	 2008).	GLYX-13-mediated	
enhancement	of	LTP	in	hippocampal	slices	was	also	observed	by	others	(Burgdorf	et	al.,	
2011b).	Analysis	of	hippocampal	 tissues	 from	rats	 that	had	 received	a	 single	 IV	dose	
(3	mg/kg)	 of	GLYX-13	 found	 facilitated	 LTP	 and	 increased	whole-cell	NMDAR	 current	
contributed	by	GluN2B-containing	NMDARs,	as	well	as	increased	mature	spine	density	
in	 the	medial	 PFC	 and	 hippocampus	 (Burgdorf	 et	 al.,	 2015).	 Ifenprodil,	 the	 GluN2B-
selective	allosteric	antagonist,	has	been	found	to	block	GLYX-13	enhanced	activation	of	
burst-driven	 extrasynaptic	 NMDARs	 (Zhang	 et	 al.,	 2008)	 and	 the	 GLYX-13-mediated	
improvement	in	positive	emotional	learning	in	rats	(Burgdorf	et	al.,	2011a).	
	
Studies	 on	 other	 glycine	 partial	 agonists	 have	 not	 been	 as	 obviously	 successful.	 D-
cycloserine	was	initially	studied	for	its	potential	as	an	antipsychotic,	and	from	voltage-
clamp	 experiments	 was	 thought	 to	 preferentially	 activate	 NMDARs	 containing	 the	
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GluN2C	subunit	(Sheinin	et	al.,	2001,	Dravid	et	al.,	2010).	D-cycloserine	has	been	found	




induction	 (Rouaud	 and	 Billard,	 2003).	 While	 early	 clinical	 trials	 suggested	 that	 D-




al.,	 2007).	 There	 have	 been	 mixed	 findings	 on	 the	 use	 of	 D-cycloserine	 in	 treating	
anxiety	 disorders;	 while	 several	 small-scale	 studies	 have	 supported	 its	 use	 in	 this	
application,	later	larger-scale	studies	have	often	showed	weak	or	no	effects	(Otto	et	al.,	
2015).	One	explanation	for	the	observed	variability	has	been	attributed	to	differences	
in	D-cycloserine	dosages	between	trials.	For	 instance,	no	 improvement	to	 immediate	
or	 delayed	 memory	 was	 found	 following	 weekly	 doses	 of	 50	mg	 D-cycloserine	 in	
healthy	 participants	 (Otto	 et	 al.,	 2009),	 yet	 hippocampus-dependent	 declarative	
learning	 was	 facilitated	 by	 a	 single	 250	mg	 oral	 dose	 of	 D-cycloserine	 (Onur	 et	 al.,	
2010).	The	discrepancy	suggests	D-cycloserine	effects	on	hippocampal	functioning	may	
be	 dose-dependent,	 and	 accordingly	 a	 phase	 II	 clinical	 trial	 is	 being	 conducted	 to	






Many	 competitive	 antagonists,	 so-called	 because	 they	 compete	 with	 endogenous	
ligands	 at	 their	 binding	 site,	 have	 been	 identified	 for	 both	 the	 GluN1	 and	 GluN2	
subunits.	 Both	 7-chlorokynurenic	 acid	 (Birch	 et	 al.,	 1988)	 and	 its	 analogue	 5,7-
dichlorokynurenic	 acid	 (DCKA;	 McNamara	 et	 al.,	 1990)	 are	 examples	 of	 GluN1	
antagonists	—	thought	 to	work	 by	 interacting	with	 the	GluN1	 LBD	 and	 stabilizing	 an	
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are	 small	 endogenous	 peptides	 exhibiting	 both	 competitive	 and	 noncompetitive	
antagonist	activity	that	have	exhibited	specificity	for	different	GluN2	subunits	(Prorok	
and	Castellino,	2007)	through	binding	to	the	glutamate	binding	pocket	(Wittekindt	et	
al.,	 2001)	 so	 are	 being	 studied	 for	 rational	 design	 of	 drugs	 to	 treat	 NMDAR-related	
pathologies,	including	chronic	pain,	stroke,	and	seizure.	
	
Subtype-selective	 noncompetitive	 antagonists	 also	 exist,	 characterized	 by	 binding	 to	
the	NMDAR	at	a	site	distinct	from	the	ligand-binding	sites.	These	include	ifenprodil,	a	
phenylethanolamine	 selective	 for	 the	 GluN2B	 subunit	 that	 binds	 to	 the	 N-terminal	
leucine/isoleucine/valine-binding	protein	(LIVBP)-like	domain	of	GluN2B	(Perin-Dureau	
et	 al.,	 2002).	 As	 well	 as	 ifenprodil,	 numerous	 other	 potent	 derivatives	 and	 subunit-
selective	 non-competitive	 antagonists	 have	 been	 identified;	 GluN2B-selective	
antagonists	 in	 particular	 have	 been	 implicated	 in	 the	 treatment	 of	 a	 variety	 of	
neurological	diseases.	For	example,	 ifenprodil	has	been	shown	to	be	neuroprotective	
in	 cases	 of	 ischemic	 brain	 injury	 in	 preclinical	 models	 (Wang	 and	 Shuaib,	 2005),	








or	 else	 risk	 cardiovascular	 interactions	 (Lynch	 and	 Gallagher,	 1996).	 This	 led	 to	 the	
development	 of	 several	 ifenprodil	 analogues	with	 greater	 selectivity	 for	GluN2B	 and	
the	 potential	 for	 reduced	 off-target	 interactions,	 including	 traxoprodil	 (CP-101,606,	
Pfizer)	 and	 Ro-25-6981,	which	 have	 been	 tested	 in	 clinical	 trials	 with	mixed	 results.	
Hence,	traxoprodil	was	well	tolerated	and	appeared	to	slightly	improve	the	symptoms	
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and	mortality	 rate	 of	 traumatic	 brain	 injury	 in	 a	 randomised,	 double-blind,	 placebo-
controlled	trial	(Yurkewicz	et	al.,	2005),	and	in	another	trial	on	TRD	it	had	a	significant	
antidepressant	 effect	 but	 approximately	 half	 the	 patients	 experienced	 dissociative	




promising,	 further	 development	 of	 traxoprodil	 has	 been	 discontinued	 due	 to	 the	
continued	 potential	 risk	 of	 cardiovascular	 toxicity	 by	 potassium	 channel	 blockade,	





NMDAR	 uncompetitive	 antagonists	 act	 as	 open-channel	 blockers	 and	 require	 the	
receptor	 pore	 to	 be	 open	 in	 order	 for	 them	 to	 bind	 and	 block	 receptor	 activity.	
Inhibition	 increases	 with	 receptor	 activity	 and	 channel	 open	 probability,	 therefore	
uncompetitive	antagonists	can	be	considered	use-dependent	blockers.		
	
The	 most	 notable	 of	 these	 NMDAR	 uncompetitive	 antagonists	 are	 the	 dissociative	
drugs	PCP,	 its	better-tolerated	anaesthetic	derivative	ketamine,	and	dizocilpine	 (MK-
801),	 a	 drug	 discovered	 by	 Merck.	 Dizocilpine	 has	 undergone	 extensive	 preclinical	
testing	 in	 rats	 for	 the	 potential	 treatment	 of	 diseases	 where	 NMDAR-related	
excitotoxicity	may	be	a	component,	such	as	stroke,	and	Huntington’s	and	Alzheimer’s	
disease.	 Indeed,	dizocilpine	 showed	promise	 in	protecting	neuronal	 cell	 cultures	and	
animal	models	from	excitotoxic	neurodegeneration	following	cellular	trauma	(Mukhin	
et	al.,	1997),	seizures	(Ayala	and	Tapia,	2005),	and	spinal	cord	ischemia	(Kocaeli	et	al.,	
2005).	 Further,	 positive	 results	with	 dizocilpine	 have	been	 seen	 in	 animal	models	 of	
depression	 (Maj	 et	 al.,	 1992,	 Papp	 and	Moryl,	 1993,	 Yang	 et	 al.,	 2016).	 In	 a	 PD	 rat	
model	 exhibiting	 L-DOPA-induced	 abnormal	 involuntary	 movements,	 high-dose	
dizocilpine	 (0.2–0.3	mg/kg)	 suppressed	 dyskinesia	 but	 worsened	 parkinsonism	
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(Paquette	 et	 al.,	 2010),	 although	 another	 study	 on	 rats	 with	 lesions	 induced	 in	 the	
substantia	 nigra	 found	 dizocilpine	 (0.2	mg/kg)	 prevented	 impairment	 of	 working	
memory	 and	 dopaminergic	 degeneration	 (Hsieh	 et	 al.,	 2012).	 The	 most	 significant	
drawback	 of	 dizocilpine	 is	 its	 lack	 of	 a	 robust	 safety	 profile	 in	 clinical	 trials,	 causing	
psychotomimetic	 effects	 such	 as	 hallucinations,	 as	 well	 as	 cardiovascular	 effects	
(Ellison,	 1995).	 The	 observation	 that	 Olney’s	 lesions,	 a	 form	 of	 neurotoxicity	











DLB,	 it	seems	 likely	that	targeting	NMDAR	neurotransmission	could	yield	drugs	to	 fill	
an	unmet	need	with	a	novel	mechanism	of	action.	Memantine,	while	mechanistically	
similar	 to	 NMDAR	 channel	 blockers	 such	 as	 ketamine	 and	 PCP,	 displays	 distinct	
pharmacological	characteristics	 including	 lower	affinity	and	 faster	dissociation,	which	
liken	 it	 more	 to	 the	 voltage-dependent	 Mg
2+
	 that	 occludes	 NMDAR	 channels.	
Memantine	 may	 re-establish	 activity-dependent	 NMDAR	 channel	 block	 to	 maintain	
proper	NMDAR	functioning	and	limit	excitotoxicity	in	AD,	causing	it	to	not	exhibit	the	
same	 severe	 cognitive	 side-effects	 (Danysz	 et	 al.,	 2000)	 as	 those	 caused	by	 stronger	
blockers	like	ketamine	and	PCP.	
	
NMDAR	uncompetitive	 antagonists	 (as	well	 as	 subunit	 specific	 antagonists)	 have	 the	





as	a	 long-term	 therapeutic	agent	until	 there	 is	 an	 improved	administration	protocol.	
The	 low-affinity	 NMDAR	 channel	 blocker	 remacemide	 has	 been	 studied	 in	 the	
treatment	 of	 acute	 ischemic	 stroke	 (Dyker	 and	 Lees,	 1999),	 epilepsy	 (Wesnes	 et	 al.,	
2009),	 Huntington’s	 disease	 (Kieburtz	 et	 al.,	 1996),	 and	 Parkinson’s	 disease.	 When	
remacemide	 was	 administered	 to	 patients	 with	 PD	 as	 an	 adjunct	 to	 dopaminergic	
therapy,	 some	 positive	 indications	 were	 observed	 but	 these	 results	 were	 not	
significant	or	 robust	enough	to	warrant	 further	study	 (Shoulson	et	al.,	2001).	Due	 to	
the	 lack	of	evidence	that	remacemide	was	an	effective	treatment	for	these	diseases,	












Glutamate	 is	 synthesised	 in	 the	cytoplasm	and	stored	 in	synaptic	vesicles	by	VGLUTs	
(Reimer	and	Edwards,	2004)	and	is	rapidly	removed	from	the	synapse	after	exocytosis	




O’Donovan	 et	 al.,	 2017).	 Accordingly,	 these	 transporters	 are	 attractive	 targets	 for	
indirectly	modulating	NMDAR	function	for	therapeutic	benefit.	
	
A	 number	 of	 VGLUT	 competitive	 inhibitors	 are	 amino	 acid	 analogues	 and	 include:	
glutamate	 analogues	 such	 as	 trans-ACPD	 (Winter	 and	 Ueda,	 1993);	 quinoline	 and	
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quinoxaline	 analogues	 and	 derivatives	 such	 as	 7-chloro-kynurenate	 (Bartlett	 et	 al.,	
1998,	 Carrigan	 et	 al.,	 2002);	 various	 azo	 dyes	 such	 as	 Trypan	 Blue,	 Evans	 Blue,	
Naphthol	 Blue	 Black,	 and	 Benzopurpruin	 4B	 (Roseth	 et	 al.,	 1998)	 as	 well	 as	
polyhalogenated	fluoresceins	and	their	derivatives,	such	as	Rose	Bengal	 (Ogita	et	al.,	
2001);	the	endogenous	molecule,	inhibitory	protein	factor	(IPF;	Ozkan	and	Ueda,	1998);	
and	 tetrapeptide	 inhibitors	 such	as	D-Gln-L-Ile-D-Glu-L-Try	 (Patel	 et	 al.,	 2007).	 These	
compounds	 vary	 in	 their	 potency	 and	 selectivity	 and	 often	 lack	 membrane	
permeability,	with	 the	exception	of	Rose	Bengal,	which	 is	membrane	permeable	but	
not	specific	 to	VGLUT.	Recently,	a	potent,	VGLUT-specific	 inhibitor	 that	 is	membrane	
permeable	was	identified	—	the	diazo	compound	Brilliant	Yellow,	which	has	equivalent	
potency	 to	 Trypan	 Blue	 but	 is	 smaller	 and	 easily	 modifiable	 (Tamura	 et	 al.,	 2014),	
meaning	it	may	have	potential	as	a	prototype	compound	for	novel	drug	therapies.	
	
Likewise,	 an	 abundance	 of	 EAAT	 inhibitors	 have	 been	 identified,	 including:	
conformationally-constrained	 glutamate	 analogues	 such	 as	
(carboxycyclopropyl)glycine	 (CCG)	 compounds	 (Shimamoto	 and	 Ohfune,	 1996);	
methyl-substituted	 glutamate	 analogues	 such	 as	 threo-3-methylglutamate	 (T3MG;	
Eliasof	et	al.,	2001);	pyrrolidine	dicarboxylate	(PDC)	derivatives	such	as	L-trans-2,4-PDC,	
a	competitive	substrate	of	EAATs	1–4	(Arriza	et	al.,	1994,	Fairman	et	al.,	1995);	serine	
derivatives	 such	 as	 serine-O-sulphate	 (Arriza	 et	 al.,	 1994);	 and	 aspartate	 derivatives	
such	 as	 threo-β-hydroxyaspartate	 (THA)	 and	 its	 derivatives	 (Shigeri	 et	 al.,	 2001).	 As	
with	VGLUT	inhibitors,	there	have	been	challenges	developing	EAAT	inhibitors	that	are	
potent	 and	 specific	 to	 EAAT	 subtypes,	 are	 non-transportable,	 and	 are	 soluble.	




facilitate	 the	 identification	 of	 a	 novel	 class	 of	 EAAT	 modulators	 with	 significant	
therapeutic	potential.	
	
An	 alternative	 target,	 which	 shows	 more	 promise	 in	 terms	 of	 having	 unique	
pharmacology	 and	 improved	 druggability,	 is	 inhibition	 of	 glycine	 reuptake	 to	 extend	
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co-agonist	 availability	 and	 activity	 at	 NMDARs.	 Extracellular	 levels	 of	 glycine	 at	




subtypes	have	distinct	distribution	patterns,	with	GlyT1	 found	 in	glial	 cells	and	some	
glutamatergic	neurons	at	NMDAR-containing	synapses	in	the	spinal	cord	and	forebrain	




NMDARs	are	co-localised	with	GlyT1-type	 transporters	 that	 regulate	 localised	glycine	
levels	 so	 can	 modulate	 NMDAR	 activity	 (Javitt,	 2006),	 therefore	 inhibiting	 glycine	
reuptake	 may	 have	 the	 same	 therapeutic	 benefit	 of	 oral	 administration	 of	 glycine	
(section	 1.6.2).	 The	 first	 indication	 that	 glycine	 transport	 inhibitors	 (GTIs)	 could	
modulate	NMDAR	function	was	when	the	glycine	derivative	glycyldodecylamide	(GDA)	
reversed	rodent	hyperactivity	induced	by	PCP	inhibition	of	NMDAR	function,	which	led	
to	 increased	 subcortical	 dopamine	 release	 (Javitt	 et	 al.,	 1997).	 In	 the	 study,	 the	
increased	 extracellular	 glycine	 resulting	 from	 GlyT1	 inhibition	 increased	 NMDAR	
activation	 to	 overcome	 the	 PCP	 effects.	 Further	 preclinical	 studies	 with	 the	 GlyT1	




Further	 GTIs	 have	 been	 developed	 with	 improved	 affinity	 and	 selectivity,	 such	 as	
Org24461	 (and	 its	 active	 enantiomer	 Org-24598)	 and	 SSR504734.	 There	 is	 strong	
supporting	evidence	for	their	efficacy,	particularly	for	SSR504734;	in	rodent	studies,	it	
has	 been	 shown	 to	 increase	 extracellular	 levels	 of	 glycine	 in	 the	 PFC	 (resulting	
enhanced	 glutamatergic	 neurotransmission),	 normalise	 activity	 in	 rat	 models	 of	
hippocampal	 and	 PFC	 hypofunctioning,	 reverse	 dizocilpine-	 and	 PCP-induced	
behaviours,	 increase	extracellular	dopamine	 in	 the	PFC,	and	 is	effective	 in	models	of	
depression	 and	 anxiety	 (Depoortère	 et	 al.,	 2005).	 Unfortunately	 the	 use	 of	 these	
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compounds	—	ALX/NPS-5407,	 Org24461/24598	 and	 SSR504734	—	in	 preclinical	
studies	on	animals	has	been	associated	with	various	side	effects	including	ataxia,	and	





competitive	 inhibitor	 of	 GlyT1	 (Zhang	 et	 al.,	 2009).	 The	 first	 was	 a	 double-blind,	
placebo-controlled	trial	which	examined	the	effects	of	sarcosine	(2	g/day)	as	an	add-on	
treatment	for	patients	with	schizophrenia,	and	found	that	patients	receiving	sarcosine	
showed	 significant	 improvements	 in	 their	 positive,	 negative,	 cognitive,	 and	 general	
psychiatric	symptoms,	as	well	as	being	well	tolerated	(Tsai	et	al.,	2004).	Another	study	
supported	 these	 findings	 and	 also	 found	 that	 sarcosine	 was	 an	 effective	 adjunctive	
therapy	 for	 those	 suffering	 with	 an	 acute	 exacerbation	 of	 symptoms,	 across	 all	
symptom	domains	(Lane	et	al.,	2005),	although	when	tested	on	drug-free	patients	with	
schizophrenia,	 sarcosine	was	only	weakly	effective	at	 reducing	positive	and	negative	
symptoms	 (Lane	 et	 al.,	 2008).	 Further	 clinical	 trials	 have	 indicated	 that	 sarcosine	
treatment	may	 be	 able	 to	 relieve	 acute	 symptoms	 of	 obsessive-compulsive	 disorder	




and	 clinical	 trials,	 such	 as	 animal	 studies	 with	 ASP2535	 (Harada	 et	 al.,	 2012)	 and	
TASP0315003	(Chaki	et	al.,	2015),	and	human	studies	with	Org-25935	(Schoemaker	et	
al.,	2014)	and	RG1678	(bitopertin),	with	studies	on	the	latter	being	the	most	extensive	
and	 best-described.	 An	 initial	 trial	 of	 bitopertin	 promisingly	 showed	 a	 reduction	 in	
negative	symptoms	in	patients	with	schizophrenia	(Umbricht	et	al.,	2014)	and	a	phase	
II/III	 trial	 showed	 a	 similar	 effect	 to	 the	 antipsychotic	 drug	 olanzapine	 in	 terms	 of	
improved	 readiness	 for	 hospital	 discharge	 after	 an	 acute	 schizophrenic	 episode	











effective	 at	 milligram-level	 dosing	 in	 contrast	 to	 the	 gram-level	 dosing	 required	 for	
sarcosine	 (Javitt,	 2006)	 and	 thus	will	 have	 genuine	potential	 as	 compounds	 that	 can	






D-serine	 is	 a	 functional	 and	 potent	 coagonist	 of	 NMDARs,	 being	 found	 in	 highest	
concentrations	in	the	forebrain,	hippocampus,	and	cerebral	cortex	(Schell	et	al.,	1995)	
in	 correlation	 with	 GluN2A/B	 subunit-containing	 NMDARs	 (Schell	 et	 al.,	 1997).	 In	
contrast,	 glycine	 is	 the	 predominant	 NMDAR	 coagonist	 in	 the	 adult	 cerebellum	 and	
hindbrain	 (Schell	 et	 al.,	 1997).	 Therefore,	 targeting	 D-serine	 metabolism	 may	 be	 a	
therapeutic	method	of	indirectly	modulating	NMDAR	function	in	certain	regions	of	the	
brain.	 D-serine	 is	 metabolised	 endogenously	 by	 D-amino	 acid	 oxidase	 (DAO),	 which	
greatly	 diminishes	 NMDAR-mediated	 neurotransmission	 (Mothet	 et	 al.,	 2000),	 so	




Mutant	 rodent	 strains	 that	 have	 disorders	 in	 DAO	 resulting	 in	 abnormal	 DAO	 gene	
expression,	 have	 been	 used	 to	 investigate	 the	 impact	 of	 DAO	 on	 D-serine	
concentration.	 In	 the	 LEA/SENDAI	 strain,	 a	 subline	 of	 a	 strain	 with	 very	 low	 DAO	
expression,	rats	had	no	DAO	activity,	DAO	protein	or	mRNA	coding	DAO	(Konno	et	al.,	
2009).	 These	 rats	have	 large	amounts	of	D-serine	 in	 forebrain	 structures	—	olfactory	
bulb,	 cerebral	 cortex,	 hippocampus,	 and	 hypothalamus	—	and	 drastically	 increased	
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levels	 of	 D-serine	 where	 high	 DAO	 activities	 are	 normally	 observed	—	cerebellum,	
medulla	 oblongata,	 and	 spinal	 cord	—	in	 relation	 to	 normal	 rats	 possessing	 DAO	
(Miyoshi	et	al.,	2011),	which	is	consistent	with	the	patterns	observed	in	DAO	knockout	





of	 the	 cerebellum,	 indicating	 a	 requirement	 to	 keep	 cerebellar	 D-serine	 levels	 low	
during	adulthood.		
	
Another	 mutant	 mouse	 strain	 lacking	 DAO	 activity	 (ddY/DAO
-




	 mice	 (Zhao	 et	 al.,	 2008).	 In	 addition,	 intravenous	 application	 of	 sodium	
benzoate,	a	DAO	competitive	 inhibitor	 (Bartlett,	1948)	 into	mice	having	normal	DAO	
activity,	 inhibited	pain	 responses	 in	 these	mice	 (Zhao	 et	al.,	 2008).	These	 results	are	
further	 supported	 by	 observations	 from	 a	 rat	 neuropathic	 pain	 model	 obtained	 by	
L5/L5	 spinal	 ligation,	 which	 caused	 allodynia	 and	 increased	 DAO	 mRNA	 and	 DAO	
activity	 in	 the	 lumbar	 spinal	 cord.	 The	 allodynia	 was	 then	 blocked	 by	 intrathecal	
injection	 of	 sodium	 benzoate	 (Zhao	 et	 al.,	 2010)	 suggesting	 a	 role	 for	 DAO	 in	
neuropathic	pain.	
	
Abnormal	 levels	of	D-serine,	possibly	 caused	by	altered	gene	expression	or	 aberrant	
homeostatic	regulation,	may	contribute	to	the	glutamate	hypothesis	of	schizophrenia,	
and	accordingly	the	 link	between	DAO	and	schizophrenia	has	been	 investigated.	This	
view	 was	 initially	 supported	 by	 the	 observation	 that	 serum	 levels	 of	 D-serine	 in	
patients	with	schizophrenia	are	significantly	reduced	(Hashimoto	et	al.,	2003),	which	is	
consistent	 with	 the	 twofold	 higher	 DAO	 activity	 seen	 in	 the	 post-mortem	 cortex	 of	
schizophrenic	 patients	 (Madeira	 et	 al.,	 2008),	 but	 these	 observations	 were	
contradicted	 by	 later	 reports	 (Hons	 et	 al.,	 2008).	 Rodent	 studies	 in	 models	 of	
schizophrenia	are	also	conflicting;	it	has	been	reported	that	DAO	inhibition	was	able	to	










blind,	 placebo-controlled	 trials	 using	 sodium	 benzoate	 as	 an	 add-on	 treatment	 for	
schizophrenia	have	showed	significant	improvement	across	symptom	domains	(Lane	et	
al.,	 2013,	 Lin	 et	 al.,	 2015)	 and	 when	 used	 as	 a	 monotherapy	 for	 early-phase	 AD,	
substantially	improved	cognitive	and	overall	functions	of	patients	(Lin	et	al.,	2014).	
	
Despite	 these	 contradictory	 reports,	 DAO	 is	 still	 a	 popular	 target	 for	 deriving	 new	
therapies	for	diseases	related	to	NMDAR	dysfunction.	Specific	novel	inhibitors	for	DAO	
have	only	been	identified	relatively	recently	(Ferraris	et	al.,	2008,	Sparey	et	al.,	2008,	
Duplantier	 et	 al.,	 2009,	 Smith	 et	 al.,	 2009).	DAO	certainly	has	 a	predominant	 role	 in	
modulating	D-serine	levels	in	glia	of	the	cerebellum,	and	also	glia	of	the	cerebral	cortex	
and	hippocampus	in	the	forebrain,	although	it	also	exists	neuronally	in	the	prefrontal	
cortex,	hippocampus,	 and	 substantia	nigra	 (Hamase	 et	al.,	 2005,	Verrall	 et	al.,	 2007,	
Sasabe	 et	al.,	 2014).	As	DAO	 is	mostly	 localised	 to	white	matter	of	 the	 forebrain,	D-
serine	levels	in	the	neurons	of	this	region	are	primarily	controlled	by	serine	racemase.	
This	 enzyme	 is	 responsible	 for	 producing	 almost	 all	 endogenous	 D-serine	 by	








As	mentioned	 in	 section	1.3.1,	 two	different	 endogenous	 coagonists	 are	 required	 to	
bind	 to	 and	 activate	 NMDARs:	 glutamate	 and	 D-serine	 (or	 glycine).	 D-serine	 is	
produced	by	the	enzymatic	conversion	of	L-serine	to	D-serine	by	serine	racemase	(SR),	
which	also	degrades	L-	and	D-serine	to	pyruvate	and	ammonia.	The	following	sections	







the	 exception	 of	 occasional	 reports	 of	 D-amino	 acids	 that	 were	 either	 limited	 to	
invertebrates	 or	 dismissed	 as	 artefacts	 (or	 ‘unnatural	 isomers’;	 Corrigan,	 1969).	 This	
was	challenged	with	the	discovery	of	large	amounts	of	free	D-serine	in	the	vertebrate	
brain	(Hashimoto	et	al.,	1992,	Nagata	et	al.,	1994),	which	prompted	further	studies	of	
the	distribution,	 function,	 and	origin	of	D-serine.	While	 it	 had	been	 reported	 that	 L-
serine	was	the	precursor	to	D-serine	in	experiments	in	rats	using	radiolabeled	L-serine	
(Dunlop	 and	 Neidle,	 1997),	 it	 was	 assumed	 that	 this	 would	 involve	 multiple	 steps	
rather	than	direct	enzymatic	conversion.	
	




enzyme	 with	 characteristics	 similar	 to	 those	 observed	 in	 SR	 partially	 purified	 from	
silkworms,	 such	 as	 an	 alkaline	 pH	 optimum	 and	 the	 requirement	 for	 the	 cofactor,	
pyridoxal	 5’-phosphate	 (PLP;	 Uo	 et	 al.,	 1998).	 Subsequent	 molecular	 cloning	
experiments	 showed	 that	 SR	has	 a	molecular	weight	of	 about	37	kDa,	 comprising	of	
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340	amino	acids,	with	a	sequence	identity	to	mouse	SR	of	88%,	and	a	highly-conserved	
PLP	 binding	 region	 that	 is	 also	 found	 in	 the	 serine/threonine	 dehydratase	 family	 of	
proteins	(De	Miranda	et	al.,	2000).	Human	SR	was	then	found	to	be	discretely	localised	
to	 brain	 regions	 high	 in	 endogenous	 D-serine,	 being	 particularly	 high	 in	 the	 white	











ATP	 (De	Miranda	 et	 al.,	 2002).	 The	 combined	 effect	 of	 ATP	 and	Mg
2+
	 resulted	 in	 a	
fivefold	 increase	 in	 D-serine	 production,	 and	 chelation	 of	 Mg
2+













et	 al.,	 2002)	 but	 the	ATP-Ca
2+





















dependent	 enzymes	 are	 very	 versatile,	 contributing	 to	 a	 large	 variety	 of	 enzymatic	
reactions	 including	 transamination,	 decarboxylation,	 β-	 and	 γ-eliminations	 and	
substitutions,	 as	 well	 as	 racemisation	 (Phillips,	 2015).	 The	 PLP-dependent	 enzymes	
that	 are	 specifically	 involved	 in	 amino	 acid	 metabolism	 can	 be	 separated	 into	 four	
groups	of	paralogous	proteins	denoted	as	fold	types	I–IV,	categorised	by	the	similarity	





inhibitor	 malonate	 (Smith	 et	 al.,	 2010).	 Both	 human	 and	 rat	 SR	 crystallised	 as	 a	
symmetric	dimer.	Human	SR	is	composed	of	a	large	and	small	domain	connected	by	a	
flexible	loop	domain	that	acts	as	a	hinge;	the	large	domain	contains	PLP	and	a	seven-
stranded	 twisted	 β-sheet	 surrounded	 by	 ten	 α-helices,	 while	 the	 small	 domain	
contains	 four	 central	 parallel	 β-sheets	 and	 three	α-helices	 (two	 close	 to	 the	 domain	





SR.	 All	 the	 crystal	 structures	 available	 of	 SR	 in	 the	 PDB,	 across	 multiple	 species	




	 in	 the	 metal	 binding	 site,	 indicating	 a	
prominent	role	for	divalent	cations	in	stabilising	the	folding	of	SR.	The	Smith	group	had	
more	success	crystallising	SR	with	the	orthosteric	 inhibitor	malonate	(Fig.	1.5),	which	

























Only	one	published	 crystal	 structure	offers	 a	 visualisation	of	 the	ATP	binding	 site,	 in	
the	yeast	 SR	 structure	bound	 to	 the	ATP	analogue,	AMP-PCP	 (PDB	code	1WTC),	 and	
the	authors	determined	its	binding	site	is	located	at	the	domain	interface	(Goto	et	al.,	









While	 the	 production	 of	 D-serine	 is	 considered	 the	 main	 functional	 role	 of	 SR,	 the	
discovery	 of	 SR	 cofactors	 revealed	 SR	 is	 capable	 of	 catalysing	 another	 physiological	
reaction	—	the	α,β-elimination	of	water	from	L-serine	to	form	pyruvate	and	ammonia	
(De	Miranda	 et	al.,	2002).	The	elimination	 function	 reflects	 the	homology	of	SR	with	
serine	 dehydratases	—	enzymes	 which	 primarily	 produce	 pyruvate	 from	 L-serine	—	
and	 suggests	 SR	may	 have	 originated	 from	 a	 serine	 dehydratase	 gene	 and	 acquired	
serine	racemisation,	with	its	β-elimination	activity	being	a	relic	from	this	evolutionary	
process	 (Wolosker	 and	Mori,	 2012).	 The	 physiological	 significance	 of	 this	 additional	
function	 of	 SR	 is	 unclear;	 while	 pyruvate	 has	 been	 shown	 to	 protect	 cells	 against	
oxidative	damage	and	zinc	neurotoxicity	 (Desagher	et	al.,	1997,	Sheline	et	al.,	2000),	
the	 contribution	 of	 SR	 α,β-elimination	 to	 pyruvate	 levels	 is	 negligible	 compared	 to	
other	 processes	 such	 as	 glycolysis	 (Wolosker	 and	Mori,	 2012).	 It	 is	 possible	 that	 SR	
modulates	D-serine	 levels,	as	 it	 is	also	capable	of	catalysing	the	α,β-elimination	of	D-
serine	(Foltyn	et	al.,	2005).	D-serine	metabolism	is	primarily	associated	with	the	DAO	




again	 supporting	 the	 idea	 that	 its	 racemisation	 activity	 is	 a	 result	 of	 convergent	
evolution	 from	 an	 unrelated	 ancestor	 gene,	 serine	 dehydratase	 (De	Miranda	 et	 al.,	










in	 Fig.	 1.6)	 depends	 on	 two	 catalytic	 residues	 located	 on	 opposite	 sides	 of	 the	 PLP-
conjugated	plane:	Lys56,	which	acts	as	a	base,	and	Ser84,	which	acts	as	an	acid.	The	
PLP	 cofactor	 is	 connected	 to	 Lys56	 via	 a	 Schiff	 base,	 and	 once	 L-serine	 binds	 to	 SR	
another	 Schiff	 base	 is	 formed	 between	 PLP	 and	 L-serine	 to	 produce	 an	 external	
aldimine	separate	from	the	active	site.	L-serine	is	deprotonated	by	Lys56	and	a	planar	









amine,	 acts	 as	 a	 base	 to	 deprotonate	 the	 α-carbon	 of	 L-serine,	 causing	 double	 bond	 rearrangement	 of	 the	 Schiff	 base	 and	 loss	 of	 aromaticity	 to	 form	 a	 planar	 PLP	
intermediate.	(C)	Ser84,	a	residue	in	the	active	site,	is	moved	into	position	to	the	opposite	side	of	the	PLP	ring	plane	via	an	induced	shift	of	the	small	domain.	The	planar	









With	 the	 initial	 purification	 of	 SR	 came	 an	 interest	 to	 identify	 which	 regions	 of	 the	
brain	 it	was	 localised	 to,	 in	 order	 to	 understand	 the	 extent	 of	 the	 role	 SR	 has	 in	D-
serine	 metabolism	 and	 signalling.	 This	 was	 especially	 pertinent	 after	 findings	 that	
indicated	 D-serine	 is	 up	 to	 three	 times	 more	 potent	 than	 glycine	 as	 an	 NMDAR	




Accordingly,	 Wolosker	 and	 colleagues	 (the	 same	 group	 that	 initially	 purified	 SR)	
performed	 co-localisation	 experiments	 on	 rats	 to	 identify	 its	 expression	 pattern	
(Wolosker	et	al.,	1999a).	They	found	that	SR	was	expressed	almost	exclusively	 in	the	
brain,	 particularly	 enriched	 in	 glial	 cells	 and	 reduced	 in	 neuronal	 cells,	 at	 levels	 that	
correlated	 with	 the	 high	 levels	 of	 endogenous	 D-serine	 in	 the	 brain.	 Further,	 they	
found	 that	 the	 distribution	 of	 SR	 closely	 mirrored	 that	 of	 D-serine,	 with	 highest	
concentrations	 of	 both	 being	 found	 in	 the	 forebrain,	 as	 well	 as	 in	 astrocytes	
throughout	 the	 cerebral	 cortex,	 dentate	 gyrus	 of	 the	 hippocampus,	 and	 corpus	






in	 these	 cells	 rather	 than	 being	 synthesised	 in	 neurons	 and	 transported	 to	 glia,	 and	
indeed	this	theory	was	supported	by	several	subsequent	studies	(Stevens	et	al.,	2003,	
Panatier	et	al.,	2006,	Sasabe	et	al.,	2007).	However,	using	 in	situ	hybridisation	 it	was	
then	 found	 that	 SR	was	 predominantly	 expressed	 in	 rat	 brain	 neurons,	 especially	 in	
forebrain	regions	(Yoshikawa	et	al.,	2007)	as	well	as	the	neuronal	ganglion	cells	of	the	
retina	 (Dun	 et	 al.,	 2008,	 Takayasu	 et	 al.,	 2008).	 Furthermore,	 immunohistochemical	
findings	 using	 polyclonal	 SR	 antibodies	 with	 improved	 sensitivity	 have	 suggested	 SR	
was	 actually	 localised	 to	 neuronal	 cells	 (Kartvelishvily	 et	 al.,	 2006,	 Wolosker	 et	 al.,	
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2008),	particularly	 in	the	cerebral	cortex	and	hippocampal	formation.	This	was	based	
on	 numerous	 previous	 observations	 that	 high	 levels	 of	 D-serine	 are	 also	 present	 in	




of	 the	 cerebral	 cortex	 and	 hippocampal	 CA1	 region,	 as	 well	 as	 in	 the	 GABAergic	
medium-spiny	 neurons	 of	 the	 striatum.	 Rather	 compellingly	 and	 in	 contradiction	 to	
earlier	studies,	they	did	not	find	any	evidence	of	SR	in	the	glia,	a	finding	corroborated	





vitro	 and	 in	 vivo	 techniques,	 spurring	 the	 need	 for	 confirmation	 in	 the	 form	 of	 SR	
knock-out	mice	models	(section	1.7.6).	
	
The	evidence	 for	neuronal	SR	would	suggest	 that	D-serine	 is	predominantly	 found	 in	
neurons,	 but	 it	 is	 actually	 present	 in	 higher	 levels	 in	 astrocytes	 (Schell	 et	 al.,	 1997,	
Kartvelishvily	et	al.,	2006,	Williams	et	al.,	2006).	Taking	into	account	this	information,	a	
‘serine-shuttle’	 model	 was	 proposed	 by	 Wolosker	 to	 explain	 how	 the	 twofold	




release.	 The	 efficiency	 of	 the	 α,β-elimination	 reaction	 of	 SR	 is	 relatively	 high,	which	
would	 explain	why	 levels	 of	 D-serine	 are	 low	 in	 neurons	 expressing	 SR,	 and	making	
astrocytes	—	which	have	low	levels	of	SR	—	ideal	for	sequestering	D-serine,	where	it	is	
protected	 from	degradation.	 The	 serine-shuttle	model	describes	 a	 complex	 interplay	
between	 neuron	 and	 astrocyte	 metabolism,	 and	 as	 such	 highlights	 the	 need	 for	
improved	 techniques	 in	order	 to	 fully	 comprehend	 the	 role	of	D-serine	 in	mediating	
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The	specific	 location	of	SR	 in	the	brain	has	yielded	some	insight	 into	 its	physiological	
role.	 The	 enzyme	 D-amino	 acid	 oxidase	 (DAO)	 is	 largely	 responsible	 for	 D-serine	
catabolism	in	peroxisomes,	but	has	minimal	expression	in	forebrain	areas,	where	SR	is	
highly	 expressed.	 It	 is	 therefore	 possible	 that	 SR	 is	 able	 to	 regulate	 D-serine	 levels	
through	its	α,β-elimination	activity.	This	is	supported	by	the	observation	that	D-serine	
levels	 in	 the	 forebrain	 are	 unchanged	 in	 mice	 expressing	 catalytically-inactive	 DAO	
(Hashimoto	et	al.,	1993)	but	is	contradicted	by	recent	findings	that	D-serine	is	localised	
to	the	same	regions	as	SR,	suggesting	the	α,β-elimination	of	SR	 is	not	predominantly	
responsible	 in	 altering	 D-serine	 levels	 (Ehmsen	 et	 al.,	 2013).	 This	 latter	 experiment	
used	mice	with	 targeted	 deletion	 of	 3-phosphoglycerate	 dehydrogenase	 (Phgdh),	 an	
enzyme	 involved	 in	 L-serine	 biosynthesis,	 to	 create	mice	 significantly	 depleted	 of	D-
serine	that	could	be	used	as	specific	negative	controls;	previous	studies	using	antibody	





in	 an	 extensive	 schizophrenia	 genome-wide	 association	 study,	 the	 SRR	 gene	 was	
identified	 as	 a	 possible	 genetic	 risk	 factor	 for	 schizophrenia	 (Schizophrenia	Working	





between	 SRR	 and	 schizophrenia	 in	 Japanese	 populations	 (Yamada	 et	 al.,	 2005).	 In	
addition,	no	association	was	 found	between	 single-nucleotide	polymorphisms	 (SNPs)	
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in	the	5’-promotor	region	of	the	SRR	gene	and	schizophrenia	 in	a	Russian	population	
(Goltsov	 et	 al.,	 2006),	 nor	 the	 3’	 and	 central	 regions	 in	 a	 German	 population	
(Strohmaier	et	al.,	2007),	a	later	Japanese	population	(Ohnuma	et	al.,	2009),	and	a	Han	
Chinese	population	(Yu	et	al.,	2015).	Another	genetic	analysis	genotyped	three	SNPs	of	
the	5’	 region	of	 the	SRR	gene	 in	patients	with	 schizophrenia	 and	 found	a	 significant	
excess	of	the	IVS1a+465C	allele	of	SNP5,	thought	to	influence	the	promoter	activity	of	
the	SRR	gene	and	lower	expression	of	SR	(Morita	et	al.,	2007).	The	authors	proposed	
the	 discrepancy	 was	 due	 to	 SNP5	 being	 more	 associated	 with	 the	 paranoid-	 over	
disorganised-subtype	of	schizophrenia,	and	differences	between	the	methods	used	by	




Results	 of	 genetic	 studies	 have	 been	 mixed,	 but	 there	 is	 some	 evidence	 that	 the	
aetiology	of	 schizophrenia	 is	 linked	 to	abnormal	modulation	of	 the	NMDAR	D-serine	
site,	 possibly	mediated	 by	 SR.	 Changes	 in	 SR	 expression	 have	 been	 described	 in	 the	
post-mortem	 hippocampus	 and	 cortex	 of	 schizophrenic	 patients,	 with	 some	 studies	
observing	 a	 decrease	 (Bendikov	 et	 al.,	 2007)	 and	 others	 an	 increase	 (Steffek	 et	 al.,	
2006,	Verrall	et	al.,	2007).	Aberrant	SR	expression	 in	schizophrenia	 is	consistent	with	




and	 binds	 to	 the	 C-terminus	 of	 SR	 to	 either	 modulate	 its	 activity,	 or	 increase	
phosphorylation	 of	 SR	 by	 PKC	 (Fujii	 et	 al.,	 2006).	 Abnormalities	 in	 DISC1	 have	 been	
consistently	 associated	 with	 psychiatric	 disorders	 (Brandon	 and	 Sawa,	 2011)	 and	
accordingly	 mutant	 DISC1	 has	 been	 shown	 to	 cause	 increased	 ubiquitination	 and	
degradation	 of	 astrocytic	 SR	 in	 vivo	 resulting	 from	 disruption	 of	 the	 normal	
physiological	binding	of	DISC1	to	SR	(Ma	et	al.,	2013).	The	mice	with	mutant	DISC1	had	





and	 L-serine	 were	 found	 to	 be	 respectively	 lower	 and	 higher	 in	 patients	 with	 AD,	
indicating	 reduced	 activity	 of	 SR	 may	 contribute	 to	 the	 pathophysiology	 of	 AD	
(Hashimoto	et	al.,	2004).	Aβ	has	been	found	to	upregulate	SR	mRNA	and	protein	and	
cause	 a	 corresponding	 increase	 in	 D-serine	 in	 hippocampal	 cell	 cultures	 (from	 the	
hippocampus	of	a	transgenic	mouse	model	of	AD	and	human	patients	with	AD)	and	rat	
microglia	 (Wu	 et	 al.,	 2004,	Madeira	 et	 al.,	 2015).	 Similarly,	 secreted	 APP	 fragments	
have	been	proposed	 to	 transcriptionally	 induce	SR,	 leading	 to	 increased	steady-state	
levels	of	dimeric	SR	and	elevated	D-serine	levels	 in	microglia	(Wu	et	al.,	2007).	 It	has	
been	 suggested	 Aβ	 increases	 microglial	 transcription	 through	 JNK-dependent	
recruitment	of	AP-1	complex	to	the	SR	promoter	 (Wu	and	Barger,	2004).	The	overall	
elevation	of	SR	mRNA	and	protein	in	microglia	and	AD	hippocampus	may	contribute	to	
















phosphoserine	by	 phosphoserine	phosphatase	 (Wood	 et	 al.,	 1996),	 or	 exogenous	D-
serine	from	intestinal	bacterial	flora.	In	mice	depleted	of	both	SR	and	DAO,	D-serine	is	
drastically	 reduced	 (by	 85%)	 in	 the	 cerebral	 cortex	 and	 hippocampus	 compared	 to	
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SR+DAO-	mice,	and	also	greatly	 reduced	 (by	50%)	 in	 the	cerebellum	and	spinal	cord,	
indicating	D-serine	is	mostly	synthesised	by	SR	in	these	tissues	(Miyoshi	et	al.,	2012),	
thereby	emphasising	the	physiological	role	of	SR	in	D-serine	regulation	in	the	brain.	To	
quantify	 the	contributions	of	astrocytes	and	neurons	 to	SR	and	D-serine	 localisation,	
SR	 conditional	 knockout	 (SRCKO)	mice	with	 selective	 suppression	of	 SR	 in	astrocytes	
(aSRCKO)	 and	 in	 forebrain	 glutamatergic	 neurones	 (nSRCKO)	 were	 studied	 and	
revealed	 that	while	 D-serine	 levels	 were	 decreased	 in	nSRCKO	mice,	 they	 remained	
unaffected	in	aSRCKO,	implicating	a	more	important	role	for	neurons	in	producing	D-
serine	 (Benneyworth	 et	 al.,	 2012).	 Despite	 this,	 the	 poor	 correlation	 between	 SR	
expression	 and	 D-serine	 levels	 in	 the	 mice	 in	 this	 study	 raises	 questions	 about	 the	
involvement	 of	 other	 pathways	 regulating	 D-serine,	 such	 as	 expression	 of	 SR	 in	 the	
liver,	altered	expression	of	DAO,	and	loss	of	SR	α,β-elimination	activity.	
	
In	 regards	 to	 expression	 of	 NMDARs	 in	 SR-KO	mice,	 the	 expression	 levels	 of	 GluN1,	
GluN2A	and	GluN2B,	which	 are	 abundant	 in	 the	 forebrain,	 are	 comparable	between	







leads	 to	 the	 formation	of	nitric	oxide	 (NO)	which	nitrosylates	and	 inactivates	SR	 in	a	
negative	 feedback	 loop	 (Mustafa	 et	 al.,	 2007).	 In	 SR-KO	 mice	 NO	 formation	 and	
nitrosylation	 of	 its	 targets	 are	 substantially	 reduced,	 emphasising	 the	 importance	 of	
NMDAR	activation	by	D-serine,	and	thus	SR,	in	NO	signalling	(Mustafa	et	al.,	2010).	SR	




memory	 formation	 compared	 to	WT	when	 evaluated	 in	 the	Morris	water	maze	 and	
increased	 locomotor	 activity	 (Basu	 et	 al.,	 2009).	 In	 a	 behavioural	 test	 that	 evaluates	
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episodic	 memory,	 SR-KO	mice	 exhibited	 an	 abnormal	 pattern	 of	 preference	 for	 the	
order	of	events	in	distinct	experiences	in	two	separate	tests	(DeVito	et	al.,	2011)	which	
could	 be	 a	 result	 of	 disrupted	 functioning	 of	 the	 PFC.	 This	 correlates	 with	 the	
observation	that	SR-KO	mice	have	less	complex	dendrites	with	reduced	spine	density	
in	the	mPFC	and	abnormal	apical	dendrites	of	the	pyramidal	neurones	(DeVito	et	al.,	
2011)	 which	 is	 consistent	 with	 these	 neurones	 receiving	 projections	 from	 limbic	





study	 disorders	 associated	 with	 dysfunctional	 NMDAR	 signalling,	 such	 as	
neurodegeneration	 and	 schizophrenia.	 As	 well	 as	 displaying	 attenuated	 NMDA-
induced	 excitotoxicity	 upon	 injection	 of	NMDA	 into	 the	 cerebral	 cortex,	 SR-KO	mice	
are	 also	 protected	 against	 Aβ1-42-induced	 neuronal	 damage	 when	 injected	 into	 the	
hippocampus	(Inoue	et	al.,	2008).	The	neurotoxic	derivatives	of	Aβ1-42	are	thought	to	
contribute	 to	 the	pathogenesis	of	Alzheimer’s	disease	 (Lambert	 et	al.,	 1998),	 so	 it	 is	
possible	 the	 observed	 effect	 implicates	 the	 involvement	 of	 D-serine	 in	 NMDAR-
mediated	neurotoxicity	by	Aβ1-42	and	neuronal	death	in	AD	(Inoue	et	al.,	2008).	Taken	
together	with	the	observation	that	D-serine	is	the	dominant	endogenous	coagonist	for	
NMDAR-excitotoxicity	 (Shleper	 et	 al.,	 2005),	 and	 that	 Aβ	 induces	 SR	 expression	 and	
stimulates	the	release	of	excitotoxic	D-serine	(Wu	et	al.,	2004),	 the	case	for	D-serine	
and	SR	playing	a	role	in	neurodegeneration	is	strong.	This	makes	SR-KO	mice	relevant	















hypofunction	 and	 hippocampal	 deficits.	 As	 well	 as	 displaying	 decreased	 NMDAR	
activity	 and	 LTP,	 SR-KO	 mice	 also	 show	 morphological	 changes	 (including	 reduced	
hippocampal	 spines	 and	 dendritic	 volume),	 neurochemical	 changes	 (including	
decreased	levels	of	miR-132	and	BDNF,	which	regulate	dendritic	spine	expression),	and	
cognitive	 deficits	 (Balu	 et	 al.,	 2013);	 all	 of	 which	 are	 associated	with	 schizophrenia.	
That	chronic	D-serine	treatment	reverses	 the	cognitive	deficits	attributed	to	reduced	
SR	 expression	 in	 these	mice	 (Balu	 et	 al.,	 2013,	 Balu	 and	 Coyle,	 2014)	 suggests	 that	





but	 not	 AMPH	 (Benneyworth	 et	 al.,	 2011)	 and	 repeated	 administration	 of	 METH	
resulted	in	behavioural	sensitisation	in	WT	but	not	SR-KO	mice	(Horio	et	al.,	2012).	The	
latter	 observation	 corresponded	 with	 an	 increase	 in	 ERK1/2	 phosphorylation	 after	
METH	 administration	 in	 WT	 but	 not	 SR-KO	 mice,	 and	 a	 smaller	 METH-induced	
dopamine	release	in	the	nucleus	accumbens	of	mice	lacking	SR	(Horio	et	al.,	2012).	SR-
KO	mice	 also	 demonstrated	 an	 inability	 to	 extinguish	 conditioned	 hyperactivity	 and	
responses	 to	 drug-associated	 stimuli	 after	 treatment	with	 AMPH	 (Benneyworth	 and	
Coyle,	 2012).	 Altogether,	 these	 results	 are	 consistent	 with	 the	 role	 of	 NMDAR	
hypofunction	in	the	comorbidity	of	substance	abuse	seen	in	schizophrenia.		
	
A	 key	 study	 for	 linking	 SR,	 D-serine	 and	 schizophrenia	 focuses	 on	 Disrupted-in-
Schizophrenia-1	 (DISC1),	 a	 gene	 which	 when	 disrupted	 has	 been	 found	 to	 be	
associated	with	schizophrenia,	MDD	and	bipolar	disorder	(St	Clair	et	al.,	1990,	Millar	et	
al.,	 2000)	 and	 whose	 variants	 and	 polymorphisms	 have	 been	 linked	 to	 psychiatric	
disorders	(Brandon	and	Sawa,	2011).	A	mouse	model	of	selective	and	inducible	DISC1	
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expression	 found	 that	 DISC1	 acts	 as	 a	 scaffold	 that	 binds	 to	 and	 stabilises	 SR,	 but	
mutant	DISC1	loses	this	function	and	instead	binds	to	and	depletes	full-length	DISC1,	
thereby	 facilitating	 ubiquitination	 and	 degradation	 of	 SR	 and	 decreased	 D-serine	
production	(Ma	et	al.,	2013).	Adult	mice	expressing	mutant	DISC1	exhibit	behavioural	
abnormalities	consistent	with	NMDAR	hypofunction	as	a	result	of	D-serine	deficiency,	





The	 schizophrenia-like	 phenotype	 of	 SR-KO	 mice	 (impaired	 NMDAR-mediated	
neurotransmission	 and	 LTP,	 cognitive	 deficits,	 behavioural	 changes)	 might	 raise	
concern	as	to	whether	similar	traits	might	be	observed	in	patients	treated	with	an	SR	
inhibitor.	 It	 is	 important	 to	 remember	 this	 phenotype	 stems	 from	 glutamate	
hypofunction	resulting	from	a	downregulation	of	NMDAR	activity	comparative	to	wild-
type,	 whereas	 an	 SR	 inhibitor	 would	 be	 used	 to	 treat	 conditions	 underpinned	 by	
glutamate	 hyperfunction	 (such	 as	 neuropathic	 pain	 and	 excitotoxicity)	 by	 aiming	 to	
reduce	NMDAR	neurotransmission	to	more	typical	levels.	Moreover,	the	aim	of	an	SR	
inhibitory	 drug	would	 not	 be	 to	 completely	 abolish	 SR	 activity	 but	 to	 reduce	 it	 to	 a	
point	 at	 which	 it	 is	 therapeutically	 relevant.	 For	 instance,	 heterozygous	 (+/–)	 SR-KO	
mice	have	cortical	D-serine	levels	that	are	70%	of	wild-type	(compared	to	10%	in	the	
homozygote)	 and	 only	 moderately	 affected	 glutamatergic	 neurotransmission	 with	
respect	 to	 the	 homozygote	 (Basu	et	 al.,	 2009).	With	 this	 in	mind,	 the	 goal	 of	 an	 SR	




The	above	considerations,	 in	combination	with	 the	evidence	 for	 the	role	of	NMDARs	




serine	 and	 LSOS	 were	 studied	 further,	 revealing	 several	 competitive	 inhibitors	
including	 glycine	 (Ki	 =	 1.63	 mM),	 malonate	 (Ki	 =	 0.077	 mM),	 and	 L-erythro-3-
hydroxyaspartate	 (L-EHA;	 Ki	 =	 0.049	 mM;	 Strísovský	 et	 al.,	 2005).	 A	 more	
comprehensive	study	of	the	effects	of	amino	acids	and	their	derivatives	on	SR	activity	
found	 that	 glycine,	 and	 compounds	 related	 to	 aspartic	 acid	 such	 as	 L-aspartate,	 L-
asparagine,	 and	 oxaloacetic	 acid,	 all	 act	 as	 substrate-mimetic	 SR	 inhibitors	 whereas	
sulfhydryl	 compounds	 such	as	 L-cysteine	can	 inhibit	 SR	by	 reacting	with	PLP	 to	 form	
thiazolidine	derivatives	(Dunlop	and	Neidle,	2005).	Substrate-product	analogues	have	





high-throughput	 screening	 of	 a	 peptide	 library	 using	 a	 one-bead	 one-compound	
combinatorial	 approach.	 The	 inhibitors,	 which	 displayed	 a	 clear	 structural	 motif	
consisting	 of	 3-phenylpropionic	 acid	 and	 histidine	 moieties,	 exhibited	 moderate	
potency	 (high	 micromolar	 Ki)	 towards	 human	 SR	 (Dixon	 et	 al.,	 2006).	 Using	 a	
biochemical	 assay	 to	 evaluate	 enzyme	 kinetics,	 the	 authors	 concluded	 the	 inhibitors	
were	slow	binding	and	were	competitive	with	respect	to	L-serine.	
	
A	new	group	of	SR	 inhibitors	was	 identified	by	Mori	and	colleagues,	by	multi-filter	 in	
silico	 screening	of	a	4	million	 compound	database	using	one	of	 the	dipeptide-like	SR	
inhibitors	reported	by	Dixon	et	al.	as	the	query	molecule,	then	follow-up	confirmation	
by	in	vitro	enzyme	assay	(Mori	et	al.,	2014).	The	compounds	identified	from	the	screen	
contained	 an	 essential	 central	 amide	 structure	 with	 a	 phenoxy	 substituent,	 and	
substitution	of	parts	of	the	structure	for	heavier	halogen	atoms	such	as	bromine	and	
iodine	 produced	 derivatives	 with	 improved	 inhibitory	 activity,	 binding	 affinity,	 and	






mouse	 strain,	 in	 which	 brain	 activity	 could	 be	 detected	 by	 bioluminescence	 signal	
(Izumi	et	al.,	2017).	Acute	injection	of	kainate	increased	signal	intensity	in	the	brain	of	
control	mice	owing	 to	activation	of	high	affinity	KA-type	glutamate	 receptors,	but	 in	
mice	 orally	 administered	 the	 SR	 inhibitor	 beforehand,	 the	 intensity	 in	 regions	 of	
interest	 was	 reduced	 by	 about	 1.4-fold.	 The	 results	 suggested	 the	 SR	 inhibitor	
suppressed	 neuronal	 activity-dependent	 Arc	 expression	 in	 vivo	 to	 regulate	 NMDAR	
overactivation.		
	
Aside	 from	these	bulky	hydrophobic	peptides,	most	 identified	SR	 inhibitors	are	small	
molecules,	indicating	an	inherent	difficulty	in	targeting	the	tight	cleft	of	the	active	site.	
Indeed,	 another	 novel	 family	 of	 SR	 inhibitors	 discovered	 through	 screening	 of	
structurally	 diverse	 small	molecules	 are	 the	hydroxamic	 acids,	with	 the	most	 potent	
being	succinodihydroxamic	acid	 (IC50	=	90	µM;	Hoffman	et	al.,	2009a).	Unfortunately,	
these	 inhibitors	 were	 non-specific,	 as	 their	 additional	 inhibition	 to	 other	 PLP-
















micromolar	 range,	 some	 studies	 have	 focused	 on	 expanding	 the	 chemical	 space	 of	
existing	hSR	inhibitors	to	 improve	their	potency.	One	group	performed	virtual	screen	
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analyses	 and	molecular	modelling	 to	 elicit	 eight	 compounds	with	 putative	 inhibitory	
activity,	 including	 two	 that	 are	 structurally	 diverse	 from	any	previously	 identified	 SR	
inhibitor	 (Dellafiora	et	al.,	2015).	When	evaluated	 in	 in	vitro	experiments	on	purified	
hSR,	 four	of	 the	eight	exhibited	a	good	 inhibitory	effect,	but	weak	potency	 (59–70%	
inhibition,	 Ki	=	1.3–1.7	mM),	 which	 are	 characteristics	 similar	 to	 inhibitors	 identified	
previously	 (Mori	 et	al.,	 2014,	Beato	 et	al.,	 2015).	 The	 common	characteristics	of	 the	
active	inhibitors	include	the	presence	of	at	least	one	carboxyl	group	that	interacts	with	
Ser83	—	part	 of	 the	 substrate-binding	 loop	 in	 the	 active	 site	—	and	 a	 simultaneous	
binding	to	Arg135	at	the	top	of	the	active	site	(Dellafiora	et	al.,	2015).	Another	group	
of	 SR	 inhibitors	 is	 composed	 of	 substrate-product	 analogues,	 which	 have	 limited	
efficacy	unless	 there	 is	a	 lot	of	 space	 in	 the	active	 site	or	 the	 inhibitor	 is	 sufficiently	




colleagues	 found	 that	 glial	 SR	 localised	 to	membranes	 is	 physiologically	 inhibited	 by	
phosphatidylinositol	 (4,5)-bisphosphate	 (PIP2),	 and	 this	 inhibition	 is	 relieved	 after	
mGluR	activation	 leads	to	phospholipase	C-mediated	degradation	of	PIP2	 (Mustafa	et	
al.,	 2009).	PIP2	acts	as	a	noncompetitive	 inhibitor	by	binding	adjacent	 to	 the	SR	ATP	
site	and	preventing	binding	of	ATP	to	SR,	which	is	critical	for	regulating	SR	activity.	This	
is	 supported	 by	 findings	 that	 when	 apyrase	 is	 used	 to	 hydrolyse	 the	 γ-	 and	 β-	






was	 found	 D-serine	 synthesis	 was	 largely	 inhibited,	 implying	 SR	 activity	 could	 be	
converted	 to	 an	 eliminase	 in	 vivo	 (Panizzutti	 et	 al.,	 2001).	 Based	 on	 the	 findings	 of	
Panizzutti	et	al.,	 the	 first	 in	 vivo	SR	 inhibitor	 study	was	performed	 in	 a	 rat	model	of	
arthritic	 pain.	 Intrathecal	 injection	 of	 LSOS	 and	 L-EHA	 decreased	wind-up	 activity	 in	
normal	and	monoarthritic	rats,	producing	antinociceptive	effects	in	both	rat	groups,	as	
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well	 as	 significantly	 lowering	 hyperalgesia	 in	 the	 monoarthritic	 rats	 (Laurido	 et	 al.,	
2012).	 Subsequent	 injection	of	D-serine	 reinstated	 the	hyperalgesia	 in	monoarthritic	
rats	and	analgesia	in	normal	rats,	possibly	implying	that	SR	inhibitors	can	modulate	D-
serine	and	NMDAR	activity	 levels	 in	 vivo	 as	well	 as	 the	development	of	 chronic	pain	




data	 that	 indicate	 targeting	 SR	 is	 a	 viable	 approach	 to	modulating	 NMDAR	 activity,	
specifically	 for	 CNS	 disorders	 resulting	 from	 NMDAR	 overactivation	 such	 as	
excitotoxicity	 and	 neuropathic	 pain.	 However,	 it	 is	 not	 clear	 at	 this	 time	 whether	
inhibiting	SR	would	have	an	overall	positive	therapeutic	benefit	in	humans	or	not.	For	
instance,	SR-KO	mice	display	cognitive	deficits,	while	upregulating	D-serine	appears	to	




but	 is	 limited	by	the	 lack	of	highly	potent	and	selective	SR	 inhibitors	that	could	drive	
the	 drug	 discovery	 process.	 It	 is	 the	 intention	 of	 this	 thesis	 to	 contribute	 to	 the	


























































































The	 entire	 drug	discovery	 process,	 from	 the	point	 of	 inception	 through	 to	 filing	 and	
licensing	of	a	compound	by	the	regulatory	authorities	(e.g.	FDA	or	EMA)	is	a	complex	
process	 that	 can	 take	 10–15	 years	 and	 cost	 over	 $1	 billion	 (Hughes	 et	 al.,	 2011).	
Normally	 a	 particular	 target	 will	 emerge	 with	 several	 years’	 worth	 of	 supporting	
evidence	 (e.g.,	 genetic	 or	 pathological	 association	 with	 a	 disease,	 pharmacological	
validation	in	cellular	or	in	vivo	models	that	compounds	targeting	the	protein	of	interest	
produce	a	disease-relevant	phenotype)	that	to	ensure	it	is	worth	the	time	and	money	
invested	 in	 the	process.	 Then,	 it	will	 be	 subject	 to	 the	preclinical	 stages	of	 the	drug	
discovery	 process	 either	 by	 the	 pharmaceutical	 industry	 or	 academic	 drug	 discovery	
centres	 to	 identify	 molecules	 that	 engage	 with	 this	 target	 and	 have	 suitable	
characteristics	 to	 make	 potential	 drugs.	 These	 key	 preclinical	 stages	 are:	 target	






Target	 identification	 requires	 a	 thorough	 understanding	 of	 the	 disease	 and	 would	
ideally	yield	a	target	that	is	efficacious,	safe,	and	most	importantly,	‘druggable’	—	that	
is,	accessible	to	drug	molecules	and	is	able	to	elicit	a	biological	response	both	in	vitro	
and	 in	 vivo.	Often	 the	 aetiology	 of	 CNS	 disorders	 can	 be	 poorly	 understood,	 which	












Here,	 the	 role	 of	 a	 target	 in	 disease	must	 be	 clearly	 defined	 by	 generating	 cellular	
and/or	in	vivo	data	to	support	the	hypothesis	that	modulation	of	the	target	produces	a	
disease-relevant	 phenotype.	 The	 techniques	 employed	 range	 from	 the	 use	 of	 tool	
compounds	to	gather	information	about	the	target	in	vitro	and	in	vivo,	to	whole	animal	
models,	 to	 modulation	 of	 a	 desired	 target	 in	 disease	 patient.	 Target	 validation	
methods	can	include	antisense	technology	to	target	mRNA,	preventing	translation	and	
blocking	synthesis	of	the	protein	of	interest	(Taylor,	1999),	and	a	related	approach	of	
using	 small	 interfering	 RNA	 (siRNA)	 that,	 once	 integrated	 into	 an	 RNA-induced	
silencing	complex	(RISC),	can	base-pair	to	their	target	mRNA	to	induce	cleavage	of	the	
mRNA	 and	 prevent	 it	 being	 translated	 (Castanotto	 and	 Rossi,	 2009).	 Methods	
employing	 monoclonal	 antibodies	 have	 the	 advantage	 of	 neutralising	 the	 target	
protein	more	efficiently	due	 to	 their	ability	 to	bind	 to	a	 larger	 region	of	 the	protein,	
often	with	 higher	 affinity,	 at	 unique	 epitopes	 outside	 of	 the	 often	 highly	 conserved	
active	site	(Hughes	et	al.,	2011).	Perturbation	of	expression	of	the	target	gene	by	any	
of	 the	 above	 techniques,	 or	 by	 overexpression	 of	 cDNA	 and	 gene	 inhibition	 by	 a	
chemical	 compound,	 can	 produce	 valuable	 cellular	 model	 systems	 with	 the	 desired	
phenotype	so	the	role	of	the	target	gene	can	be	studied	(Gashaw	et	al.,	2012).		
	
Chemical	 genomics	 is	 an	 approach	 that	 aims	 to	 provide	 small	 molecules	 targeting	
every	 protein	 encoded	 by	 the	 genome	 (Zanders	 et	 al.,	 2002),	 and	 has	 been	 largely	
made	possible	by	developments	 in	 in	 silico	 technology	 to	 aid	 the	 synthesis	of	 highly	
focused	 libraries	 containing	 structures	 with	 a	 high	 probability	 of	 interacting	 with	
ligand-binding	sites	on	the	target	protein.	
	
If	 possible,	 the	 relevance	 of	 a	 target	 in	 disease	 can	 be	 evaluated	 in	 knockout	 or	
transgenic	animal	models	of	 the	disease,	 assuming	appropriate	models	exist.	Animal	
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models	 can	 be	 useful	 because	 they	 allow	 the	 effect	 of	 gene	 manipulation	 to	 be	







An	 assay	 format	 needs	 to	 be	 developed	 to	 enable	 characterization	 of	 novel	
compounds	and	their	potency	against	the	target,	which	can	then	be	used	to	develop	
structure-activity	relationships	(SARs).	Generally,	two	types	of	assay	are	preferentially	
used:	 cellular	 assays,	 which	 depend	 on	 the	 creation	 of	 mammalian	 cell	 lines	 over-
expressing	the	target	of	interest	and	are	most	applicable	for	membrane	receptors,	ion	
channels,	and	nuclear	receptors	(Michelini	et	al.,	2010);	and	biochemical	assays,	which	
are	 used	 to	 evaluate	 and	 characterise	 purified	 recombinant	 protein.	 Both	 generate	
different	 data,	 with	 cell-based	 assays	 giving	 a	 functional	 read-out	 if	 there	 is	 any	
compound	 activity,	 and	 biochemical	 assays	measuring	 the	 affinity	 of	 the	 compound	
with	 the	 target	 protein,	 and	 enzyme	 activity.	 A	 number	 of	 requirements	 have	 to	 be	
met	 before	 an	 assay	 can	 be	 used	 for	 screening	—	data	 must	 be	 reproducible	 and	
repeat	literature	values	where	relevant,	the	assay	signal	must	be	robust,	it	needs	to	be	





A	 ‘hit’	 compound	 is	 often	 defined	 as	 one	 that	 has	 a	 desired	 activity	 in	 a	 compound	
screen	and	whose	activity	is	confirmed	upon	retesting.	These	hits	may	be	identified	by	
high	throughput	screening	(HTS)	which	involves	screening	an	entire	compound	library	
against	 the	 drug	 target	 in	 the	 previously	 established	 assay.	 This	 method	 requires	
automated	 laboratory	 machinery	 to	 achieve	 high	 throughput	 processing,	 so	 can	




the	 protein	 target,	 based	 on	 knowledge	 of	 the	 target	 and	 chemicals	 with	 similar	
structures	which	are	already	known	to	have	some	activity	at	the	target	(Boppana	et	al.,	
2009).	 The	 information	 obtained	 from	 knowledge-based	 screening	 has	 enabled	 the	
rapid	 development	 of	 computational	 screening	 methods	 that	 use	 known	






A	 newer	 approach,	 focusing	 on	 using	 much	 smaller	 molecules	 than	 in	 a	 standard	






are	 required	 to	 span	 the	 chemical	 diversity	 space	 than	with	 lead	 compounds;	 this	 is	
useful	 for	 popular	 targets	 where	 the	 surrounding	 literature	 may	 be	 saturated	 with	
identified	compounds	and	so	provides	an	additional	approach	to	tackle	the	target.	The	
other	 advantage	 of	 FBDD	 methods	 is	 that	 they	 can	 find	 chemotypes	 that	 bind	 to	
difficult	 targets,	 such	as	ones	seemingly	not	very	 ‘druggable’	when	put	 through	HTS.	
This	has	particular	relevance	to	SR,	whose	two	domains	form	a	very	tight	cleft	that	is	
not	 accessible	 to	 large	 molecular	 weight	 compounds,	 and	 has	 meant	 previous	
compound	screens	of	SR	in	a	biochemical	assay	system	yielded	no	hits.	Any	fragments	
that	 are	 found	 to	have	weak	 interactions	with	 the	 target	protein	 are	 assessed	using	
structural	knowledge	of	the	binding	site	to	allow	for	optimization	of	these	compounds	











SAR	based	on	what	 structural	 information	 is	 known	about	 the	 target	and	where	 the	







The	 aims	 of	 this	 thesis	 were	 as	 follows.	 Firstly,	 to	 develop	 a	 biochemical	 assay	 for	
measuring	 SR	 activity	 that	 could	 be	 optimised	 to	 a	 medium-throughput	 screening	
format.	Secondly,	to	conduct	a	fragment	screen	using	this	biochemical	assay	and,	using	
a	 fragment-based	 drug	 discovery	 strategy,	 identify	 potential	 inhibitors	 of	 SR	 with	
desirable	potencies.	Thirdly,	 to	confirm	binding	of	any	promising	 inhibitory	hits	using	
biophysical	methods,	 principally	 X-ray	 crystallography.	 The	 overall	 aim	 of	 this	 thesis	
was	 to	 generate	 novel	 hit	 matter	 that	 could	 ultimately	 be	 used	 to	 drive	 medicinal	
chemistry	 efforts	 in	 the	 development	 of	 novel	 SR	 inhibitory	 compounds	 that	 have	 a	








drug	 discovery	 projects,	 which	 often	 comprise	 biochemical	 assay	 development,	
compound	 library	 screening,	 biophysical	 validation	 methods	 and	 crystallography.	 In	
many	cases,	 including	 the	current	 study,	protein	 is	produced	 in-house	 to	 circumvent	
the	 expense	 of	 repeatedly	 purchasing	 commercial	 samples.	 The	 large-scale	 protein	
generation	 described	 in	 this	 chapter	 consists	 of	 SR	 expression	 in	 a	 bacterial	 host,	






modifications,	 low	 cost,	 and	 potential	 for	 mass	 production	 (Demain	 and	 Vaishnav,	
2009).	The	use	of	bacterial	expression	systems	in	reports	of	recombinant	SR	expression	
has	been	almost	unanimous	since	the	method	was	first	described	(Foltyn	et	al.,	2005,	
Nagayoshi	 et	 al.,	 2005,	 Strísovský	 et	 al.,	 2005,	 Ohnishi	 et	 al.,	 2008,	 Hoffman	 et	 al.,	
2009b).	 The	 abundance	 of	 literature	 describing	 expression	 of	 recombinant	 SR	 in	
bacterial	systems	influenced	the	ultimate	selection	of	an	E.	coli	expression	system	for	
the	 experiments	 described	 in	 this	 chapter.	 Specifically,	 SR	 was	 expressed	 in	 E.	 coli	
BL21-CodonPlus	(DE3)-RIL	cells,	which	contain	a	chloramphenicol	resistance	gene	and	








protein	 aggregates,	 commonly	 known	 as	 inclusion	 bodies	 (Singh	 et	 al.,	 2015).	 	 It	 is	





method	 of	 SR	 purification	 resulted	 in	 His-hSR	 being	 expressed	 in	 bacterial	 inclusion	
bodies,	with	 50%	 able	 to	 be	 refolded	 (Nagayoshi	 et	 al.,	 2005),	 subsequent	methods	
where	 hSR	 is	 expressed	 in	 BL21-CodonPlus	 (DE3)-RIL	 cells	 resulted	 in	 its	 purification	
directly	from	the	soluble	fraction	(Dixon	et	al.,	2006,	Hoffman	et	al.,	2009b).	
	
IMAC	 is	 used	 to	 purify	 recombinant	 proteins	 containing	 a	 short	 affinity	 tag	 of	 six	
histidine	residues,	which	is	able	to	interact	with	a	transition	metal	ion	(Co2+,	Ni2+,	Cu2+,	
Zn2+)	 immobilised	 on	 a	 matrix	 (Bornhorst	 and	 Falke,	 2000).	 The	 development	 of	
commercially	available	matrices	 such	as	nickel-nitrilotriacetic	acid	 (Ni2+-NTA)	coupled	
to	a	solid	support	resin	have	 improved	protein	yields	and	purity	by	preventing	metal	
leaching	 from	 the	 matrix	 (Hochuli	 et	 al.,	 1987).	 Histidine	 contains	 electron	 donor	
groups	on	its	imidazole	ring	that	readily	form	coordination	bonds	with	the	immobilised	





purifying	 proteins	 such	 as	 SR	 with	 polyhistidine	 tags.	 However,	 the	 potential	 for	
nonspecific	 binding	 to	 occur	 by	 histidine	 residues	 in	 contaminating	 proteins,	 or	 by	
nonspecific	 hydrophobic	 residues,	means	 that	 achieving	 highly	 homogenous	 protein	
samples	is	only	possible	with	additional	purification	techniques	such	as	SEC.	
	
SEC	 is	used	 to	separate	proteins	by	 their	 size	as	 they	pass	 through	a	column	packed	
with	SEC	medium	that	consists	of	inert	spherical	particles	containing	pores.	Superdex,	
			 79	
used	 here	 (Mw	 range	 10–600	kDa),	 consists	 of	 dextran	 covalently	 attached	 to	 highly	
cross-linked	agarose	 (GE	Healthcare	Life	Sciences,	2017).	Buffer	pumped	through	the	
column	is	in	equilibrium	between	the	stationary	phase	(liquid	in	the	pores)	and	mobile	
phase	 (liquid	 outside	 the	 particles).	 Small	 proteins	 and	 molecules	 diffuse	 more	
frequently	 into	 the	 bead	 pores	 so	 are	 delayed	 when	 passing	 through	 the	 column,	
causing	 the	 largest	molecules	 to	 be	 eluted	 first	 and	 subsequent	 proteins	 to	 elute	 in	
order	 of	 decreasing	 size	 (Hong	 et	 al.,	 2012).	 Detection	 by	 UV	 at	 280	nm	 is	
predominantly	used	for	SEC	analyses,	which	gives	a	response	for	aromatic	amino	acids	
such	 as	 tryptophan	 (Hong	 et	 al.,	 2012).	 As	 SEC	 separates	 proteins	 based	 on	 size,	
different	oligomers	and	aggregated	protein	would	be	distinguishable	by	distinct	peaks	
in	 the	 resulting	 UV	 chromatogram.	 For	 example,	 aggregates	 usually	 have	 a	 high	
molecular	weight	so	are	characterised	by	their	elution	in	the	void	volume2.		
	
SEC	 purification	 has	 the	 additional	 benefit	 of	 improving	 and	 assessing	 protein	
homogeneity.	 For	 successful	 crystallisation,	 purified	 protein	must	 be	monodispersed	
—	meaning	 that	 it	 exists	 in	 solution	a	 single	oligomeric	 species	 such	as	monomer	or	
dimer	—	and	it	must	be	free	of	aggregates.	To	some	extent,	the	monodispersity	of	the	
purified	 protein	 can	 predicted	 from	 the	 shape	 of	 the	 SEC	 elution	 peaks;	 single	
symmetrical	Gaussian	peaks	usually	correspond	to	monodisperse	protein,	while	wide	
asymmetrical	 peaks	with	 shoulders	 or	 tailing	 edges	 signify	 polydisperse,	 unstable	 or	
unfolded	 protein	 (Ricker	 and	 Sandoval,	 1996).	 In	 this	 case,	 the	 only	way	 to	 confirm	
monodispersity	is	by	dynamic	light	scattering	(DLS).	Knowing	the	dominant	oligomeric	
species	 of	 SR	 also	 has	 particular	 relevance	 because	 the	 X-ray	 crystal	 structure	 of	 SR	
revealed	 it	 exists	 as	 a	 dimer	 (Smith	 et	 al.,	 2010)	 and	 because	 previous	 studies	 have	
demonstrated	SR	is	most	active	as	a	dimer	(Wang	and	Barger,	2011).	
	
The	 purification	 procedure	 outlined	 in	 this	 chapter	 was	 based	 on	 a	 pre-existing	
protocol	and	utilised	a	custom	pET-24a	plasmid	containing	the	human	SR	gene	linked	
to	 a	 polyhistidine	 tag.	 Both	 the	 protocol	 and	 plasmid	 were	 kindly	 provided	 by	 our	
																																																								




collaborators	 at	 Evotec,	who	were	 the	 authors	 behind	 the	 seminal	 paper	 describing	
the	first	solved	crystal	structures	of	SR	(Smith	et	al.,	2010).	Their	protocol	gave	several	
insights	 on	 the	 purification	 procedure	 with	 respect	 to	 optimising	 stability	 of	 SR,	 in	
particular	 the	 addition	 of	 pyridoxine	 to	 expression	media	 for	 its	 ultimate	 formation	
into	 the	 PLP	 cofactor,	 the	 addition	 of	 SR	 cofactors	 (such	 as	 ATP	 and	 Mg2+)	 to	
purification	buffers,	and	the	 importance	of	maintaining	protein	solubility.	The	Evotec	
authors	 introduced	cysteine-to-aspartate	point	mutations	 to	 two	N-terminal	 surface-
exposed	 residues,	Cys2	and	Cys6	 (C2,6D),	which	were	hypothesised	 to	affect	protein	
solubility	(Smith	et	al.,	2010).		
	
This	 chapter	 describes	 the	 protein	 expression	 and	 purification	 process	 utilised	 for	
large-scale	 generation	 of	 highly	 pure	 recombinant	 SR,	 from	 the	 initial	 steps	 of	 gene	
sequencing	 followed	 by	 transformation	 of	 E.	 coli	 with	 the	 pET-24a	 vector,	 to	 the	
expression	 of	 SR	 in	 liquid	 media,	 to	 the	 extraction	 and	 purification	 of	 SR	 from	 cell	
pellets.	Also	discussed	are	the	optimisation	steps	taken	to	improve	solubility	of	SR	and	
thus	 increase	 the	 final	 yield,	 as	 well	 as	 the	 numerous	 quality	 control	 methods	 that	
were	employed	to	confirm	the	presence	and	purity	of	SR,	such	as	SDS-PAGE,	western	
blot,	 and	 mass	 spectrometry.	 The	 methods	 described	 herein	 were	 imperative	 for	













































































































































purification	 purposes.	 Plasmid	 sequencing	 was	 performed	 by	 Eurofins	 Scientific	 UK.	











A	 100	μL	 aliquot	 of	 competent	 cells	 was	 thawed	 on	 ice	 for	 10	min,	 and	 2	μL	 of	 β-
mercaptoethanol	 (diluted	1:10	 in	dH2O	 from	kit	 stock	 solution)	was	added.	The	cells	
were	 incubated	 on	 ice	 for	 10	min,	 after	 which	 1	μL	 of	 the	 expression	 plasmid	 DNA	

















To	 prepare	 the	 preculture,	 a	 transformed	 colony	 was	 picked	 and	 inoculated	 into	
200	mL	LB	supplemented	with	chloramphenicol	(34	µg/mL)	and	kanamycin	(50	µg/mL),	
which	was	 then	 incubated	 at	 37	°C	overnight	with	 constant	 shaking	 at	 200	rpm.	Cell	
density	measurements	were	performed	using	 the	optical	 density	 at	 a	wavelength	of	
600	nm	(OD600)	to	determine	the	number	of	cells	present	in	the	bacterial	suspension.	
The	 OD600	 of	 the	 preculture	 was	 measured	 in	 the	 morning	 and	 typically	 reached	 a	
																																																								
3	SOC	(Super	Optimal	broth	with	Catabolite	repression)	is	a	nutrient-rich	bacterial	growth	medium	with	




the	 preculture	 was	 diluted	 into	 1	L	 LB	 medium	 (1%	 v/v)	 in	 eight	 2	L	 flasks,	
supplemented	with	the	antibiotics	and	0.01%	pyridoxine.	 	Pyridoxine	is	the	precursor	
of	pyridoxal	phosphate	 (PLP)	and	 is	used	by	 the	expressing	cells	 to	produce	PLP,	 the	
cofactor	essential	for	the	racemisation	and	β-elimination	activity	of	SR.		
		
The	main	cultures	were	 incubated	with	 shaking	at	37	°C,	200	rpm,	 for	approximately	
3–4	h.	The	OD600	was	checked	periodically	until	it	reached	0.6–0.8,	at	which	point	the	
flasks	were	kept	at	4	°C	to	stall	growth	until	the	end	of	the	day.	The	cultures	were	then	
induced	 with	 0.5	mM	 IPTG	 and	 incubated	 for	 a	 further	 16	h	 overnight	 at	 25	°C,	
200	rpm.	 The	 cells	 were	 harvested	 by	 centrifugation	 at	 8	500	×	g,	 4	°C	 for	 25	min	






immobilised	 metal	 ion	 affinity	 chromatography	 (IMAC)	 and	 size-exclusion	





Sonics)	 at	 40%	amplitude,	 30	s	 pulse	 on	 and	 30	s	 pulse	 off	 for	 2.5	min	 (total	 5	min).	
Following	 this,	 cell	 debris	 was	 pelleted	 by	 centrifugation	 at	 40	000	×	g,	 4	°C,	 for	 1	h	




Resin	 (Generon).	 The	 histidines	 of	 the	 protein	 (His)6-tag	 contain	 an	 imidazole	 side	




rinsing	with	water	 to	 remove	air	bubbles,	after	which	8	mL	 resin	 suspension	 (in	20%	
ethanol)	was	added	to	the	column.	The	ethanol	was	discarded	in	the	flow-through	and	
the	column	was	washed	with	10	CV	 (column	volumes,	 i.e.	 resin	volume	used)	water.	
The	 column	 was	 then	 washed	 with	 10	CV	 Buffer	 B	 to	 equilibrate	 the	 resin.	 The	
supernatant	from	the	cell	 lysis	step	was	filtered	(0.45	mm)	and	added	to	the	column,	






imidazole	 concentration	 (250	mM)	 to	 displace	 the	 SR-(His)6	 from	 the	 beads.	 The	






SEC	 purification.	 A	 HiLoad	 26/600	 Superdex	 75	 prep	 grade	 column	 (GE	 Healthcare)	
connected	 to	an	ÄKTA-purifier	 fast	protein	 liquid	 chromatography	 (FPLC)	 system	 (GE	
Healthcare)	 was	 used	 throughout	 the	 SEC	 purification	 process.	 One	 CV	 of	 the	 SEC	
column	is	equal	to	320	mL.	The	column	was	first	washed	with	1	CV	phosphate-buffered	




















spectrophotometer	 (ThermoFisher	 Scientific).	 The	 molecular	 weight	 (Mw)	 and	
extinction	 coefficient	 (ε)	were	 taken	 from	 the	 ProtParam	 tool	 on	 the	 ExPASy	 online	





Fractions	were	assessed	 for	 the	presence	and	purity	of	 SR	by	SDS-PAGE,	based	on	a	
process	 first	 described	 by	 Laemmli	 (Laemmli,	 1970).	 Samples	 were	 denatured	 with	
NuPage®	 LDS	 (Lithium	 Dodecyl	 Sulfate)	 4X	 sample	 buffer	 (Life	 Technologies)	 and	
heated	at	 95	°C	 for	3–5	min.	Non-aqueous	 samples	 (such	as	whole-cell	 pellets)	were	




well	 NuPage®	 Novex®	 4-12%	 BisTris	 protein	 gels,	 (Life	 Technologies)	 in	 conjunction	








well,	 in	conjunction	with	a	Precision	Plus	Protein™	Dual	Color	 stained	protein	 ladder	
(Bio-Rad).	 PVDF	 membranes	 were	 cut	 to	 the	 same	 size	 as	 the	 gels	 and	 soaked	 in	
methanol	 for	5–10	min.	 The	 cassette	was	prepared	by	 soaking	 it	with	 the	 two	mesh	
layers	 and	 two	 filter	 papers	 in	 prechilled	 Towbin	 buffer.	 Once	 the	 cassette	 was	
assembled,	protein	transfer	onto	the	membrane	was	achieved	with	a	constant	voltage	
of	100	V	for	30	min.	To	prevent	non-specific	interactions	between	the	membrane	and	
the	antibodies,	 the	membranes	were	 incubated	 in	TBST	buffer	+	5%	non-fat	dry	milk	
and	rocked	for	2	h.	For	the	primary	antibody	incubation	(SR	rabbit	polyclonal	IgG),	the	




for	 1	h,	 and	 the	 membrane	 washed	 as	 before.	 The	 membrane	 was	 blot	 dried	 and	
transferred	to	Clingfilm	where	ECL	reagent	was	pipetted	on	top	(1:1	of	A	and	B)	and	
was	sealed	with	Clingfilm	after	2	min.	The	membrane	was	exposed	to	X-ray	 film	 in	a	





SR	was	 analysed	 by	 SDS-PAGE	 and	 the	 bands	were	 visualised	with	Quick	 Coomassie	
Stain	(Generon).	Bands	were	excised	and	were	prepared	for	mass	spectrometry	with	a	
trypsin	digestion	(In-Gel	Tryptic	Digestion	Kit,	ThermoFisher	Scientific)	according	to	the	
manufacturer	 protocol,	which	 is	 briefly	 as	 follows:	 the	 destained	 band	was	 reduced	
and	 alkylated	 to	 maximise	 the	 sequence	 coverage,	 then	 shrunk	 with	 acetonitrile.	
Activated	 trypsin	 was	 applied	 to	 the	 band	 and	 incubated	 for	 15	min	 at	 RT.	 The	














unanimously	 revealed	 that	 the	 plasmid	 contained	 a	 nucleotide	 sequence	 for	Homo	
sapiens	 serine	 racemase,	 with	 a	 sequence	 homology	 of	 99–100%	 depending	 on	 the	
transcript	variant.		
	
The	 plasmid	 sequence	 and	 the	 first	 transcript	 variant	 (accession	 number	
XM_011523974.2)	 were	 then	 directly	 compared	 via	 a	 pairwise	 sequence	 alignment	
using	 the	 EMBOSS	Needle	 online	 tool.	 The	 sequence	 alignment	 (Fig.	2.1)	 showed	 an	
almost	 identical	 (99.5%)	 sequence	 identity	 between	 the	 plasmid	 sequence	 and	 the	
most	 closely	matched	 transcript	 variant,	with	 the	exception	of	 four	nucleotide	point	
mutations,	 TGT	 to	 GAT	 and	 TGC	 to	 GAC.	 These	 codon	 changes	 correspond	 to	 two	
cysteine-to-aspartate	substitutions	(C2D,	C6D),	which	are	unique	to	this	gene	construct.	





Following	cell	 lysis	and	centrifugation,	SR	was	purified	 from	the	soluble	 fraction.	The	
solubilised	SR	was	applied	 to	a	Co2+-NTA	 resin	 so	 the	polyhistidine	 tag	could	bind	 to	
the	 beads.	 The	 column	 was	 washed	 twice	 with	 Buffer	 B,	 which	 contained	 a	 small	
amount	(10	mM)	of	imidazole	to	remove	non-binding	proteins	by	eluting	contaminants	
that	are	weakly	bound	to	the	column	through	non-specific	binding	or	integral	histidine	










Analysis	 of	 all	 the	 purification	 fractions	 was	 performed	 by	 SDS-PAGE	 and	 the	 gel	 is	
presented	 in	 Fig.	2.2.	 Bands	 at	 approximately	 37	kDa,	 the	 molecular	 weight	 of	 SR,	
appear	in	almost	all	of	the	lanes.	It	was	to	be	expected	that	small	amounts	of	SR	would	
remain	 in	 the	 whole-cell	 insoluble	 fraction	 and	 the	 unbound	 fraction	 because	 it	 is	




The	 dense	 bands	 at	 approximately	 37	kDa	 in	 the	 elution	 fractions	 indicate	 the	
presence	 of	 concentrated	 SR,	 so	 those	most	 enriched	 (usually	 E1,	 E2	 and	 E3)	 were	
pooled	 and	 concentrated	 to	 10	mL	 prior	 to	 loading	 onto	 the	 SEC	 column.	 The	 faint	
bands	at	approximately	74	kDa	correlate	with	the	molecular	weight	of	dimeric	SR;	it	is	
not	unusual	for	trace	amounts	of	oligomeric	or	aggregated	protein	species	to	remain	
after	 SDS-PAGE,	 even	 under	 denaturing	 conditions.	 Other	 bands	 that	 appear	 in	 the	





The	 protein	 purity	 achieved	 with	 IMAC	 purification	 would	 be	 suitable	 for	 assay	
development,	 but	 the	 much	 greater	 degree	 of	 purity	 (>95%)	 required	 for	
crystallography	 is	 only	 achieved	 by	 additional	 SEC	 purification.	 Ideally	 a	 singular,	
isolated	 peak	 of	 pure	 protein	 would	 appear	 in	 the	 UV	 trace,	 but	 often	 they	 may	
coincide	 with	 other	 peaks;	 these	 may	 reflect	 aggregated	 protein,	 or	 a	 different	
oligomeric	form	of	the	target	protein.	The	aggregation	peaks	are	discernable	by	their	










fraction	was	 removed	 from	 the	 IMAC	column	and	checked	 for	 trace	amounts	of	unbound	SR	 (5).	 The	
column	was	washed	twice	with	SR	equilibration	buffer,	giving	two	75	mL	fractions	(6	&	7).	SR	was	finally	
eluted	with	a	high-imidazole	buffer,	giving	five	18	mL	fractions	(8,	9,	10,	11	&	12).	The	 lysate,	soluble,	

















In	 initial	experiments,	a	 large	aggregation	peak	appeared	 in	 the	UV	 trace	during	SEC	
purification	 (Fig.	2.3A),	 almost	 equal-sized	 to	 the	 purified	 SR	 peak	 and	 so	
representative	 of	 a	 significant	 amount	 of	 protein	 that	 had	 been	 lost	 to	 aggregate.	



















to	be	made	 to	 the	purification	 conditions	 to	 improve	 SR	 solubility,	 thereby	 reducing	
aggregation	and	maximising	the	overall	yield	of	purified	SR.	Glycerol	is	well-known	to	










(A)	 UV	 chromatogram	 detected	 at	 280	nm	 of	 the	 fractions	 eluted	 from	 the	 SEC	 column;	 each	 2	mL	
fraction	was	eluted	into	a	96-well	plate	and	the	well	positions	are	shown	the	red	lettering	above	the	x-
axis.	 Peak	 1	 (aggregate)	 eluted	 at	 117	mL	 and	 Peak	 2	 (soluble	 protein)	 eluted	 at	 137	mL.	 (B)	 The	
fractions	corresponding	to	the	each	peak	were	analysed	by	denaturing	SDS-PAGE	and	bands	at	approx.	










coupled	 biochemical	 assay.	 The	 soluble	 SR	 isolated	 from	Peak	 2	 had	 an	 approximate	 fivefold	 greater	







Moreover,	 the	SDS-PAGE	analysis	of	 the	 fractions	 corresponding	 to	 the	 soluble	peak	
(Fig.	2.5B)	shows	bands	of	highly	concentrated,	ultra	pure	SR	 that	correlate	with	 the	
increase	 in	 solubilised	 SR	 between	 the	 two	 SEC	 purifications,	 as	 indicated	 by	 the	
increase	in	UV	signal	(270	mAU	to	430	mAU).	SR	consistently	purified	in	this	manner	in	
successive	experiments,	and	 from	each	only	 the	purest	 fractions	of	 the	 soluble	peak	
were	isolated	and	concentrated	for	further	use.	 	




























(A)	 UV	 chromatogram	 detected	 at	 280	nm	 of	 the	 fractions	 eluted	 from	 the	 SEC	 column.	 Peak	 1	

















observing	 the	order	 in	which	 they	elute.	 It	 is	a	 relevant	application	here	as	 the	SDS-
PAGE	experiments	(Fig.	2.2,	2.3	and	2.5)	would	have	denatured	dimeric	SR.	A	46	kDa	









Western	 blot	 utilises	 antibodies	 that	 are	 specific	 to	 a	 unique	 epitope	 on	 the	 target	
protein	in	order	to	detect	specific	proteins	in	a	sample.	In	this	case,	the	epitope	of	the	
SR	antibody	corresponded	to	amino	acids	191–340	mapping	at	the	C-terminus	of	the	
protein.	 Three	 concentrations	 of	 SR	 (10	ng,	 50	ng,	 and	 100	ng)	 were	 run	 on	 an	
electrophoresis	 gel	 and	 analysed	 by	 chemiluminescent	 western	 blot	 (Fig.	2.7),	






Larger	 proteins	 elute	 from	 the	 SEC	 column	 first,	 so	 the	 order	 in	 which	 SR	 (Mw	=	37.4	kDa	monomer,	
74.8	kDa	dimer)	and	ovalbumin	(Mw	=	46	kDa)	elute	could	to	used	to	estimate	the	oligomeric	species	of	
SR.	Both	SR	(black	trace)	and	ovalbumin	(blue	trace)	were	loaded	onto	a	Superdex	75	10/300	GL	column	
and	 eluted	 at	 10.7	mL	 and	 11.8	mL,	 respectively.	 SR	 eluted	 from	 the	 column	 first,	 suggesting	 its	














































SR	was	purified	 in-house	and	 three	 concentrations	of	 SR	were	used	 to	perform	a	western	blot:	 10	ng	
(lane	 2),	 50	ng	 (lane	 3)	 and	 100	ng	 (lane	 4)	 per	 well.	 Lane	 1	 contains	 the	Mw	marker	 (Precision	 Plus	
Protein	Dual	Color,	Bio-Rad).	The	western	blot	was	performed	using	anti-SR	 rabbit	polyclonal	primary	
antibody,	 and	 goat	 anti-rabbit	 secondary	 antibody	 conjugated	 to	 HRP	 (both	 from	 Santa	 Cruz	
Biotechnology).	Bands	 in	 the	 region	of	 37	kDa	and	75	kDa	 correspond	 to	 SR	monomer	 (37.4	kDa)	 and	







in	 a	 sample,	 as	 well	 as	 the	 relative	 abundance	 of	 those	 compounds,	 so	 gives	 an	
indication	of	sample	purity	as	well.	Both	the	monomer	and	dimer	bands	were	excised	

















15	-	20	 722.4	 722.4	 K.AHINIR.D	
41	-	45	 667.4	 667.4	 R.NLFFK.C	
46	-	51	 823.4	 823.4	 K.CELFQK.T	
59	-	65	 699.4	 699.4	 R.GALNAVR.S	
66	-	74	 998.5	 998.5	 R.SLVPDALER.K	
78	-	96	 1911.0	 1911.0	 K.AVVTHSSGNHGQALTYAAK.L	
97	-	114	 1970.0	 1970.0	 K.LEGIPAYIVVPQTAPDCK.K	
116	-	135	 2228.0	 2228.0	 K.LAIQAYGASIVYCEPSDESR.E	
116	-	140	 2769.3	 2769.3	 K.LAIQAYGASIVYCEPSDESRENVAK.R	
199	-	205	 741.5	 741.5	 K.ALKPSVK.V	
206	-	221	 1816.8	 1816.8	 K.VYAAEPSNADDCYQSK.L	
224	-	241	 1958.0	 1958.0	 K.GKLMPNLYPPETIADGVK.S	
226	-	241	 1756.9	 1756.9	 K.LMPNLYPPETIADGVK.S	
242	-	253	 1355.8	 1355.8	 K.SSIGLNTWPIIR.D	
254	-	268	 1750.8	 1750.9	 R.DLVDDIFTVTEDEIK.C	
269	-	277	 1161.6	 1161.6	 K.CATQLVWER.M	
Figure	2.8.	Peptide	sequences	from	mass	spectrometry	analysis	of	purified	SR.	
(A)	Identified	peptides	(red)	from	SR	sample	matched	with	SR	sequence,	giving	50%	sequence	coverage.	










The	 results	 detailed	 in	 the	 preceding	 sections	 are	 a	 representative	 SR	 purification.	
















5.6	 2.5	 14	 Purification	optimisation	




5	 23.2	 1.2	 27.8	
Thermal	shift,	mass	spec,	
western	blot,	crystallography	
6	 27.7	 1.1	 30.5	 MST,	ITC,	crystallography	
7	 13.6	 1.2	 16.3	 MST,	ITC,	crystallography	





The	 SR	 production	 described	 in	 the	 current	 chapter	 was	 fundamental	 for	 this	 drug	
discovery	strategy	to	generate	the	large	amounts	of	protein	required	for	biochemical	
and	 biophysical	 assays,	 fragment	 screening,	 and	 crystallography.	 To	 this	 end,	 the	
purification	procedure	was	successfully	optimised	to	reduce	aggregation	and	maximise	






gene.	 Previous	 studies	 of	 recombinant	 SR	 purification	 reported	 high	 levels	 of	 SR	
located	 in	bacterial	 inclusion	bodies,	 caused	 in	part	 by	 codon	bias	 (Nagayoshi	 et	 al.,	
2005).	Likewise,	the	Evotec	authors	(Smith	et	al.,	2010)	initially	found	that	expression	
of	 wild-type	 SR	 yielded	 very	 low	 levels	 of	 soluble	 protein.	 By	 studying	 a	 homology	
model	 of	 the	 S.	 pombe	 SR	 structure,	 they	 identified	 the	 two	 N-terminal	 surface-
exposed	 cysteines,	 Cys2	 and	 Cys6	 as	 candidates	 for	 influencing	 protein	 solubility.	
Mutation	of	the	cysteines	to	aspartates	did	indeed	improve	protein	expression	and	the	
levels	of	soluble	enzyme,	possibly	by	preventing	the	formation	of	erroneous	disulphide	
bonds	 that	 could	 contribute	 to	 aggregation.	 The	 authors	 further	 stabilised	 the	 SR	
mutant	 with	 the	 addition	 of	 a	 C-terminal	 His-tag,	 yielding	 highly	 pure,	 stable,	 and	
homogenous	protein	that	had	comparable	activity	to	wild-type	SR	when	assessed	in	a	
biochemical	 assay.	 The	 availability	 of	 the	 optimised	 mutant	 SR	 plasmid	 here	
undoubtedly	facilitated	the	work	conducted	in	this	chapter.	
	
Although	 the	expression	construct	was	optimised	 to	mitigate	aggregation,	 there	was	
still	a	challenge	keeping	SR	solubilised	when	the	purification	was	performed	in-house.	
Aggregation	of	protein	molecules	into	inclusion	bodies	during	high-level	expression	of	




level	 of	 metabolic	 burden	 on	 the	 cells	 and	 a	 strain	 on	 the	 cellular	 quality	 control	
system	 of	 proteins,	 so	 partially-folded	 and	 misfolded	 proteins	 are	 more	 likely	 to	
aggregate	 (Carrió	and	Villaverde,	2005).	 It	 is	possible	 that	while	 the	BL21	CodonPlus	
(DE3)-RIL	 competent	 cells	minimise	 codon	 bias,	 they	may	 actually	 contribute	 to	 the	
aggregation	 observed	 throughout	 the	 purification	 by	 increasing	 expression	 levels.	
Additionally,	 the	 E.	 coli	 bacterial	 environment	 may	 lack	 the	 apparatus	 required	 to	
correctly	 fold	 human	 proteins	 like	 hSR,	 such	 as	 eukaryotic	 chaperones	 and	 post-
translational	machinery	(Carrió	et	al.,	2000).	
	
It	 is	 therefore	 likely	 that	 inclusion	 bodies	 will	 form	 during	 the	 expression	 and	
purification	 process,	 but	 this	 can	 be	 mitigated	 by	 altering	 the	 conditions	 so	 that	
inclusion	 bodies	 are	 solubilised	 and	 then	 refolded	 to	 recover	 functionally	 active	
protein	(Singh	et	al.,	2015).	Typically,	inclusion	bodies	can	be	solubilised	by	chaotropic	
agents	such	as	MgCl2	and	reducing	agents	such	as	DTT,	both	of	which	are	contained	in	
the	 lysis,	 equilibration,	 and	 elution	 buffers	 at	 concentrations	 of	 2mM	 and	 5mM,	
respectively.	The	solubilised	protein	can	then	be	refolded	by	removal	or	reduction	of	
the	solubilisation	agents,	which	in	this	case	occurs	during	elution	from	the	SEC	column	
in	a	refolding	buffer	containing	DTT	and	half	 the	concentration	of	MgCl2	 (1mM).	 It	 is	
during	this	process	of	refolding	that	the	problem	of	aggregation	commonly	occurs,	and	
indeed	was	seen	in	the	initial	purification	experiments	with	SR.	The	addition	of	glycerol	










yield	 and	 activity	 of	 SR	 were	 above	 that	 required	 for	 assays	 and	 crystallisation	
			 106	
experiments.	All	 purifications	 following	aggregation	optimisation	 consistently	 yielded	
approximately	3	mg	SR	per	litre	of	expression	medium,	sufficient	to	meet	the	demands	






optimise	 assays	 in	 the	 three	 key	 areas	 underpinning	 this	 thesis:	 biochemical	 assay	
development,	biophysical	methods,	and	crystallography.	The	next	chapter	focuses	on	









method	 of	 measuring	 SR	 activity	 needed	 to	 be	 developed	 to,	 firstly,	 characterise	
purified	 SR	 with	 respect	 to	 literature	 data,	 and	 secondly,	 develop	 an	 assay	 format	
suitable	 for	 screening	 large	 numbers	 of	 compounds	 against	 SR.	 The	 literature	 on	 SR	
was	 a	 valuable	 resource	 in	 this	 process	 because	 of	 the	 numerous	 different	 assay	
formats	from	which	to	draw	inspiration.		
	
A	 common	 published	method	was	 the	 use	 of	 separation	 techniques	 to	 quantify	 the	
relative	 amount	 of	 each	 serine	 isomer	 (L-serine	 and	 D-serine)	 such	 as	 capillary	
electrophoresis	 (CE;	Koval	et	al.,	2006,	Singh	et	al.,	2012)	or	high	performance	 liquid	
chromatography	(HPLC;	Wolosker	et	al.,	1999a,	Wolosker	et	al.,	1999b,	Strísovský	et	al.,	
2003,	 Foltyn	 et	 al.,	 2005).	 The	other	most	 frequently	 used	method	was	 the	 coupled	
enzyme	 assay,	 so	 called	 because	 it	 paired	 the	 racemisation	 reaction	 with	 a	 second	
reaction	 that	 degraded	 D-serine,	 and	 a	 third	 reaction	 quantified	 the	 resulting	
breakdown	 products.	 The	 final	 detection	 reaction	 could	 use	 lactate	 dehydrogenase	
(LDH)	 with	 spectrophotometric	 monitoring	 of	 decreasing	 NADH	 to	 detect	 pyruvate	
(Strísovský	 et	 al.,	 2003).	 Or,	 with	 the	 addition	 of	 DAO	 and	 horseradish	 peroxidase	




An	 important	 requirement	 for	 the	 assay	 format	 selected	 for	 this	 study	 was	 the	
potential	 to	be	modified	 for	medium-throughput	 screening.	This	 ruled	out	HPLC	and	
mass	 spectrometry	 assays,	 which	—	although	 beneficial	 for	 directly	 determining	 the	
presence	and/or	concentration	of	isomers	—	are	slow,	low-throughput,	and	unable	to	
screen	 thousands	 of	 molecules	 with	 follow-up	 IC50	 determinations	 in	 the	 384-well	
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format	 required	 for	 fragment	 screening.	 In	 contrast,	 a	 biochemical	 assay	 enabled	
important	 kinetic	 parameters	 to	 be	 determined	 (such	 as	Michaelis-Menten	 constant	





assay	 developed	by	 Smith	et	 al.	and	 the	 chemiluminescence	 assay	 developed	 in	 the	
Wang	and	Barger	paper	and	by	Wolosker	et	al.	The	 fluorescence	assay	was	 selected	
because	 the	 authors	 also	 utilised	 the	mutant	 SR	 (C2,6D)	 construct	 so	 data	 obtained	
here	would	be	directly	comparable.	Their	fluorescence	assay	coupled	the	racemisation	
of	L-serine	to	the	degradation	of	D-serine	product	by	DAO,	and	the	resulting	H2O2	was	
quantified	 by	 the	HRP-catalysed	 oxidation	 of	 AmpLite	 Red,	 a	 detection	 reagent	 that	
forms	a	fluorescent	product	after	oxidation.	The	luminescence	assay	was	also	selected	
as	 a	 viable	 option	 because	 of	 its	 similarity	 to	 the	 fluorescence	 assay	 (AmpLite	
substituted	 for	 luminol)	 and	 the	well-established	 record	of	using	 chemiluminescence	
to	quantify	H2O2	production.	To	summarise,	from	the	SR	assays	described	extensively	
in	the	literature,	coupled	biochemical	assays	were	deemed	the	most	attractive	method	
for	 measuring	 SR	 activity,	 and	 from	 those,	 fluorescence	 and	 luminescence	 were	
selected	as	potential	detection	techniques	pending	further	investigation.		
	
The	 assay	 ultimately	 used	 for	measuring	 activity	 of	 SR	was	 a	 coupled	 luminescence	
assay	 that	 indirectly	 quantified	 D-serine	 using	 luminol	 as	 a	 substrate	 (Fig.	 3.1).	 SR	
converts	 L-serine	 to	 D-serine,	 and	 the	 produced	 D-serine	 was	 then	 degraded	 by	 D-
amino	acid	oxidase	 (DAO)	 into	α-keto	acid	 (pyruvate),	 ammonia	 (NH3)	and	hydrogen	
peroxide	 (H2O2).	 The	 H2O2	 produced	 in	 the	 assay	 was	 quantified	 by	 the	 addition	 of	
horseradish	peroxidase	(HRP)	and	 luminol.	HRP	catalysed	the	oxidation	of	 luminol	by	
H2O2,	 producing	 a	 luminescent	 product	 that	was	measured	 in	 relative	 luminescence	









derivatives	 (Vorlová	 et	 al.,	 2015)	 and	 has	 also	 been	 crystallised	 in	 the	 SR	 active	 site	
(Smith	 et	 al.,	 2010).	 Malonate	 is	 one	 of	 the	 most	 potent	 SR	 inhibitors	 to	 date,	








An	 additional	 important	 consideration	 is	 the	 dual	 functionality	 of	 SR	—	racemisation	
and	β-elimination	—	and	the	effect	it	may	have	on	determining	the	assay	parameters.	
As	well	 as	 isomerising	 serine,	 SR	has	 the	 ability	 to	 catalyse	 the	 elimination	of	water	
from	L-serine	to	form	pyruvate	and	ammonia	(De	Miranda	et	al.,	2002).	Both	reactions	







Although	SR	β-elimination	may	have	 little	physiological	 relevance	 in	 terms	of	energy	
contribution,	 since	 its	 rate	 of	 pyruvate	 production	 is	 less	 than	 0.1%	 of	 pyruvate	
production	 from	 glucose	 (Dunlop	 and	 Neidle,	 2005),	 it	 still	 has	 the	 potential	 to	
compete	 with	 racemisation	 activity.	 The	 assay	 employed	 throughout	 this	 chapter	
measures	H2O2	as	an	 indirect	quantification	of	D-serine	produced,	and	as	H2O2	 is	not	
produced	 in	 the	 β-elimination	 reaction,	 this	 detection	 method	 can	 be	 considered	
specific	to	the	racemisation	reaction.	The	D-serine	measured	by	DAO	degradation	and	
chemiluminescence	 technically	 only	 reflects	 the	 net	 amount,	 that	 is,	 the	 D-serine	
produced	by	racemisation	minus	the	substrate	consumed	by	elimination.	With	this	in	
mind,	 a	 few	 other	 assumptions	 have	 to	 be	made	 regarding	 the	 coupled	 assay:	 that	





of	 AmpLite	 Red	 in	 favour	 of	 luminol,	 to	 the	 optimisation	 of	 assay	 reagents	 and	
conditions,	to	the	determination	of	kinetic	parameters,	and	ultimately	modification	of	
the	 assay	 for	medium-throughput	 screening.	 The	 latter	 step	 consisted	 of	 optimising	
the	 biochemical	 assay	 in	 384-well	 plates,	 with	 the	 multiple	 addition	 steps	 being	




















































































The	 following	 sections	 describe	 the	 methodology	 employed	 to	 develop	 a	 coupled	
biochemical	assay	using	luminol	as	a	detection	substrate,	and	the	adaptations	made	to	






Tris	mix	buffer	 (100	mM	Tris	pH	8.5,	 0.05%	Pluronic	 F-127,	 1	mM	MgCl2,	 1	mM	ATP,	
10	mM	PLP)	and	incubated	at	RT	for	20-30	min	for	single-point	experiments	and	up	to	
3	h	 for	 time-dependency	 experiments.	 The	 ‘back-end’	 chemiluminescence	 reaction	
was	 initiated	 after	 addition	 of	 30	μL	 of	 Detection	 Solution	 A	 (100	mM	 Tris	 pH	 8.5,		
0.05%	Pluronic	 F-127,	 2	mM	EDTA,	 1	U/mL	DAO,	 0.5	U/mL	HRP,	 50	µM	 luminol)	 and	
incubated	at	RT	 for	5-10	min	 to	allow	non-specific	 luminol	 luminescence	to	decrease	
before	 the	 signal	 was	 read	 with	 a	 BMG	 PHERAstar	 plate	 reader.	 The	 gain	 of	 the	




The	 above	 protocol	 was	 adapted	 slightly	 to	 test	 the	 effects	 of	 compounds	 (such	 as	















virtually	 all	 commercial	 samples.	 Up	 to	 200	mM	 L-serine	 was	 catabolised	 with	
1.5	U/mL	porcine	DAO	in	conjunction	with	3	U/μL	catalase	in	100	mM	Tris-HCl,	pH	8.5.	
The	mixture	was	incubated	overnight	at	37	°C	with	gentle	shaking,	then	was	heated	at	
95	°C	 for	 10	min	 to	 inactivate	 the	 enzymes.	 After	 centrifugation	 at	 13	000	rpm	 for	
10	min,	 the	 supernatant	 was	 collected	 and	 stored	 at	 -20	°C.	 Successful	 removal	 of	





Preliminary	 experiments	 were	 performed	 using	 AmpLite	 Red™	 (Stratech)	 as	 a	








Time	 course	 experiments	 enable	 the	 linear	 phase	 of	 the	 enzyme	 reaction	 to	 be	
observed.	A	 3	h	 time	 course	was	 first	 performed	 to	determine	 the	 reaction	plateau.	
Reaction	mixtures	were	prepared	 in	384-well	plates	 in	Tris	mix	buffer	and	contained	
five	 concentrations	 of	 SR	 (5	µL;	 final	 concentrations	 0.2,	 0.3,	 0.4,	 0.5,	 2	µM)	 and	 at	
each	 time	 interval	 (0–180	min)	 L-serine	 solution	 I	 was	 added	 (5	µL;	 final	 substrate	
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The	 Km	measures	 the	 affinity	 of	 an	 enzyme	 for	 its	 substrate	 and	 is	 constant	 for	 an	
enzyme/substrate	pair	under	a	specific	 set	of	assay	conditions.	Determination	of	 the	
Km	 allows	 comparison	 of	 kinetic	 parameters	 between	 enzyme	 sources,	 such	 as	 in-
house	 purification	 batches	 or	 literature	 data.	 A	 substrate	 concentration	 around	 or	
below	 the	Km	 should	be	used	 to	prevent	 excess	 substrate	overcoming	 the	action	of	
competitive	inhibitors	in	IC50	experiments.	
	
A	 10-point	 1:2	 serial	 dilution	 of	 L-serine	 was	 prepared	 in	 Tris	 mix	 buffer.	 Reaction	
mixtures	in	384-well	plates	containing	SR	solution	I	(5	µL;	final	concentration	400	nM)	
and	 each	of	 the	 ten	 concentrations	 of	 L-serine	 (5	µL;	 final	 concentrations	 0–50	mM)	
were	incubated	for	20	min	at	RT,	after	which	30	µL	Detection	Solution	A	was	dispensed	





The	 purpose	 of	 a	 dimethyl	 sulfoxide	 (DMSO)	 tolerance	 test	 is	 to	 ensure	 that	 the	
enzyme	being	tested	is	not	inhibited	by	DMSO	at	concentrations	required	for	screening,	









400	nM)	were	 incubated	with	each	of	 the	 ten	 intermediate	 concentrations	of	DMSO	
(2	μL;	final	concentrations	0–10%)	for	15	min	at	RT.	The	SR	reaction	was	started	with	
the	addition	of	L-serine	solution	II	(4	µL;	final	substrate	concentration	2	mM)	and	the	
reaction	 was	 incubated	 for	 20	min	 at	 RT.	 30	μL	 Detection	 Solution	 A	 was	 then	





The	 IC50	is	 the	concentration	of	a	compound	that	results	 in	50%	inhibition	of	enzyme	
activity,	 and	 is	 important	 for	 assessing	 the	 potency	 of	 an	 inhibitor,	 as	 well	 as	





prepared	 in	 100%	 DMSO	 from	 compound	 stocks	 of	 100	mM	 or	 10	mM	 DMSO.	 The	






started	 with	 the	 addition	 of	 L-serine	 solution	 II	 (4	µL;	 final	 substrate	 concentration	
2	mM)	 and	 the	 reaction	was	 incubated	 for	 20	min	 at	 RT.	 30	μL	Detection	 Solution	A	
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was	 then	 dispensed	 to	 all	 wells,	 and	 after	 a	 further	 10	min	 incubation	 the	
luminescence	signal	was	measured.	
	
Data	 were	 plotted	 as	 percentage	 inhibition	 using	 Graphpad	 Prism.	 IC50	 values	 were	
calculated	 and	 curves	 fitted	 using	 a	 variable	 slope	 model	 (four-parameter	 dose-
response	curve)	according	to	the	following	equation:	
	






The	 purpose	 of	 the	 plate	 test	 experiments	 was	 to	 develop	 an	 assay	 suitable	 for	
medium-throughput	 screening,	 therefore	 in	 addition	 to	 optimising	 standard	 assay	
parameters,	 further	optimisation	steps	were	performed	to	account	for	any	variability	
caused	 by	 introducing	 automation.	 Screening	 entire	 fragment	 libraries	 required	 the	
use	of	automated	liquid	handlers,	namely	a	Multidrop	Combi	(with	a	small	tube	metal	
tip	 dispensing	 cassette)	 for	 dispensing	 SR,	 L-serine,	 and	 Detection	 Solution,	 and	 a	
FluidX	Xpp-721	for	transferring	plates	of	compounds.	
	
Before	use,	 the	dispensing	head	of	 the	Multidrop	Combi	was	primed	with	 the	 assay	
solution	 to	ensure	 there	were	no	air	bubbles	 in	 the	 tubes	or	blocked	 tips.	After	use,	





The	purpose	of	 the	 first	plate	 test	was	 to	assess	 the	assay	window	with	automation	





A	 384-well	 plate	was	 preloaded	with	 Tris	mix	 buffer	 (5	μL)	 in	 columns	 1–12	 and	 SR	
solution	I	(5	μL;	final	concentration	400	nM)	in	columns	13–24.	L-serine	solution	I	(5	µL;	
final	 concentration	2	mM)	was	dispensed	 into	 all	wells	 to	 start	 the	 reaction	 and	 the	
plate	was	incubated	for	20	min	at	RT.	30	μL	Detection	Solution	A	was	then	dispensed	








As	with	 the	manual	 IC50	 assay,	 the	 automated	 IC50	 assay	 required	 an	 initial	 dilution	
from	 stock	 in	 DMSO,	 followed	 by	 an	 intermediate	 dilution	 into	 assay	 buffer,	 then	 a	




For	 the	 stock	 plate,	 a	 1:3	 serial	 dilution	 from	 1	M	malonate	 stock	 was	 prepared	 in		
100%	DMSO	in	all	rows	of	a	96-well	polypropylene	plate	(FluidX	Xpp-721	liquid	handler	
with	EZ-Load	8-channel	strip	tips).	The	intermediate	96-well	plate	was	preloaded	with	








23,	 and	 24	 (see	 Fig.	 3.2A	 for	 plate	 map).	 SR	 solution	 II	 (4	µL;	 final	 concentration	
400	nM)	was	 dispensed	 to	 columns	 3–22.	 The	 intermediate	 dilution	 series	was	 then	






this	 time,	 30	μL	Detection	 Solution	A	was	 dispensed	 to	 all	wells,	 and	 after	 a	 further	
incubation	 the	 luminescence	 signal	 was	 measured.	 For	 optimisation	 purposes,	 the	
length	of	this	final	incubation	was	varied	between	5–15	min,	and	the	interval	time	(the	










different	 inhibitor	 concentration	 in	 the	 10-point	 1:3	 dilution	 series.	 Each	 row	 represents	 one	
concentration	 series,	 therefore	 eight	 inhibition	 curves	 are	 obtained	 from	 each	 plate.	 (B)	 Plate	 map	







Data	 from	 plate	 test	 1	 were	 assessed	 for	 the	 robustness	 of	 the	 assay	 window	 and	
variability	 of	 signal	 using	 the	 coefficient	 of	 variation	 (CV).	 The	 CV	 is	 a	 standardised	
measure	of	dispersion	 that	describes	 the	amount	of	 variability	 relative	 to	 the	mean.	































colour	of	DAO,	caused	by	 its	cofactor	 flavin	adenine	dinucleotide	(FAD)	which	has	 its	
own	excitation	and	emission	spectra	of	450	nm	and	535	nm,	respectively	(Ramanujam,	







D-serine	 (refer	 to	 Methods	 3.3.2).	 To	 confirm	 the	 efficacy	 of	 this	 step,	 2	mM	 pre-
treated	 L-serine	 and	 untreated	 L-serine	 were	 used	 as	 substrates	 in	 the	
chemiluminescence	 reaction	of	 the	coupled	SR	assay.	As	 L-serine	 is	not	degraded	by	
DAO	 to	 produce	H2O2,	 little	 to	 no	 signal	would	 indicate	 contaminating	D-serine	 had	
been	 adequately	 removed.	 A	 single-point	 assay	 comparing	 5	mM	 pre-treated	 and	
untreated	L-serine	was	performed	and	the	data	(Fig.	3.3)	illustrate	that	pre-treatment	



























While	 raw	 signal	 values	 can	 be	 compared	 for	 optimisation	 purposes,	 it	 is	 more	
applicable	to	define	data	quantitatively	 in	terms	of	specific	enzyme	activity	based	on	
the	 level	 of	 product	 produced.	 Hence,	 D-serine	 standard	 curves	 were	 obtained	 by	
measuring	 the	 RLU	 signals	 achieved	 with	 increasing	 concentrations	 of	 product	 (D-
serine)	in	the	chemiluminescence	reaction	with	DAO,	HRP,	and	luminol	(Fig.	3.4).	The	
standard	curves	were	 repeated	 for	each	of	 the	different	 interval	 times	 tested	within	
this	chapter	(0.5,	0.1,	0.02	s)	because	each	elicited	proportionally	different	RLU	values.	
For	 subsequent	 assays,	 D-serine	 produced	 (x)	 was	 interpolated	 from	 RLU	 values	 (y)	
using	 GraphPad	 Prism,	 and	 from	 there,	 specific	 enzyme	 activity	 could	 be	 calculated	
from	 SR	 concentration	 and	 time	 length	 of	 the	 racemisation	 step	 (μmol	 D-serine	
produced	per	minute	per	μg	of	SR).	
	
The	 plateaus	 observed	 in	 Fig.	 3.4	 may	 be	 representative	 of	 DAO	 saturation	 in	 the	
presence	 of	 high	 concentrations	 of	 D-serine,	 but	 product	 inhibition	 of	 DAO	 by	H2O2	
may	also	be	a	contributing	factor	because	H2O2	has	damaging	oxidative	properties	and	














A	 concentration	 series	 of	 D-serine	was	 prepared	 and	 degraded	 by	 DAO.	 The	 resulting	 H2O2,	which	 is	
produced	 in	 a	 1:1	 stoichiometry	with	 D-serine,	was	 quantified	 in	 a	 chemiluminescence	 reaction	with	












































the	 respective	 luminescence	and	 fluorescence	assays	 that	were	 the	 stimulus	 for	 this	
chapter,	and	HEPES	had	been	routinely	used	in	several	published	SR	assays.	The	useful	
pH	 ranges	 are	 similarly	 basic	 for	 Tris	 (7.0–9.0)	 and	 CHES	 (8.6–10.0),	 while	 that	 for	
HEPES	 more	 closely	 reflects	 physiological	 pH	 (6.8–8.2).	 A	 principle	 feature	 of	 Tris	










the	 addition	 of	 a	 detection	 solution	 containing	 100	mM	 Tris,	 CHES,	 or	 HEPES,	 with	
2	mM	 EDTA,	 1	U/mL	 DAO,	 0.5	U/mL	 HRP,	 and	 50	μM	 luminol.	 The	 results	 are	
presented	in	Fig.	3.5	as	the	raw	luminescence	values	in	the	presence	and	absence	of	SR	
(Fig.	 3.5A)	 and	 the	 assay	 window	 after	 background	 correction	 (Fig.	 3.5B).	 The	 data	
clearly	demonstrate	that	SR	was	most	active	in	Tris	buffer,	which	elicited	the	greatest	











and	 100	mM	HEPES	pH	8.5,	 all	 supplemented	with	 0.05%	Pluronic	 F-127,	 1	mM	ATP,	 and	10	μM	PLP.	
Results	 shown	 are	 the	 raw	 luminescence	 values	 (A)	 and	 the	 assay	 window	 once	 background	
luminescence	 had	 been	 removed	 (B).	 The	 greatest	 assay	 window	 was	 achieved	 with	 Tris	 buffer,	
therefore	 all	 subsequent	 experiments	 were	 performed	 using	 Tris.	 Experiments	 were	 performed	 in	
triplicate;	 graphs	 are	 the	 means	 from	 three	 independent	 experiments	 (n	=	3).	 Error	 bars	=	SEM,	
[SR]	=	500	nM.		 	











































Common	 features	 in	 literature	 SR	 assays	 were	 used	 to	 determine	 which	 assay	
conditions	 were	 important	 to	 control.	 Two	 consistent	 features	 of	 practically	 all	
published	SR	assays	is	that	the	racemisation	reaction	was	incubated	at	37	°C,	and	that	
the	 assays	 were	 performed	 at	 pH	 8–9.	 Both	 incubation	 temperature	 and	 buffer	 pH	
were	investigated	in	this	study	to	identify	the	conditions	that	were	most	favourable	for	







minimal,	 and	was	 accompanied	 by	more	 variable	 data	 as	 represented	 by	 the	 larger	
margins	 of	 error	 at	 37	°C	 (Fig.	 3.6A).	 The	 signal	 variability	 could	 have	 been	 a	 plate	
effect	resulting	from	inconsistent	heat	distribution	across	the	plate,	or	caused	by	the	
proclivity	of	Tris	buffer	to	fluctuate	pH	in	different	temperatures.	This	characteristic	of	
















a	 37	°C	 incubation	 step,	when	 the	 objective	was	 to	 optimise	 the	 assay	 for	medium-
throughput	screening.	All	dispensing	steps	and	the	compound	transfer	steps	were	not	
possible	 to	 perform	 at	 37	°C	 due	 to	 the	 nature	 of	 the	 equipment,	 and	 it	 was	 not	
practical	to	keep	transferring	plates	to	and	from	an	incubator	while	screening	multiple	

































































to	 cause	 this	 effect	 by	 elevating	 the	 levels	 of	 active	 SR	 dimer	 and	 preventing	 the	
formation	 of	 aggregates	 and	 tetramers	 via	 its	 reducing	 action	 at	 any	 of	 SR’s	 eight	
cysteine	residues	 (Wang	and	Barger,	2011).	A	DTT	concentration-response	assay	was	
performed	 to	 evaluate	 any	 changes	 in	 SR	 activity	 in	 the	 presence	 of	 DTT.	 The	




Interestingly,	 the	 data	 indicate	 that	 SR	 activity	 was	 considerably	 reduced	 in	 the	
presence	 of	 DTT,	 becoming	 effectively	 abolished	 at	 concentrations	 above	 0.08	mM,	
while	maintaining	 activity	 in	 the	 absence	of	DTT.	 It	would	be	 reasonable	 to	 link	 this	
discrepancy	 to	 the	 two	 cysteine-to-aspartate	 point	 mutations	 in	 the	 SR	 primary	
sequence.	The	mutations	were	introduced	to	improve	SR	solubility	during	purification	
and	thus	increase	the	recovery	of	active,	dimeric	SR	(Smith	et	al.,	2010).	It	is	possible	
the	mutation	 of	 these	 exposed	 cysteine	 residues	 removed	 the	 previously	 described	
DTT-dependent	 activity	 increase	 by	 also	 preventing	 or	 breaking	 randomly-formed	
disulphide	 bonds	 that	 could	 cause	 aggregation.	 Although,	 this	 does	 not	 explain	why	
extra	DTT	would	then	abolish	activity.		
	
In	 the	 current	 study,	DTT	was	 included	during	 SEC	purification	 to	 facilitate	 refolding	
and	quaternary	structure	formation	of	SR,	so	it	is	unlikely	SR	stability	is	sensitive	to	DTT.	
Another	 possibility	 is	 that	 a	 different	 assay	 component	 is	 intolerant	 to	 DTT.	 For	
example,	 previous	 reports	 have	 found	 that	 DTT	 drastically	 decreases	 the	 stability	 of	
HRP	 (Chattopadhyay	 and	 Mazumdar,	 2000).	 Further,	 detection	 of	 luminescence	 is	
dependent	on	the	HRP-catalysed	oxidation	of	luminol	by	the	oxidising	agent	H2O2,	but	
high	 concentrations	 of	 DTT	 (approx.	 1	mM)	 can	 react	 directly	 with	 the	 peroxide	
(Nelson	and	Parsonage,	2011),	potentially	depleting	H2O2	produced	in	the	assay.	If	this	
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were	 the	 case,	 it	 would	 be	 incongruous	 with	 other	 published	 SR	 assays	 involving	 a	
chemiluminescence	reaction	that	did	not	observe	the	same	effect	with	DTT	(Wolosker	






A	 20	min	 single-point	 assay	 of	 400	nM	 SR	 activity	 was	 performed	 in	 the	 presence	 of	 increasing	
concentrations	of	DTT	up	to	5	mM.	Results	shown	are	the	raw	luminescence	values	(A),	and	the	specific	
activity	calculated	from	the	signal	once	corrected	for	background	luminescence	(B).	The	reporter	signal	






ensure	 the	 rate	 of	 the	 racemisation	 reaction	 was	 not	 being	 limited	 by	 insufficient	
concentrations	 of	 other	 reagents.	 This	was	 achieved	 by	 performing	 a	 20	min	 single-
point	 assay	 with	 400	nM	 SR	 and	 2	mM	 L-serine,	 and	 for	 the	 detection	 reaction	 a	
concentration	series	of	either	DAO	(0–4	U/mL),	HRP	(0–4	U/mL),	or	luminol	(0–100	μM)	




































































Increasing	 concentrations	of	DAO	and	HRP	both	demonstrated	a	marked	 increase	 in	
signal	that	peaked	and	was	followed	by	a	gradual	decline.	The	reason	for	the	decrease	
in	 signal,	 rather	 than	a	plateau	as	might	be	expected,	may	be	a	 consequence	of	 the	
luminescence	 signal	 being	 quenched,	 or	 aggregation	 and/or	 precipitation	 of	 the	

















Enzyme	 activity	 was	 effectively	 abolished	 in	 the	 presence	 of	 EDTA	 (Fig.	3.9B),	















that	 uses	 DAO,	 HRP	 and	 luminol	 to	 detect	 the	 D-serine	 produced,	 so	 these	 reagents	 must	 be	 non-
limiting.	Concentration-response	curves	for	(A)	DAO,	(B)	HRP,	and	(C)	luminol	were	performed	in	the	SR	
coupled	 assay,	 concentrations	 that	 elicited	 high	 signals	 were	 selected	 for	 subsequent	 experiments:	
1	U/mL	DAO,	0.5	U/mL	HRP,	and	50	μM	luminol.	Experiments	were	performed	in	triplicate;	data	are	the	
means	from	three	(A	and	B)	or	two	(C)	experiments;	error	bars	=	SD.		 	



































(A)	A	 1	h	 SR	 time	 course	of	 L-	 to	D-serine	 racemisation	was	performed,	 after	which	 the	 reaction	was	
stopped	 with	 either	 1	mM	 or	 2	mM	 EDTA	 and	 the	 D-serine	 produced	 was	 quantified	 by	
chemiluminescence	 reaction.	 EDTA	 inhibits	 SR	 racemisation	 by	 chelating	Mg2+	 required	 for	 structural	
stabilisation	 of	 SR.	 The	 increased	background	 signal	 observed	 for	 1	mM	EDTA	 suggests	 there	 is	 some	
residual	L-serine	turnover	with	1	mM	EDTA	after	the	reaction	was	stopped.	(B)	L-serine	saturation	curve	
performed	 in	 the	 presence	 of	 2	mM	 EDTA	 increased	 the	 Km	 from	 10	mM	 to	 >>200	mM	 (projected),	





It	 has	 been	 reported	 SR	 activity	 is	 increased	 in	 phosphate	 buffer	 in	 relation	 to	 Tris,	
which	 was	 attributed	 to	 a	 change	 in	 oligomer	 population	 as	 determined	 by	 gel-
filtration	 chromatography.	SR	 was	 found	 to	 be	 predominantly	 dimeric	 in	 phosphate	
buffer	 and	 monomeric	 in	 Tris	 buffer,	and	 had	 higher	 activity	 in	 phosphate	 buffers	
potentially	 due	 to	 its	 similarity	 to	 physiological	 conditions	 (Wang	 and	Barger,	 2011).	
The	profound	 effect	 prompted	 a	 comparison	of	 Tris	 and	phosphate	 buffer	 in	 a	 time	
course	(Fig.	3.10),	although	the	results	 illustrate	the	exact	opposite	effect.	SR	activity	
was	much	higher	 in	Tris	buffer	compared	 to	phosphate	buffer,	 in	disagreement	with	
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The	 discrepancy	 in	 effects	 between	 the	 published	 studies	 and	 Fig.	 3.10	 could	 be	
attributed	to	the	different	methodologies	that	were	used	and	the	influence	they	would	
have	on	oligomeric	species	formation.	The	Wang	and	Barger	paper	utilised	a	coupled	
chemiluminescence	 assay	 very	 similar	 to	 that	 used	 in	 the	 present	 study,	 with	 the	
additional	inclusion	of	0.2	mM	DTT	in	the	reaction	buffer.	The	authors	suggested	DTT	
was	 a	 critical	 component	 in	 influencing	 the	 dominant	 oligomeric	 species	 of	 SR	 (and	




buffer	 in	 the	 current	 study,	 and	 analytical	 SEC	 and	 crystallography	 indicated	 SR	was	
mostly	 dimeric,	 not	 monomeric	 as	 described	 by	 Wang	 and	 Barger.	 A	 fundamental	
difference	 that	may	 contribute	 to	 these	 contrasting	 results	 is	 that	 the	 assay	 of	 this	







A	2	h	 time	 course	 in	 the	 SR	 coupled	 assay	was	 performed	 in	 Tris	 buffer	 (100	mM	Tris-HCl	 pH	 8.5)	 or	
phosphate	 buffer	 (100	mM	 sodium	 phosphate	 pH	 8.5,	 50	mM	NaCl)	 supplemented	with	 SR	 cofactors	
1	mM	 Mg2+,	 1	mM	 ATP,	 and	 10	μM	 PLP.	 The	 data	 indicate	 that	 SR	 racemisation	 activity	 is	 greatly	
attenuated	in	phosphate	buffer	compared	to	Tris	buffer.	Experiments	were	performed	in	triplicate;	n	=	2.	
	


























less	 than	 10%	 of	 the	 substrate	 had	 been	 converted	 to	 substrate.	 It	 is	 imperative	
reactions	occur	in	this	linear	phase	so	the	reaction	is	not	limited	by	enzyme	saturation,	
substrate	 depletion,	 or	 product	 inhibition.	 A	 3	h	 time	 course	 of	 SR	 concentrations	
between	 0.2–2	μM	 was	 performed	 (Fig.	 3.11A)	 to	 determine	 the	 linear	 phase.	
Saturation	occurred	early	with	2	μM	SR	whereas	the	other	concentrations	(0.2–0.5	μM)	
exhibited	 linear	 kinetics	 for	 a	 longer	 time	 period,	 suggesting	 it	would	 be	 optimal	 to	
keep	SR	below	0.5	μM.	
	
The	 position	 of	 the	 2	μM	 plateau	 was	 used	 to	 estimate	 the	 point	 at	 which	
approximately	10%	product	had	been	formed.	A	20	min	time	course	was	performed	on	
two	SR	concentrations	(200	nM	and	400	nM)	to	analyse	the	linear	phase	in	more	detail	








saturation	 curve	 to	 determine	 the	 Km,	 according	 to	 the	 Michaelis-Menten	 kinetic	
model	 that	 defines	 the	 Km	 as	 the	 substrate	 concentration	 at	 half	 the	 Vmax.	 The	 L-
serine	 Km	 performed	 here	 (Fig.	 3.12)	 was	 determined	 to	 be	 10	mM	 for	 combined	
Batches	1–3,	9.2	mM	for	Batch	4,	and	16	mM	for	Batch	5.	All	values	were	evidently	in	
agreement,	 and	 also	 fell	 well	 within	 the	 range	 of	 reported	 L-serine	 Km	 values	 of	
10	mM	 (Wolosker	 et	 al.,	 1999b)	 and	 4.1	mM	 (Hoffman	 et	 al.,	 2009b).	 The	 substrate	
concentration	used	must	be	around	or	below	the	Km	so	that	the	velocity	is	sensitive	to	
changes	 in	 substrate	 concentration,	 and	 relatedly,	 so	 that	 competitive	 inhibitors	 can	
be	identified	in	IC50	experiments	without	being	out-competed	by	excess	substrate.	The	
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D-serine	 produced	 by	 SR	 racemisation	was	 quantified	 in	 (A)	 a	 3	h	 timecourse,	 and	 (B)	 a	 30	min	 time	
course.	 From	 the	 saturation	 level	 of	 2	μM	 SR	 in	 (A),	 the	 initial	 velocity	 region	where	 ~10%	 substrate	
conversion	occurred	was	estimated	 to	be	within	20	min.	 The	 time	course	 in	 (B)	 focused	on	 the	 initial	
velocity	region,	repeating	two	SR	concentrations	from	(A),	and	the	reaction	was	found	to	be	linear	up	to	
at	 least	 20	min	 with	 400	nM	 SR.	 Experiments	 were	 performed	 in	 triplicate;	 data	 are	 from	 three	
independent	experiments	(n	=	3);	error	bars	=	SEM.		 	



































































graph)	were	 in	 agreement	with	 each	 other,	 confirming	 reproducibility	 of	 the	 SR	 purification	 process.	
Experiments	were	performed	 in	triplicate;	data	are	from	three	 independent	experiments	 (n	=	3);	error	
bars	=	SEM.	 	






























Km = 10 ± 2 mM 
Vmax = 13 ± 1 µmol/min/µg






























Km = 9.2 ± 1.2 mM
Vmax = 12 ± 1 µmol/min/µg






























Km = 16 ± 2 mM 






Incubation	 of	 SR	 with	 increasing	 concentrations	 of	 DMSO	 revealed	 that	 SR	 was	
reasonably	 tolerant	 to	 DMSO,	 with	 a	 perceptible	 but	 minor	 reduction	 in	 enzyme	








values	were	determined	by	plotting	the	percentage	 inhibition	against	 log	of	 inhibitor	
concentration.	Because	of	its	utility	as	a	positive	control	when	testing	fragment	screen	
hits	 and	 literature	 compounds,	 a	 great	 number	 of	 malonate	 IC50	 experiments	 have	
been	 performed	 throughout	 this	 study.	 A	 graph	 combining	 data	 from	 twelve	
independent	experiments	can	be	seen	in	Fig.	3.14A.	The	IC50	of	malonate	determined	




inhibitory	 potential	 because	 of	 its	 use	 as	 a	 control	 reference	 compound	 in	 the	DAO	
counter	 screen	 (section	 7.4.2).	 IC50	 determination	 was	 not	 performed	 for	 benzoate	
because	 the	 concentration	of	DAO	 in	 the	 chemiluminescence	 reaction	was	 in	 excess	
and	had	not	been	optimised	to	be	sensitive	to	substrate	and	inhibitor	levels.	Instead,	
the	 activity	 of	 DAO	 was	 tested	 with	 10	μM	 D-serine	 in	 the	 presence	 of	 four	


















(A)	 Inhibition	 of	 400	nM	 SR	 by	 a	 concentration	 series	 of	 malonate	 between	 0–5	mM;	 the	 IC50	 of	
malonate	 was	 determined	 to	 be	 63	±	5	μM.	 (B)	 Inhibition	 of	 1	U/mL	 DAO	 by	 benzoate	 in	
chemiluminescence	 reaction	 using	 10	μM	 D-serine	 as	 a	 substrate;	 benzoate	 was	 able	 to	 sufficiently	
inhibit	 to	 levels	 required	 for	 fragment	 screen	 controls	 (50%	 and	 100%	 inhibition).	 Bars	 represent	





























































































5	 33.2	 8.6	 0.69	
10	 35.5	 9.0	 0.67	
0.1	
5	 19.4	 9.9	 0.57	
10	 22.9	 8.1	 0.53	
0.5	
5	 14.7	 9.1	 0.64	
10	 19.4	 8.1	 0.68	
	
After	 optimisation	 of	 the	 assay	 procedure,	 the	 luminescence	 signal	 was	 generally	
consistent	across	the	plate	with	typically	a	7–8-fold	assay	window.	The	Z’	scores	were	









deviations	 result	 in	a	greater	percentage	deviation	 from	the	mean.	Therefore,	 the	%	
CV	obtained	here	for	the	negative	controls	were	not	considered	problematic.	
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The	 second	 plate	 test	 of	malonate	 IC50	 experiments	 was	more	 difficult	 to	 optimise,	
because	despite	the	experiments	for	plate	test	1	resulting	in	satisfactory	%	CV	and	Z’	
scores,	 there	 was	 a	 great	 disparity	 between	 them	 and	 those	 for	 plate	 test	 2.	 	 This	
observation	 was	 related	 to	 considerable	 variability	 in	 the	 signal	 measured	 in	 the	
positive	control	wells,	specifically	a	decay	in	luminescence	down	the	plate.	Fig.	3.15A	
shows	the	luminescence	signal	of	the	malonate	IC50	experiments	with	a	0.5	s	 interval	
time	 and	 10	min	 read	 delay,	 and	 there	 is	 a	 clear	 spread	 of	 the	 top	 values	 that	





It	was	unclear	why	the	control	data	 for	 this	plate	 test	was	so	 inconsistent.	The	main	
difference	from	plate	test	1	was	the	introduction	of	the	FluidX	Xpp-721	liquid	handler	
and	manual	pipetting	of	the	control	wells.	Minor	adjustments	to	the	procedure	(such	







protocol	 that	 generated	 IC50	 values	 (27	±	3	µM)	 similar	 to	 those	 obtained	 manually	
(63	±	5	µM),	as	well	as	an	acceptable	Z’,	was	Fig.	3.15D.	Both	IC50	values	do	fall	within	a	
threefold	range,	although	the	discrepancy	between	the	two	values	may	be	a	result	of	








0.02	s	 interval	 time	 and	 5	min	 delay.	 Z’	 scores	 were	 -0.4,	 0.35,	 0.46,	 and	 0.55,	 respectively.	 Bars	

















Z’ = -0.4 










Z’ = 0.35 










Z’ = 0.46 





























A	 0.5	 10	 -0.4	 9.5	 5.2	±	0.5	
B	 0.1	 10	 0.35	 7.5	 19	±	3	
C	 0.1	 5	 0.46	 8.2	 10	±	1	




The	 purpose	 of	 this	 chapter	 was	 to	 develop	 and	 optimise	 a	 biochemical	 assay	 for	
quantifying	SR	activity	 that	 could	be	 implemented	 for	medium-throughput	 screening	
as	 part	 of	 a	 drug	 discovery	 strategy.	 The	 coupled	 assay	 is	 a	 classic	 method	 of	




considered	 ‘gold-standard’	 due	 to	 the	 multifunctional	 behaviour	 of	 SR,	 the	
determination	 of	 assay	 parameters	 that	 fall	 in	 line	 with	 published	 values	 certainly	
supports	the	technique	as	a	method	of	SR	characterisation.	Moreover,	the	successful	
adaptation	of	the	 luminescence	assay	for	use	with	automation	fulfils	the	aims	of	this	
chapter	 and	 represents	 a	 novel	 means	 of	 screening	 SR	 that	 could	 have	 particular	
relevance	for	related	drug	discovery	endeavours.	
	
There	 were,	 however,	 limitations	 and	 challenges	 of	 the	 coupled	 assay.	 The	
multifaceted	nature	of	the	coupled	assay	meant	there	were	multiple	points	at	which	
the	 assay	 was	 susceptible	 to	 complications.	 For	 instance,	 as	 was	 discovered	 during	
optimisation	 with	 automation,	 the	 luminescence	 signal	 produced	 could	 be	 unstable	
and	 decline	 over	 time,	 possibly	 due	 to	 non-specific	 luminol	 luminescence.	 The	













contaminants	 over	 time),	 and	 the	 fans	 inside	 the	 liquid	 handling	 cabinet	 causing	 an	
uneven	 temperature	 distribution	 across	 the	 plate.	 Performing	 the	 assay	 at	 room	
temperature,	 far	 from	the	temperature	of	the	physiological	environment	(37	°C)	may	





a	 high	 Km	 for	D-serine	 (41	mM)	 therefore	 it	 is	 possible	 that	 the	 chemiluminescence	
reaction	 had	 not	 proceeded	 to	 completion.	 Although,	 this	 was	 unlikely	 to	 be	 a	
contributing	factor	at	the	low	levels	of	D-serine	being	produced	by	SR	and	with	DAO	in	
excess.	 The	 greater	 challenge	 would	 be	 that	 multiple	 time	 points	 and	 incubation	
periods	 had	 to	 be	 incorporated	 in	 the	 coupled	 assay,	 which	 can	 be	 difficult	 when	















its	 overall	 utility.	 To	 begin	 to	 characterise	 purified	 SR	 with	 respect	 to	 published	
information,	and	to	have	a	method	for	low-	and	medium-throughput	screening	of	SR,	
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the	 coupled	 assay	 serves	 its	 original	 purpose	 and	 was	 demonstrably	 robust	 and	
reproducible.	However,	it	 is	also	important	to	employ	additional	orthogonal	assays	in	
conjunction	with	methods	that	 indirectly	quantify	enzyme	activity.	To	this	end,	three	
biophysical	 assay	 techniques	—	thermal	 shift,	 MST,	 and	 ITC	—	were	 optimised	 as	



























characterising	 SR	 activity	 and	 stability,	 as	 well	 as	 providing	 the	 means	 of	 medium-
throughput	 screening	 required	 for	 a	 fragment-based	 drug	 discovery	 approach.	
Complementary	 to	 biochemical	 assays,	 which	 assess	 enzyme	 activity,	 are	 the	
biophysical	techniques	that	characterise	binding	events	between	proteins	and	ligands.	
Biophysical	methods	 serve	 to	 confirm	 binding	 of	 hits	 with	 unknown	mechanisms	 of	
action	 that	 are	 generated	 from	 biochemical	 screening;	 hits	 that	 could	 be	
demonstrating	 inhibition	 via	 off-target	 activity	 or	 protein	 destabilisation.	 The	









compound	addition,	 but	may	also	 refer	 to	 something	as	 simple	 as	pH	 changes	or	 as	
















(A)	 Protein	 melting	 as	 temperature	 increases;	 (B)	 dye	 binds	 to	 internal	 hydrophobic	 residues;	 (C)	




of	 compounds	 and	 hit	molecules	 to	 assess	 their	 effect	 on	 protein	 stability.	 Thermal	
shift	is	a	limited	biophysical	approach	because	it	cannot	determine	KD	or	stoichiometry,	
it	is	target-dependent,	and	it	does	not	always	definitively	indicate	a	binding	event.	For	
instance,	 results	 can	be	obscured	by	protein	denaturation	 to	 fibrils	 (which	 interferes	
with	 the	 fluorescence	 emission),	 high	 background	 signal	 due	 to	 the	 fluorophore	
binding	 to	 the	 protein	 in	 its	 native	 state,	 or	 an	 insufficiently	 hydrophobic	 core	





Microscale	 Thermophoresis	 (MST)	 is	 a	 technique	 used	 to	 analyse	 the	 interaction	 of	




















fusion	 proteins	 or	 intrinsic	 tryptophan	 fluorescence.	 Changes	 in	 the	 hydration	 shell,	
charge,	or	size	of	the	molecules,	and	the	reciprocal	fluorescence	that	is	detected,	can	
be	 indicative	of	a	binding	event,	whether	 it	be	small	molecules	 to	proteins,	 complex	
protein-protein	 interactions,	 ligands	 to	 enzyme,	 or	 with	 other	 biomolecules	 such	 as	







properties	 as	 the	 temperature	 quickly	 changes.	 The	 thermodiffusion	 of	 the	 fluorescently	 labelled	
molecules	can	be	detected	(for	approximately	30	s),	usually	away	from	the	heat	source	but	occasionally	
towards	it.	Once	the	laser	is	deactivated	there	is	a	rapid	mass	diffusion	of	the	molecules	back	into	their	
previously	 occupied	 space.	 The	 change	 in	 thermophoresis	 is	 expressed	 as	 the	 change	 in	 normalised	

















































two	 cells	 at	 exactly	 the	 same	 temperature.	 If	 binding	 occurs	 upon	 each	 injection	 of	
ligand,	heat	changes	are	detected	and	measured	to	a	sensitivity	of	a	few	millionths	of	a	
degree,	 and	 this	 continues	 until	 binding	 has	 reached	 equilibrium.	 The	 differential	
power	 (DP)	 is	 a	measurement	 of	 the	 power	 differential	 between	 the	 reference	 and	




binding	 partners,	 meaning	 they	 are	 tested	 in	 their	 native	 state.	 ITC	 produces	 an	
impressive	 breadth	 of	 thermodynamic	 information	 such	 as	 the	 KD,	 the	 reaction	
stoichiometry	 (n),	 enthalpy	 (ΔH),	 and	 entropy	 (ΔS),	 which	 can	 all	 be	 simultaneously	









reaction	 is	 exothermic,	meaning	 the	 sample	 cell	 becomes	warmer	 than	 the	 reference	 cell.	 The	 signal	
returns	 to	 its	 starting	 position	 as	 the	 temperature	 of	 the	 two	 cells	 returns	 to	 equal.	 This	 process	 is	
repeated,	and	with	each	 injection	 the	protein	becomes	more	saturated	with	 ligand	as	 the	molar	 ratio	





The	 purpose	 of	 this	 chapter	 was	 to	 optimise	 the	 three	 biophysical	 techniques	
described	 above,	 and	 authenticate	 their	 suitability	 for	 an	 SR	drug	discovery	 strategy	


























































Thermal	 shift	 assays	 quantify	 the	 changes	 in	 thermal	 denaturation	 temperature	
(melting	point,	 Tm)	between	 the	 complexed	and	uncomplexed	protein	under	 varying	
conditions,	such	as	the	presence	of	conformational	stabilisers	(Pantoliano	et	al.,	2001).	
	
CHES	 buffer	 was	 used	 for	 thermal	 shift	 assays	 because	 Tris,	 the	 buffer	 used	 during	
biochemical	 assay	 development	 (Chapter	 3),	 cannot	 maintain	 pH	 with	 changes	 in	




a	 reaction	 volume	 of	 20	μL	 per	well.	 Apart	 from	 in	 the	 initial	 optimisation	 steps,	 in	
which	 the	 concentrations	 of	 SR	 and	 SYPRO	 Orange	 were	 varied,	 all	 experiments	










solution	 of	 the	 fluorescently	 labelled	 protein	 and	 the	 ligand	 to	 be	 tested,	 and	 16	










(as	 with	 the	 biochemical	 assay),	 supplemented	 with	 0.1%	 Pluronic	 F-127	 (as	






achieve	 final	 assay	 concentrations	 of	 50	nM	 SR	 and	 0–2	mM	 inhibitor.	 The	 positive	





incubated	 for	 10	min	 at	 RT	 then	 centrifuged	 at	 13	000	rpm	 for	 3	min.	 Samples	were	
transferred	 into	 a	 capillary	 by	 inserting	 the	 capillary	 into	 a	 tube	 and	 letting	 it	 fill	 by	
capillary	 action.	 Each	 ligand	 was	 tested	 in	 duplicate.	 Once	 all	 capillaries	 had	 been	
inserted	 into	 the	 sample	 tray,	 it	was	 loaded	 into	 the	NanoTemper	Monolith	NT.115	
machine	and	left	to	equilibrate	for	5	min.		
	











Once	 the	 samples	 are	 placed	 on	 a	 tray	 and	 inserted	 into	 the	 instrument,	 a	 fluorescence	 scan	 is	
performed	across	 the	capillaries	 to	accurately	determine	the	position	of	 the	capillaries	and	assess	 the	








inhibitor	mixtures	were	 combined	with	 denaturation	 solution	 (5%	 SDS	 +	 1	mM	DTT)	
and	 heated	 at	 95	°C	 for	 10	min.	 The	 tubes	were	 then	 centrifuged	 at	 13	000	rpm	 for	
3	min,	 loaded	 into	 the	 capillaries,	 and	 the	 MST	 experiment	 was	 repeated.	 If	 upon	
denaturation	 the	 fluorescence	of	 the	 samples	was	 restored	 to	an	equal	 value	across	
the	 dilution	 series,	 it	 indicated	 the	 changes	 observed	 were	 protein-dependent	 and	
could	therefore	be	attributed	to	a	binding	event,	rather	than	being	caused	by	sample	
loss	 due	 to	 adsorption	 or	 precipitation.	 If	 fluorescence	 remained,	 it	 would	 not	 be	
possible	 to	 analyse	 the	 thermophoresis	 signal	 as	 it	 would	 be	 biased	 by	 different	
fluorescence	intensities	of	the	bound	and	unbound	molecules.	
	
Data	 interpretation.	 The	 initial	 fluorescence	 of	 each	 peak	 from	 the	 capillary	 scan	
should	not	vary	by	more	than	10%;	strong	random	variations	suggest	samples	are	not	
well	 mixed,	 dilutions	 are	 imprecise,	 or	 buffer	 conditions	 need	 to	 be	 optimised.	














Data	 from	 the	MST	 and	 Fnorm	 traces	were	 exported	 as	 raw	data	 and	 plotted	 using	





Dynamics	 of	 the	 ITC	 experiment.	 Obtaining	 a	 complete	 binding	 curve	 is	 heavily	
dependent	 on	 the	 stoichiometry	 of	 protein	 and	 ligand	 in	 relation	 to	 the	 KD	 of	 the	
ligand,	and	their	relationship	is	quantified	by	the	equation	c	=	[Protein]/KD,	where	c	is	
the	 product	 of	 the	 predicted	 affinity	 of	 the	 system	 and	 is	 used	 to	 determine	 the	
optimal	 protein	 concentration	 (Duff	 et	 al.,	 2011).	 The	 c	 value	 of	 the	 system	 is	
considered	very	good	when	between	10–100,	good	between	5–500,	fair	between	1–5	







of	 malonate,	 was	 simply	 a	 titration	 of	 malonate	 into	 the	 sample	 cell,	 which	 itself	
contained	 either	 buffer	 (for	 the	 heat	 of	 dilution	 control)	 or	 SR	 (for	 the	 binding	
experiment).	 The	 second,	 for	 assessing	 binding	 of	 the	 fragment	 hits,	 was	 a	
displacement	 experiment,	 which	 was	 incorporated	 to	 account	 for	 the	 very	 weak	
binding	 (≈	1	mM)	 of	 the	 fragment	 molecules.	 These	 assays	 allow	 for	 interactions	







heat	 and	 will	 detect	 heat	 of	 dilution	 as	 well	 as	 binding	 heats.	 For	 this	 reason,	 all	
solutions	 needed	 to	 be	 in	 the	 exact	 same	 buffer.	 Prior	 to	 an	 ITC	 experiment,	 up	 to	
500	μL	SR	stock	was	dialysed	overnight	 in	1	L	 ITC	dialysis	buffer	(Tris	mix	buffer,	with	
no	Pluronic	F-127)	using	Slide-A-Lyzer	dialysis	cassettes	with	10	kDa	molecular	weight	
cut-off	 (ThermoFisher	 Scientific).	 The	 SR	 concentration	 was	measured	 by	 NanoDrop	
after	 dialysis	 to	 account	 for	 some	 protein	 loss	 and	 buffer	 equilibration.	 The	 dialysis	
buffer	was	also	used	to	make	all	working	solutions	of	SR	and	inhibitor.	
	
Assay	 procedure.	 SR	 was	 tested	 at	 concentrations	 of	 either	 50	μM	 or	 100	μM.	
Concentrations	were	adapted	during	optimisation	based	on	the	fit	of	the	curve	and	the	










Care	 was	 taken	 when	 loading	 the	 cell	 to	 avoid	 bubble	 formation;	 bubbles	 at	 the	
bottom	of	the	cell	could	be	released	by	gently	knocking	the	sides	of	the	cell	with	the	
Hamilton	 syringe.	 The	 injection	 syringe	was	 then	 loaded	with	 the	malonate	 solution	
and	lowered	into	the	cell.	
	












peaks	 in	 the	 baseline	 where	 injections	 did	 not	 occur.	 The	 baseline	 was	 adjusted	 to	
account	 for	 aberrant	 peaks,	 and	 artefactual	 data	was	 removed.	 If	 a	 heat	 of	 dilution	
control	 experiment	was	 performed	 first,	 the	 adjusted	 data	was	 subtracted	 from	 the	
binding	experiment	with	SR	and	malonate.	
	
















To	 find	 the	optimum	concentrations	 of	 SR	 and	dye,	 an	 initial	 screen	was	 performed	
with	 increasing	 concentrations	 of	 enzyme	 (0.16,	 0.3125,	 0.625,	 1.25,	 2.5,	 5	µM)	 and	
SYPRO	 Orange	 dye	 (2x,	 5x,	 10x,	 20x).	 The	 thermal	 denaturation	 curves	 for	 the	
conditions	tested	with	their	corresponding	melting	temperatures	are	shown	in	Fig.	4.5.	
	





for	 subsequent	 thermal	 shift	 experiments.	 Although	 2.5	µM	 SR	 did	 not	 saturate	 the	
signal	when	in	the	presence	of	2x	dye,	ideally	the	protein	concentration	would	be	kept	
low	to	reduce	depletion	of	enzyme	stocks.	Increasing	the	concentration	of	dye	appears	
to	 have	 a	 detrimental	 effect	 on	 the	 strength	 of	 the	 fluorescence	 signal,	 which	 is	
damped	for	all	but	the	highest	SR	concentrations	as	the	level	of	dye	increases	to	10x	
and	 20x.	 Of	 the	 two	 remaining	 dye	 concentrations,	 2x	 and	 5x,	 a	 greater	 signal	 was	



















2x	 46.3	 46.7	 47.4	 48.4	 49.3	 48.9	
5x	 42.1	 44.4	 45.5	 47.2	 46.4	 44.4	
10x	 Undefined	 54.8	 44.7	 45.6	 47.6	 44.9	
20x	 Undefined	 Undefined	 51.4	 38.7	 46.0	 48.4	
Figure	4.5.	Optimisation	of	SR	and	dye	concentrations	for	the	thermal	shift	assay.	
(A)	Thermal	denaturation	curves	of	six	concentrations	of	SR	(0.16,	0.3125,	0.625,	1.25,	2.5,	5	µM)	and	
four	concentrations	of	SYPRO	Orange	dye	 (2x,	5x,	10x,	20x)	 to	determine	the	optimal	conditions	 for	a	













































































































are	 presented	 in	 Fig.	4.6	with	 the	 corresponding	 SR	melting	 temperatures.	 Although	
the	peak	fluorescence	signal	was	marginally	increased	for	a	few	DMSO	concentrations,	
the	 Tm	 values	were	 consistent	 across	 the	 dilution	 series.	 As	 DMSO	 can	 improve	 the	






Thermal	 denaturation	 analysis	was	 performed	on	 1	µM	 SR	 in	 the	 presence	 of	 1	mM	
malonate	and	1	mM	L-serine	to	observe	effects	on	protein	stabilisation	(Fig.	4.7).	The	
Tm	of	 SR	alone	was	determined	 to	be	47.4	±	0.5	°C,	with	malonate	53.8	±	0.4	°C,	 and	
with	L-serine	44.6	±	0.8	°C.	These	data	give	thermal	shifts	of	+6.4	°C	for	malonate	and		
-2.8	°C	for	L-serine.	The	positive	thermal	shift	observed	with	malonate	corresponds	to	
stabilisation	 of	 the	 closed	 conformation	 of	 SR,	 which	 then	 requires	 a	 higher	
temperature	to	unfold	the	protein.	The	negative	thermal	shift	with	L-serine	 indicates	








SYPRO	 Orange	 dye.	 Select	 concentrations	 of	 DMSO	 (0.3125–2.5%)	 result	 in	 an	 increase	 in	 the	 peak	
fluorescence	 signal,	 but	 otherwise	 SR	 remains	 stable	 across	 the	 dilution	 series,	 as	 indicated	 by	





































































































































Thermal	 denaturation	 analysis	was	performed	on	1	µM	SR	 alone	 and	 in	 the	presence	of	 either	 1	mM	
malonate	or	1	mM	L-serine.	The	Tm	of	SR	 in	 the	presence	of	malonate	 increased	 from	47.4	±	0.5	°C	 to	






Initial	 optimisation	 steps	 involved	 performing	 scans	 of	 the	 capillaries	 and	 adjusting	
either	 the	 conditions	 inside	 the	 capillaries	 or	 the	 instrument	 settings	 to	 achieve	 a	



























Tm = 47.4 °C
SR + malonate
Tm = 53.8 °C
SR + L-serine
Tm = 44.6 °C
			 165	
Centrifuging	 the	 samples	 removes	 aggregated	 protein	 that	 can	 exacerbate	 surface	
adhesion,	 causing	 a	 subtle	 improvement	 in	 the	 shapes	 of	 the	 peaks	 between	
centrifuged	and	non-centrifuged	samples.	There	was	also	clearly	a	higher	fluorescence	
signal	 achieved	 with	 the	 SR	 buffer,	 which	 may	 be	 because	 of	 the	 presence	 of	 SR	


















the	 capillary	 tubes	 is	 indicated	 by	 dips	 or	 shoulders	 in	 the	 peaks	 (e.g.	 as	 seen	 in	 Buffer	 3a).	 Each	
condition	was	performed	in	duplicate,	giving	two	peaks.		
	
	 	 	 	
Buffer	1	 Buffer	2	 Buffer	3	 Buffer	4	













fluorescence	 signal	 within	 the	 optimum	 range	 at	 approximately	 800	 counts,	 so	 no	
further	 adjustments	 on	 this	 factor	 were	 deemed	 necessary.	 Following	 this,	 an	MST	
experiment	was	performed	with	SR	and	1%	DMSO	at	three	MST	powers	—	20%,	40%,	
and	 60%	 (Fig.	 4.9).	 The	 MST	 power	 selected	 was	 based	 on	 the	 data	 points	 that	
displayed	 the	 most	 consistency	 and	 a	 narrow	 assay	 window.	 The	 resulting	 data	
illustrated	 that	 20%	 power	 produces	 a	 noisy	 signal	 (Fig	 4.9A;	 blue	 trace),	 with	 a	







The	 effect	 of	 the	 MST	 positive	 and	 negative	 controls	 (malonate	 and	 DMSO)	 on	
thermophoresis	was	examined	using	the	previously	established	40%	MST	power.	The	
results	 (Fig.	4.10)	 suggest	both	 controls	 could	be	 consistently	and	 reliably	measured,	
and	there	was	a	clear	Fnorm	shift	of	12–15	counts	when	SR	was	present	with	250	µM	
malonate.	The	size	of	this	shift	is	in	agreement	with	published	values	describing	Fnorm	







The	 data	 show	MST	 traces	 of	 the	 change	 in	 normalized	 fluorescence	 over	 time	 (A)	 and	 single-point	









time	 (A)	 and	 calculated	 Fnorm	 for	 the	 experiment	 (B)	 represents	 a	measurement	 from	 an	 individual	
capillary.	 Binding	 is	 indicated	 by	 an	 upwards	 or	 downwards	 shift	 in	 fluorescence	 from	 the	 negative	
control.	 Data	 were	 collected	 using	 the	 Monolith	 NT.115	 system.	 Black	 horizontal	 bars	=	mean;	 error	
bars	=	SD;	LED	power	=	30%;	MST	power	=	40%.	 	








































































two	 screens	 were	 plotted	 in	 the	 order	 the	 trays	 were	 read	 (Fig.	 4.11).	 With	 a	 few	
exceptions,	there	was	generally	a	negative	shift	in	the	fluorescence	upon	the	inclusion	
of	 malonate.	 The	 size	 of	 the	 shift	 itself	 was	 small,	 ranging	 from	 approximately	 5–
15	counts.	Over	 time,	 there	was	a	 clear	 gradual	decline	 in	 the	 fluorescence	 for	both	





Hits	 identified	 from	 the	 SR	 fragment	 screen	 using	 the	 biochemical	 assay	 were	 analysed	 by	 MST	 to	



























A	 concentration-response	 curve	 of	malonate	was	 performed	 using	MST	 to	 ascertain	




caused	 by	 protein	 precipitation	 or	 aggregation	 in	 the	 capillary,	 a	 malonate	
concentration	of	375	µM	was	used	as	a	positive	control	throughout	MST	screening.	
	
The	 malonate	 binding	 curve	 (Fig.	4.12)	 indicates	 Fnorm	 shifted	 in	 a	 concentration-






MST	 analysis	 was	 performed	 on	 50	nM	 SR	 and	 0–2	mM	 malonate	 in	 MST-optimised	 Tris	 mix	 buffer	
(100mM	Tris	pH	8.5,	0.1%	Pluronic	F-127,	1	mM	MgCl2,	1	mM	ATP,	10	µM	PLP).	The	KD	of	malonate	was	
calculated	to	be	28.2	±	10.3	µM.	Data	are	from	one	MST	experiment.	












An	 ITC	 experiment	 was	 first	 performed	 on	 malonate,	 a	 known	 binder.	 Initial	
concentrations	 of	 100	µM	 SR	 and	 1	mM	 malonate	 were	 selected	 from	 software	
predictions	based	on	the	c	value	calculated	from	the	approximate	KD	of	the	ligand	of	
interest.	 The	 result	was	 a	 partial	 exothermic	 binding	 curve	 (Fig.	 4.13A)	which,	when	
extrapolated	by	the	analysis	software,	calculated	a	KD	of	4.3	µM.	Although	this	value	is	
similar	 to	 the	malonate	KD	determined	 via	MST,	 the	 calculation	 is	 highly	 likely	 to	be	
error	prone	without	a	 full	 binding	 curve.	Only	 the	 top	plateau	and	part	of	 the	 slope	




The	malonate	 concentration	 was	 then	 reduced	 by	 half	 in	 order	 to	 slow	 the	 rate	 at	
which	the	reaction	reached	saturation.	The	outcome	was	a	complete	binding	curve	(Fig.	
4.13B)	with	a	calculated	malonate	KD	of	8.5	±	1.7	μM,	which	is	within	range	of	the	KD	
determined	 by	 MST	 (28.2	µM).	 ITC	 can	 additionally	 be	 used	 to	 calculate	 the	
stoichiometry	of	ligand	to	protein	binding.	It	is	known	from	the	crystal	structure	of	the	
SR-malonate	 complex	 that	 only	 one	 molecule	 of	 malonate	 binds	 per	 SR	 monomer,	
which	 is	why	 it	was	not	expected	 for	 the	 stoichiometry	 to	be	0.5,	 i.e.	 1	molecule	of	
ligand	binds	per	two	protein	molecules.	There	are	two	possible	explanations.	First,	the	
protein	sample	contained	a	sizeable	inactive	portion	from	protein	denaturation	during	
purification,	over	 time,	or	during	 the	experiment.	 Indeed,	 if	 the	N	value	 is	 fixed	 to	1	
and	the	cell	concentration	allowed	to	vary,	the	software	determined	the	concentration	
of	 ‘active’	 SR	 to	 be	 approximately	 50	μM.	 Second,	 not	 every	 SR	monomer	 bound	 a	
molecule	of	malonate.	The	stabilised	closed	conformation	of	one	malonate-bound	SR	






(A)	 Initial	 ITC	 experiment	 with	 100	µM	 SR	 and	 1	mM	malonate	 elicited	 a	 partial	 exothermic	 binding	
curve	 caused	 by	 SR	 becoming	 rapidly	 saturated	 by	 excess	 malonate.	 (B)	 Reducing	 the	 malonate	
concentration	by	half	(500	µM)	enabled	a	full	binding	curve	to	be	achieved	by	slowing	the	equilibrium	
shift	 towards	 saturation.	 The	 KD	 of	 malonate	 was	 calculated	 to	 be	 8.5	±	1.7	µM.	 Left	 figures	 show	
differential	power	(DP)	of	injection	peaks	obtained	throughout	the	ITC	experiment	with	the	baseline	in	
red.	Right	figures	are	the	binding	curves	plotted	from	integration	of	the	DP	peaks.	






































potential	 hits.	 Biophysical	 techniques,	 such	 as	 the	 ones	 used	 here,	 help	 support	
biochemical	data	and	build	a	case	for	promising	candidates	to	be	progressed	to	hit-to-
lead	 development.	 This	 chapter	 has	 outlined	 the	 optimisation	 of	 all	 three	 methods	
(thermal	 shift,	 MST,	 and	 ITC)	 and	 has	 successfully	 demonstrated	 their	 utility	 from	
binding	data	obtained	with	the	SR	inhibitor	malonate.	
	




to	detect	binding	events	between	SR	and	 inhibitors	 (such	as	malonate)	 that	 cause	a	




which	 is	 important	 to	 ascertain	 for	 a	 potential	 hit	 lest	 it	 is	 actually	 a	 destabilising	
compound.	The	primary	limitation	with	thermal	denaturation	is	that	it	cannot	be	used	





of	useful	kinetic	 information	down	 to	 the	picomolar	 range.	 In	 this	 chapter,	MST	was	
used	to	obtain	a	binding	curve	for	SR	and	malonate,	as	well	as	calculate	a	malonate	KD	
for	SR	 (Fig.	4.13).	This	was	a	novel	application	 for	MST	and	 represents	 the	 first	 time	
biophysical	data	has	been	obtained	for	SR	and	malonate	using	this	technique.	Further,	
the	MST	data	obtained	with	malonate	indicate	it	is	possible	to	use	MST	as	a	means	of	
characterising	 fragment	 hits,	 as	malonate	 has	 features	 in	 common	with	 those	 from	
			 173	
fragment	libraries	(e.g.	Mw	<	300	Da,	ClogP	<	3).	The	primary	reason	MST	was	not	used	
as	 the	 sole	 biophysical	method	 in	 this	 thesis	 is	 because	 of	 its	 potential	 to	 generate	
false	 positives.	 The	 fluorescent	 protein	 labelling	 that	 is	 required	 may	 cause	 non-
specific	binding,	and	a	compound	that	is	fluorescent	or	binds	close	to	the	fluorophore	
may	 generate	 artefactual	 data.	 To	 mitigate	 this	 issue,	 specific	 denaturation	 and	
fluorescence	controls	have	been	 included	during	 the	screening	process	 in	Chapter	7.	















destabilisers	 and	 inhibitors.	 The	 medium-throughput	 functionality	 of	 MST	 has	 been	
used	 to	 screen	 the	 hits	 progressed	 from	 biochemical	 screening	 and	 follow-up	 KD	
determination.	 Finally,	 a	 small	 number	 of	 the	 most	 promising	 candidate	 inhibitors	
were	 assayed	 by	 ITC,	 to	 attempt	 to	 characterise	 their	 binding	 affinities	 to	 SR	 in	 its	







The	 crystallisation	 of	 proteins	 has	 historically	 been	 a	 considerable	 challenge,	 often	
requiring	a	multifaceted	approach	to	a	problem	that	cannot	be	solved	empirically.	 In	
drug	discovery,	protein	crystallisation	and	crystallography	is	invaluable	for	elucidating	
the	 structure	 of	 a	 target	 protein,	 confirming	 binding	 of	 hits,	 and	 developing	 SAR.	







(Smith	 et	 al.	 2010;	 PDB	 code	 3L6B)	 provided	 the	 starting	 conditions	 used	 for	
crystallising	 inhibitor-bound	 SR	 in-house.	 The	 authors	 successfully	 crystallised	 hSR	 in		
25%	 polyethylene	 glycol	 (PEG)	 3350,	 200	mM	 sodium	malonate,	 and	 50	mM	MnCl2.	
During	their	crystallisation	experiments,	sodium	malonate	acted	as	a	precipitant	in	the	
reservoir	 solution	 as	 well	 as	 binding	 to	 the	 active	 site	 to	 stabilise	 the	 closed	






When	 published	 conditions	 are	 not	 available,	 de	 novo	 crystallisation	 is	 frequently	










drop	 containing	 protein	 and	 precipitant	 solutions	 in	 a	 chamber	 containing	 pure	
precipitant	(the	reservoir	solution)	in	multi-well	plates.	Water	vapour	then	diffuses	out	
of	 the	 drop	 until	 the	 osmolarity	 between	 the	 drop	 and	 precipitant	 are	 equilibrated,	
resulting	 in	 a	 slow	 concentration	 of	 both	 solutions	 until	 protein	 nucleation	 and	
precipitation	occurs.		
	
The	 two	 types	 of	 vapour	 diffusion	 are	 sitting-drop	 and	 hanging-drop.	 In	 both	
techniques	the	reservoir	is	filled	with	precipitant,	and	equal	volumes	of	precipitant	and	
protein	are	present	in	the	drop.	In	sitting-drop,	the	drop	is	put	on	a	shelf	next	to	the	







frequently	 employed	when	working	with	 insoluble	 compounds	 or	 proteins	 prone	 to	
aggregation,	 as	 precipitated	 samples	 can	 be	 removed	 by	 centrifugation	 or	 filtration	
before	use.	Most	commonly,	the	protein	is	pre-incubated	with	the	ligand	immediately	
prior	 to	 the	 crystallisation	experiment,	 although	an	alternative	method	 involves	pre-
coating	 crystallisation	 wells	 with	 ligand	 (Gelin	 et	 al.,	 2015).	 The	 compound	





small	 number	 of	 compounds	 are	 required.	 A	 co-crystallisation	 protocol	 for	 one	
protein-ligand	 complex	 cannot	 necessarily	 be	 applied	 to	 the	 same	 protein	 with	 a	
different	compound,	and	that	can	be	a	limitation	when	studying	large	numbers	of	hit	
compounds,	 for	example.	Another	 typical	challenge	with	co-crystallisation	 is	 reduced	






limited	 and	 a	 soakable	 crystal	 form	 is	 readily	 available,	 and	 involves	 putting	 the	
crystals	 into	 ‘stabilisation’	 buffers	 before	 immersing	 them	 in	 a	 concentrated	 ligand	
solution	(Hassell	et	al.,	2007).	The	typical	ligand	concentration	used	for	soaking	is	ten	
times	the	KD	to	aim	to	achieve	90%	ligand	occupancy,	and	where	the	binding	affinity	is	
not	 known	 a	 concentration	 of	 20–50	mM	 for	 fragments	 and	 0.1–1	mM	 for	 higher	
molecular-weight	 compounds	 is	 usually	 tested	 (Müller,	 2017).	 As	 it	 is	 common	 for	
several	good-quality	crystals	 to	grow	 in	 the	crystallisation	drop	once	conditions	have	
been	 optimised,	 all	 can	 be	 used	 for	 separate	 soaking	 experiments	 to	 maximise	 the	
production	of	co-crystals	compared	with	the	slower	process	of	co-crystallisation.	The	
primary	 caveat	 of	 crystal	 soaking	 is	 the	 requirement	 for	 a	 crystal	 form	 with	 an	
accessible	 binding	 site,	 which	 is	 soakable	 without	 the	 crystal	 lattice	 becoming	
disrupted	 by	 conformational	 changes	 and	 causing	 crystal	 degradation.	 In	 addition,	
conditions	 such	as	 the	 ligand	concentration,	DMSO	 tolerance,	 and	 soaking	 time	may	
have	 to	 be	 optimised,	 additives	may	 be	 required	 to	 achieve	 effective	 ligand	 binding	
(Hassell	et	al.,	2007),	and	it	has	been	reported	that	ligand-soaked	crystals	may	change	
their	diffraction	properties	or	even	 their	 space	group	 (Skarzynski	 and	Thorpe,	2006).	
However,	the	potential	to	generate	many	co-crystals	from	one	crystallisation	protocol	






Both	 co-crystallisation	 and	 soaking	 are	 frequently	 accompanied	 by	 the	 challenge	 of	
reproducing	crystal	growth.	A	crystal	that	formed	one	week	may	not	grow	in	the	same	
conditions	the	next,	due	to	variations	within	the	well	(e.g.	contaminants,	precipitation,	














The	aim	of	 this	 chapter	was	 to	 crystallise	purified	 SR	 in-house,	 in	both	 the	holo	 and	
malonate-bound	 form,	 using	 multiple	 techniques	 (sitting-	 and	 hanging-drop,	































































SR	 stock	was	 stored	 at	 -80	°C	 and	 diluted	with	 SR	 SEC	 buffer	 to	 test	 concentrations	
ranging	from	5–12	mg/mL.	Additionally,	5	mM	DTT	was	always	included	in	the	protein	





Research)	 with	 the	 reservoir	 solution	 that	 produced	 the	 crystal,	 from	which	 1–10%	
dilutions	 were	 prepared	 and	 added	 to	 the	 protein	 solution.	 For	 co-crystallisation	
experiments,	 the	 protein	 solution	 was	 incubated	 with	 5	mM	 or	 10	mM	 ligand	 for	






or	 MRC	 2-drop	 96-well	 crystallisation	 plates	 (Swissci),	 either	 manually	 or	 using	 an	
Oryx4	 protein	 crystallisation	 robot	 (Douglas	 Instruments).	 The	 reservoirs	 contained	
either	 100	μL	 (48-well)	 or	 50	μL	 (96-well)	 precipitant.	 48-well	 plates	 were	 used	
because	they	allowed	bigger	drop	sizes,	and	thus	potentially	bigger	crystals,	while	96-
well	plates	enabled	screening	of	a	higher	number	of	conditions.	The	dispensed	protein	













Hanging	 drop	 trials	 were	 performed	 manually	 in	 24-well	 XRL™	 plates	 (#MD3-11,	
Molecular	Dimensions),	which	were	prepared	with	1	mL	precipitant	in	the	reservoirs.	A	








Crystals	 selected	 for	 soaking	 were	 picked	 and	 placed	 into	 a	 1	μL	 drop	 of	 reservoir	
solution	supplemented	with	successive	concentrations	of	10%,	20%,	and	30%	glycerol	











internal	 crystal	 structure,	 so	 the	 ideal	 crystal	 will	 have	 multiple	 faces	 from	 which	
diffraction	data	can	be	collected	and	will	be	larger	or	approximately	equal	sized	to	the	








nitrogen.	 Crystals	 were	 first	 screened	 in-house	 at	 100	K	 using	 a	 Rigaku	 007HFM	
rotating	anode	X-ray	generator	and	a	Saturn	944+	CCD	detector.	If	the	initial	diffraction	
images	 indicated	 poor	 resolution,	 the	 crystals	 were	 stored	 in	 liquid	 nitrogen	 and	 a	
dataset	 was	 collected	 at	 Diamond	 Light	 Source	 (beamline	 I03)	 using	 synchrotron	
radiation.	 The	 diffraction	 dataset	 collected	 was	 handled	 by	 our	 resident	
crystallographer	 Dr	 Mark	 Roe,	 for	 phase	 determination,	 structure	 solution,	 and	
refinement.	 Data	 collection	 statistics	were	 obtained	 from	Mark	 Roe	 and	MolProbity	
statistics	 from	 the	MolProbity	web	 server	 (molprobity.biochem.duke.edu/index.php);	
statistics	 tables	 can	 be	 viewed	 in	 Appendix	 10.5.	 For	 comparing	 superimposed	









The	 first	 step	 was	 to	 attempt	 to	 replicate	 the	 crystallisation	 of	 SR	 in	 complex	 with	
malonate	based	on	the	conditions	published	by	Smith	et	al.	 (25%	PEG	3350,	200	mM	







(25%).	 The	 plate	 was	 incubated	 at	 20	°C	 and	 checked	 for	 crystal	 growth	 each	 day.	
Many	 of	 the	 drops	 showed	 brown	 amorphous	 precipitation,	 suggesting	 that	 the	





then	 prepared	 that	 screened	 a	 narrower	 range	 of	 concentrations	 to	 pinpoint	 the	
optimum	 conditions	 for	 crystal	 growth.	 Eight	 concentrations	 of	 malonate	 (180–
250	mM)	and	six	concentrations	of	MnCl2	(4–24	mM)	were	tested	with	25%	PEG	3350.	



















A	 25	 250	 14	
B	 25	 180	 12	
C	 25	 200	 10	






A	 single	 crystal	 was	 picked	 from	 a	 drop	 containing	 25%	 PEG	 3350,	 230	mM	 sodium	





were	 generally	 well	 ordered,	 and	 almost	 all	 residues	 were	 well	 defined,	 with	 the	
exceptions	 of	 1,	 2,	 69–75,	 and	 322–340.	 The	 missing	 residues	 69–75	 belong	 to	 a	










into	contact	with	 several	other	 residues	within	 the	active	 site	 (Fig.	5.2C),	which	may	
contribute	to	its	occlusion	of	the	active	site	and	related	competitive	inhibition.	PLP	is	













large	 (teal)	 and	 small	 (purple)	 domains	 linked	 by	 a	 flexible	 loop	 region	 (orange).	 In	 both	 (A)	 and	 (B),	
malonate	is	represented	by	green	carbon	sticks,	PLP	(SR	cofactor)	by	yellow	carbon	sticks,	and	Mn2+	by	a	
















PEG	 3350	 concentrations	 (10–27.5%)	 or	 eight	 MgCl2	 concentrations	 (170–310	mM).	
Crystallisation	 experiments	 with	 holo	 SR	 used	 MgCl2	 rather	 than	 MnCl2	 based	 on	
observations	 by	 Evotec	 crystallographers	 that	holo	 crystal	 formation	 favoured	MgCl2	




The	 optimised	 crystals	 grew	 to	 30	µm	 following	 a	 seven-day	 incubation	 at	 20	°C	 in	
100	mM	 Bis-Tris	 pH	 6.5,	 across	 several	 concentrations	 of	 PEG	 3350	 (15–20%)	 and	






Sparse-matrix	 screens	 were	 performed	 with	 increasing	 concentrations	 of	 PEG	 3350	 and	 MgCl2	 in	
100	mM	Bis-Tris	(A)	pH	6.0;	(B)	pH	6.25;	(C)	pH	6.50;	(D)	pH	6.75;	(E)	pH	7.0;	and	(F)	pH	7.25.	The	protein	







A	 ligand-free	 SR	 crystal	 diffracted	 to	 1.9	Å	 resolution	 using	 radiation	 generated	 in-
house.	The	crystal	structure	of	the	SR	holoenzyme	(Fig.	5.4A)	was	organised	in	a	similar	
arrangement	 to	 the	 SR-malonate	 complex,	 comprising	 a	 large	 domain	 (teal),	 a	 small	
domain	 (purple)	 and	 a	 flexible	 loop	 region	 (orange).	 The	 PLP	 cofactor	 and	 Mg2+	
occupied	 the	 same	 space	 as	 their	 counterparts	 in	 the	 SR-malonate	 crystal	 structure.	
The	ordering	of	residues	appeared	to	be	improved	for	the	SR	open	conformation,	and	
a	 few	 residues	 were	 not	 well	 defined:	 1–3,	 132–135,	 and	 339–340.	 Aside	 from	 the	









revealed	 the	 arrangement	 of	 the	 large	 domains	 was	 nearly	 identical	 whereas	 the	
orientation	 of	 the	 small	 domains	 deviated	 considerably.	 The	 small	 domain	 is	
positioned	 much	 closer	 to	 PLP	 in	 the	 malonate-bound	 structure,	 and	 most	 notably	




variation.	The	degree	of	 conformational	 shift	 is	 reflective	of	 the	high	mobility	of	 the	
small	domain,	resulting	from	the	flexibility	allowed	by	the	loop	region.		
	
Smith	 et	 al.	 made	 the	 same	 observations	 from	 a	 structural	 alignment	 of	 the	 rat	





The	unbound	SR	crystal	 structure	was	determined	 to	a	 resolution	of	1.9	Å.	 (A)	Holoenzyme	monomer	
showing	 the	 large	 domain	 (teal),	 small	 domain	 (purple),	 flexible	 loop	 region	 (orange),	 PLP	 cofactor	
(yellow	 sticks),	 and	 magnesium	 ion	 (pink	 sphere).	 (B)	 Superimposition	 of	 SR	 holoenzyme	 	 (‘open’	
conformation,	grey)	and	malonate-bound	(‘closed’	conformation,	orange).	The	arrangement	of	the	large	






















Bis-Tris	 (10–100	mM)	 and	 buffer	 pH	 (6.0–7.25),	 with	 either	 0.1%,	 1%,	 5%,	 or	 10%	
microseed	in	each	quadrant.	Images	of	the	optimised	crystals	and	their	corresponding	
growth	 conditions	 are	 shown	 in	 Fig.	 5.5A–D.	 Crystals	 grew	 prolifically	 in	 many	
conditions,	 and	 the	 optimum	 conditions	 for	 crystal	 growth	 with	 microseed	 were	





In	 parallel	 to	 the	 microseeding	 experiments,	 SR	 was	 trialled	 in	 several	 commercial	
sparse-matrix	screens	to	try	to	 identify	new	crystallisation	conditions	that	might	 lead	
to	 more	 reproducible	 holo	 crystals.	 Four	 screens	 were	 performed	 (JCSGplus™,	
MIDASplus™,	Morpheus™,	ProPlex™)	with	SR	increased	to	7.5	mg/mL	to	facilitate	new	
crystal	 growth.	 Any	 resulting	 crystalline	material	was	 of	 a	much	 poorer	 quality	 than	
that	 obtained	 in	 previous	 experiments,	 so	 the	 conditions	 from	 these	 commercial	
screens	 were	 not	 pursued	 further.	 A	 commercial	 additive	 screen	 (ANGSTROM)	 was	
then	 performed	 cooperatively	 with	 one	 of	 the	 holo	 crystal	 conditions	 that	 had	
previously	yielded	twinned	crystals	 (100	mM	Bis-Tris	pH	6.5,	17%	PEG	3350,	250	mM	
























A	 100	 15	 220	 0.1	
B	 100	 20	 250	 1	
C	 100	 20	 240	 5	












Two	 24-well	 matrix	 screens	 of	 PEG	 3350	 (15–25%)	 and	 MgCl2	 (220–280	mM)	 with	
either	Bis-Tris	pH	6.0	or	6.5	were	screened	against	5	mg/mL	SR	and	10%	microseed	by	
hanging-drop	method.	 After	 two	 days	 of	 incubation	 at	 20	°C,	 large	 SR	 crystals	 with	
good	 morphology	 began	 to	 form	 in	 19–21%	 PEG	 3350	 and	 in	 all	 concentrations	 of	
MgCl2.	Select	crystals	grew	to	60	µm	(Fig.	5.6A–B)	and	diffracted	well	upon	preliminary	


















In	 this	 chapter,	purified	SR	was	 successfully	 crystallised	both	as	 the	malonate-bound	
complex	 and	 as	 the	 unbound	 holoenzyme,	 and	 their	 structures	were	 determined	 to	
respective	 resolutions	 of	 2.4	Å	 and	 1.9	Å.	 The	 in-house	 crystal	 structure	 of	 the	 SR-
malonate	complex	corroborated	the	findings	of	Smith	et	al.:	SR	 is	a	dimer,	with	each	
monomer	 comprising	 a	 large	 and	 small	 domain,	 the	 smaller	 of	 which	 undergoes	 a	





range	 of	 motion	 of	 the	 small	 domain	 is	 larger	 and	 more	 continuous,	 owing	 to	 the	
flexibility	of	the	hinge	region	that	connects	the	large	and	small	domains.	Indeed,	when	















It	 was	 imperative	 to	 develop	 a	 reproducible	 crystallisation	 protocol	 for	 the	 SR	
holoenzyme	to	enable	soaking	of	hits	generated	through	fragment	screening,	of	which	
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there	could	be	many.	Although	 it	 is	possible	 to	perform	soaking	with	co-crystals,	 the	
soaked	ligand	would	only	displace	the	co-crystallised	ligand	if	it	has	an	equal	or	greater	
affinity	 for	 the	 enzyme	 (Müller,	 2017),	 which	 is	 highly	 unlikely	 with	 weakly-binding	
fragment	 inhibitors.	 To	 this	 end,	 the	 inclusion	 of	 5	 or	 10%	microseed	 improved	 the	
reproducibility	 of	 holoenzyme	 crystal	 growth,	 and	 when	 used	 in	 conjunction	 with	
hanging-drop	vapour	diffusion,	produced	many	large	crystals	that	diffracted	well	upon	
preliminary	 X-ray	 analysis.	 These	 crystals	 were	 also	 tolerant	 of	 up	 to	 40%	 DMSO,	
indicating	they	are	suitable	for	soaking	with	high-concentration	ligands.	
	
Overall,	 crystallisation	 of	 the	 SR	 holoenzyme	 and	 malonate-bound	 enzyme	 in	 this	
chapter	showed,	firstly,	the	homogeneity	and	purity	of	the	target	protein;	secondly,	a	
reproducible	crystallisation	protocol	for	soaking	with	the	SR	holoenzyme;	and	thirdly,	








The	 development	 of	 SR	 inhibitors	 is	 a	 relatively	 new	 field,	 with	 the	 first	 group	 of	
inhibitors	 derived	 from	 L-serine	 and	 L-serine-O-sulfate	 (LSOS)	 only	 being	 identified	
little	more	than	a	decade	ago	 (Strísovský	et	al.,	2005).	This	 followed	the	observation	
that	LSOS,	 from	which	SR	generates	pyruvate	via	 its	β-elimination	activity,	acts	as	an	




thought	 to	 be	 competitive	 inhibitors	 (Dixon	 et	 al.,	 2006).	 Further	 studies	 described	
additional	 inhibitor	 families	 including	 hydroxamic	 acids	 (Hoffman	 et	 al.,	 2009a),	
cyclopropane	 derivatives	 (Beato	 et	 al.,	 2015),	 and	 more	 malonate-based	 inhibitors	
such	as	2,2-dichloromalonate	(Vorlová	et	al.,	2015).		
	
A	 new	 series	 of	 peptide	 inhibitors	 was	 later	 characterised	 through	 in	 silico	 and	
pharmacological	screening	based	on	one	of	 the	dipeptide-like	 inhibitors	 identified	by	









from	 the	 aforementioned	 literature	 inhibitors,	 as	 well	 as	 six	 pyrazole	 compounds	
identified	by	Evotec	from	an	SR	compound	screen	(40	in	total)	were	either	purchased	
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or	 synthesised	 and	purified	 in-house	 for	 assessment	 in	 the	biochemical	 and	 thermal	
shift	assays.	Many	of	 these	 inhibitors	have	not	had	 their	activity	 confirmed	by	other	
laboratories,	 so	 the	 first	objective	was	 to	 try	 to	 reproduce	 their	 inhibitory	effects	 in-
house.	Those	that	proved	to	be	effective	inhibitors	in	the	biochemical	assay	and	show	
a	discernable	 Tm	 shift	 in	 the	 thermal	denaturation	assay	 could	be	promising	 starting	
points	 for	 structural	 optimisation,	 ultimately	 to	 create	 SR	 inhibitors	 with	 increased	
potency	 and	 improved	 physicochemical	 properties.	 The	 identification	 of	 novel	 and	
potent	 inhibitors	using	this	method	of	studying	existing	inhibitors	 is	often	considered	
to	 have	 a	 higher	 chance	 of	 success	 compared	 to	 screening	 and	 analysing	 unknown	




Forty	 SR	 inhibitors	 from	 the	 literature	 including	 malonate-derivatives,	 pyrazole-
derivatives,	 amino	 acid	 derivatives,	 and	 peptides	 inhibitors	 were	 selected	 for	
characterisation	 in	 the	 SR	 biochemical	 assay	 (refer	 to	 Chapter	 3)	 and	 thermal	 shift	
assay	 (refer	 to	 Chapter	 4).	 The	 aim	 was	 to	 then	 collaborate	 with	 chemists	 in	
synthesising	 novel,	 potent	 derivatives	 with	 activities	 that	 could	 be	 verified	 in	 the	
biochemical	 assay.	 This	 chapter	 details	 the	 characterisation	 of	 these	 literature	
inhibitors,	the	findings	that	published	inhibitory	data	could	not	be	replicated	in-house	
with	 the	 SR	biochemical	 assay,	 and	 the	 eventual	 conclusion	 that	 none	of	 those	 that	










































































of	20	μL	per	well	 in	 LightCycler	Multiwell	plates.	Plates	were	centrifuged	and	 sealed	
before	 being	 equilibrated	 briefly	 on	 ice,	 and	 thermal	 denaturation	 analysis	 was	









coupled	 biochemical	 assay.	 Experiments	 were	 repeated	 at	 least	 twice,	 with	 at	 least	
one	of	the	repeats	using	inhibitor	that	had	been	repurified	in-house.		
	
Surprisingly,	almost	all	of	the	 inhibitors	exhibited	no	 inhibition	 in	the	SR	assay;	those	
that	did	are	displayed	in	Fig.	6.1.	The	most	potent	inhibitors	with	IC50	values	of	below	1	
mM	 were	 either	 malonate	 (3;	 96	μM)	 or	 derivatives	 of	 malonate,	 namely	 dimethyl	
maleate	 (4;	 180	μM),	 and	 hydroxymalonate	 (6;	 66	μM).	 Another	 compound	 that	
showed	inhibition	but	was	far	less	potent	was	L(+)-tartaric	acid	(1;	2700	μM),	although	
this	 agrees	 with	 published	 data	 describing	 the	 D-isomer	 as	 a	 much	 more	 potent	
inhibitor	 than	 the	 L-isomer	 (Strísovský	 et	 al.,	 2005).	 Two	 pyrazole-derivatives	







control	 malonate	 inhibited	 SR	 completely	 and	 consistently,	 and	 that	 inhibition	 was	
observed	 for	 a	 compound	 from	 each	 key	 group	 (malonate	 derivatives,	 pyrazoles,	
peptides)	 suggests	 this	 discrepancy	 was	 not	 assay	 related.	 The	 comparatively	 high	
concentration	 of	 SR	 could	 be	 obscuring	 the	 inhibitory	 activity	 of	 some	 of	 the	







inhibitors	 in	 the	 literature	 (Appendix	10.3).	Those	for	which	complete	 inhibition	curves	were	obtained	
are	shown	above	with	their	IC50	values	below	each	graph,	and	consist	of:	malonate	(3)	and	its	derivatives	
dimethyl	 maleate	 (4)	 and	 hydroxymalonate	 (6);	 two	 pyrazole	 derivatives	 (2	 and	 5);	 and	 4-fluoro	
methylphenoxyacetate	(28).	Assays	were	performed	in	triplicate	and	data	shown	are	the	mean	of	three	
experiments;	error	bars	=	SEM.		















IC50 = 480 ± 90 µM
2. 3-(1-ethyl-3-methyl-1H-
pyrazol-4-yl)propanoic acid















IC50 = 150 ± 20 µM
3. Malonate















IC50 = 180 ± 30 µM
4. Dimethyl maleate















IC50 = 1250 ± 210 µM
5. 2-(3,5-demethyl-1H-
pyrazol-4-yl) acetic acid















IC50 = 66 ± 7 µM
6. Hydroxymalonate




















The	 thermal	 shifts	 of	 all	 literature	 compounds	 tested	 here	 are	 shown	 in	 Fig.	 6.2.	 A	
thermal	 shift	was	defined	as	 significant	 if	 it	was	equal	or	greater	 than	 the	 threshold	
determined	by	3	×	σ	 (SR	+	DMSO	controls).	The	standard	deviation	of	the	SR	+	DMSO	




in	 the	biochemical	 assay.	Unsurprisingly,	malonate	 (3)	 and	 its	hydroxyl	derivative	 (6)	
caused	the	greatest	thermal	shifts	of	5–6	°C,	and	were	the	only	compounds	for	which	
both	 good	 inhibition	 and	 thermal	 shift	 data	were	 collected.	 After	 these,	 the	 largest	
thermal	 shifts	were	elicited	by	10	 (dimethyl	malonate),	 and	21	 (L-malic	 acid).	 It	was	
interesting	 that	D-malic	 acid	 (20)	 had	 a	much	 lower	 thermal	 shift	 than	 L-malic	 acid,	
with	DL-malic	acid	 (18)	 falling	 in	between,	 suggesting	 that	 the	 L-isomer	has	a	higher	




One	 literature	 compound	 (34;	 small	 peptide)	 caused	 a	 significant	 negative	 thermal	
shift.	As	a	negative	thermal	shift	is	associated	with	protein	destabilisation,	it	is	possible	
this	compound	is	not	an	inhibitor	but	instead	interacts	with	SR	to	cause	denaturation.	
The	 small	 peptide	 compound	33	 (and	34,	which	 elicited	 a	moderate	 but	 statistically	
insignificant	 thermal	 shift)	 is	 distinct	 from	 the	 other	 peptides	 in	 the	 series	 by	 the	










compounds)	 was	 established	 and	 compared	 to	 SR	+	DMSO	 controls	 to	 find	 the	 thermal	 shift.	 The	
threshold	 for	 significant	 shifts	 (3σ)	 was	 determined	 to	 be	 2.5	°C	 from	 the	 SR	+	DMSO	 controls.	 Red	
arrows	indicate	significant	thermal	shifts.	Experiments	were	performed	in	triplicate;	data	are	from	three	
independent	experiments	(n	=	3).	 	
























































could	 have	 signified	 a	 shift	 away	 from	 malonate-based	 inhibitors.	 These	 bulky	
hydrophobic	peptides	were	described	as	having	IC50	values	similar	to	malonate	(Mori	
et	 al.,	 2014)	 in	 distinct	 but	 conceptually	 analogous	 coupled	 assays	 to	 the	 one	 used	
here	 (Table	6.1).	The	authors	of	 the	 first	 report	on	peptide	SR	 inhibitors	claimed	the	





outcompeted	 by	 an	 inhibitor,	 therefore	 it	 is	 unlikely	 the	 peptide	 compounds	 were	
interacting	with	the	Mg-ATP	site.		
	
It	 could	 be	 that	 the	 stoichiometry	 between	 enzyme,	 substrate,	 and	 inhibitor	 had	 a	
significant	 influence	 on	 the	 level	 of	 inhibition	 observed.	 The	 study	 by	 Mori	 and	
colleagues	used	1	μM	hSR,	20	mM	L-serine	(unusually	high,	given	the	reported	Km	of	L-
serine	racemisation	by	SR	is	around	5	mM),	and	1	mM	peptide	compound;	whereas	in	
this	 study,	 the	 concentrations	 used	 were	 400	nM	 SR,	 2	mM	 L-serine,	 and	 500	μM	
maximum	 peptide	 concentration.	 That	 inhibition	 is	 not	 relieved	 with	 such	 a	 high	
concentration	of	 substrate	 in	 the	Mori	 study	gives	 credence	 to	 the	possibility	of	 the	
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mode	 of	 inhibition	 being	 noncompetitive	 or	 uncompetitive.	 Alternatively,	 substrate	
inhibition	could	be	occurring	instead	of	or	in	conjunction	with	peptide	inhibition	due	to	
the	 high	 levels	 of	 L-serine.	 Substrate	 inhibition	 occurs	 in	 about	 20%	 of	 all	 known	
enzymes	and	 is	primarily	caused	by	more	than	one	substrate	molecule	binding	to	an	
active	 site	 meant	 for	 just	 one,	 usually	 by	 different	 parts	 of	 the	 substrate	 molecule	
binding	to	separate	subsites.		
	
Table	 6.1.	 Comparison	 of	 assay	 parameters	 from	 the	 present	 study	 and	 two	 reports	 on	 SR	 peptide	
inhibitors.	
Assay	parameter	 Dixon	et	al.	2006	 Mori	et	al.	2014	 Koulouris	2017	
SR	 Human	 Human,	1	µM	 Human,	400	nM	
Enzyme	purity	 ?	 80%	 >	95%	
[L-serine]	 1.25	mM	 20	mM	 2	mM	

















Inhibitor	incubation	 40	min	 ?	 15	min,	RT	
Substrate	incubation	 ?	 8	h,	37	°C	 20	min,	RT	
	
The	 molecular	 docking	 studies	 performed	 by	 Mori	 and	 colleagues	 do	 build	 a	
compelling	 case	 for	 the	 peptide	 compounds	 as	 novel	 SR	 inhibitors.	However,	 during	
biochemical	 analysis	 the	 same	 study	 also	 described	 an	 enzyme	 purity	 of	 80%	 for	
human	 SR,	 which	 although	 adequate	 for	 assay	 purposes,	 does	 increase	 the	 risk	 of	
detecting	contaminating	enzyme	activity	when	combined	with	the	high	concentrations	
of	enzyme	used	 in	coupled	assays.	 In	consideration	of	 these	 factors,	 it	was	expected	
the	 assay	 described	 in	 the	 present	 studies	 would	 be	 sufficiently	 sensitive	 to	 detect	
inhibition	by	the	peptide	compounds.	That	it	did	not	could	most	likely	be	attributed	to	
differences	 in	assay	 format,	or	potentially	 the	proposed	slow-binding	kinetics	 for	 the	
peptide	 inhibitors	 (Dixon	 et	 al.,	 2006).	 Indeed,	 Dixon	 et	 al.	 incubated	 SR	 with	
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compound	for	40	min	to	account	for	a	slow	binding	mechanism,	wherein	the	inhibitor	
initially	binds	 in	a	 loose	complex	with	SR,	 followed	by	slow	 isomerisation	to	the	final	
tighter	 complex.	 Further,	 they	 noted	 a	 slower	 loss	 of	 enzyme	 activity	 over	 time	
following	 an	 initial	 decrease,	 indicating	 slow	 dissociation	 of	 the	 inhibitor	 from	 the	





such	 as	 malic	 acid	 and	 succinic	 acid,	 did	 not	 exhibit	 inhibition.	 At	 least	 with	 the	
pyrazole	 and	 peptide	 compounds,	 one	 could	 argue	 that	 experimental	 discrepancies	
may	be	expected	because	the	data	had	not	been	verified	by	other	sources.	Malonate	
derivatives	 and	 related	 carboxylic	 acids,	 on	 the	 other	 hand,	 have	 been	 well	
characterised	 in	 the	 literature	 for	 their	 inhibitory	 potential	 against	 SR.	 Succinic	 acid	
(17),	L-malic	acid	(21),	and	dihydroxyfumaric	acid	(7)	were	all	expected	to	demonstrate	
SR	 inhibition	 in	 the	 SR	 assay,	 especially	 as	 their	 structural	 similarity	 to	 malonate	
suggested	they	would	be	suitable	for	IC50	determination	using	this	method.	Ultimately,	
most	of	the	carboxylic	acids	only	elicited	thermal	shifts	that	were	insignificant,	as	well	
no	 measurable	 IC50,	 which	 together	 suggests	 no	 inhibition	 was	 occurring	 despite	
published	data	to	the	contrary.		
	












The	 development	 of	 new	 drugs	 targeting	 therapeutically	 relevant	 proteins	 is	 a	
particular	 challenge	when	 there	 are	 few	 or	 no	 pre-existing	 chemical	 starting	 points.	
Screening	of	compound	libraries	has	been	a	traditional	approach	in	drug	discovery,	but	
is	 plagued	 by	 a	 high	 attrition	 rate	 of	 chemical	 compounds	 and	 a	 poor	 record	 of	





With	respect	to	SR,	there	 is	still	a	distinct	 lack	of	potent	and	selective	 inhibitors	that	
could	function	as	chemical	starting	points	for	drug	development.	Previous	efforts	have	
focused	either	on	compound	screening	or	creating	derivatives	of	pre-existing	inhibitors	
with	 improved	 potency,	 but	 overall	 progress	 has	 been	 slow,	 and	 only	 very	 recently	
have	inhibitors	been	developed	that	are	structurally	distinct	from	malonate	and	amino	
acid	 analogues	 (see	 section	 1.7.7).	 To	 date,	 no	 studies	 have	 employed	 FBDD	 as	 an	
approach	 to	 develop	 novel	 SR	 inhibitors.	 FBDD	 may	 be	 particularly	 suited	 to	 SR	
because	 its	 crystal	 structure	 revealed	 that	 targeting	 its	 active	 site	would	 require	 an	
inhibitor	small	enough	to	enter	 the	tight	cleft	between	the	 large	and	small	domains.	
Fragment	 molecules	 such	 as	 those	 found	 in	 screening	 libraries	 may	 overcome	 this	
difficulty	 because	 they	 have	 a	 very	 low	 molecular	 mass	 (<	300	Mw)	 and	 can	 be	
structurally	understood	by	X-ray	crystallography	and	NMR	(Rees	et	al.,	2004).		
	
One	 of	 the	 major	 benefits	 of	 FBDD	 is	 that	 it	 requires	 significantly	 fewer	 fragment	
molecules	 to	be	screened	and	synthesised	prior	 to	generating	new	 lead	compounds,	
compared	 to	 the	 numbers	 of	 compounds	 needed	 for	 HTS.	 There	 are	 a	 number	 of	
reasons	for	this:	firstly,	fragments	have	a	higher	probability	of	binding	to	the	target	site	
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ligand	 (Hopkins	 et	 al.,	 2004).	 Thirdly,	 there	 is	 much	 more	 potential	 for	 inhibitory	




novel	 chemical	modulators	 of	 SR	 that	 have	 potential	 for	 structural	 optimisation	 and	
medicinal	 chemistry,	 and	 accordingly,	 FBDD	 has	 been	 employed	 as	 the	 primary	
approach	in	this	thesis.	The	process	of	fragment	screening	and	hit	validation	discussed	
herein	 employs	 the	 techniques	 optimised	 in	 the	 preceding	 chapters,	 and	 are	 all	
important	components	of	a	FBDD	strategy.	The	use	of	multiple	techniques	—	medium-
throughput	 biochemical	 assay,	 three	 biophysical	 methods,	 and	 an	 optimised	





the	 Life	 Chemicals	 3D	 Fragment	 Library	 (containing	 642	 fragments).	 The	Maybridge	
Ro3	library	has	been	specifically	engineered	to	improve	Ro3	(rule	of	three)	compliance,	
which	is	a	set	of	parameters	that	ideal	fragments	should	follow:	Mw	<	300,	ClogP	<	3,	
the	 number	 of	 hydrogen	 bond	 donors	 and	 acceptors	 each	 should	 be	 <	3,	 and	 the	
number	 of	 rotatable	 bonds	 should	 be	 <	3	 (Congreve	 et	 al.,	 2003).	 The	 Maybridge	
library	 also	 contains	 computationally	 engineered	 structural	 diversity,	 useful	 levels	 of	
solubility	 in	 DMSO	 and	 buffer,	 and	 omits	 potentially	 problematic	 reactive	 groups	 to	
overall	make	 it	 suited	 for	generating	hit	matter	 in	drug	discovery	 (Maybridge,	2017).	
The	Life	Chemicals	3D	library	was	developed	based	on	the	concept	that	higher	three-
dimensionality	of	molecules	is	a	desirable	feature	of	drug	candidates	and	is	thought	to	
correlate	 with	 successful	 passage	 of	 molecules	 at	 various	 stages	 of	 clinical	
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development	 (Life	 Chemicals,	 2017).	 Other	 key	 features	 of	 the	 Life	 Chemicals	 3D	
library	include	ClogP	≤	3,	at	least	one	chiral	centre,	no	more	than	one	–cyano,	–nitro,	
or	 bromine	 group,	 and	 ideally	 two	 points	 of	 functionalization.	 The	 Life	 Chemicals	
library	 has	 also	 removed	 undesirable	 functionalities,	 such	 as	 pan-assay	 interference	
compounds	(PAINS)	that	manifest	frequently	as	false	positives	and	artefacts	(Baell	and	
Walters,	 2014).	 Together,	 these	 two	 fragment	 libraries	 cover	 a	 broad	 range	 of	




FBDD	 strategy	 with	 SR,	 by	 a)	 screening	 the	 two	 aforementioned	 fragment	 libraries	
using	 the	 biochemical	 assay	 optimised	 for	 medium-throughput	 screening,	 b)	
characterising	 binding	 of	 any	 hits	 using	 a	 combination	 of	 the	 three	 biophysical	
methods	 (thermal	 shift,	 MST,	 ITC)	 and	 deducing	 their	 KD	 where	 possible,	 and	 c)	
confirming	 binding	 to	 SR	 with	 X-ray	 crystallography.	 As	 will	 be	 described	 in	 further	
detail	hereafter,	this	process	led	to	the	elucidation	of	a	novel	SR	inhibitor	—	3-pyridin-
4-yl	benzoic	acid	(referred	to	as	F01	in	this	chapter)	 	—	that	not	only	showed	activity	
and	 binding	 in	 the	 biochemical	 and	 biophysical	 assays,	 but	 most	 excitingly,	 was	
successfully	 crystallised	bound	 to	SR.	The	crystal	 structure	of	SR	bound	 to	 this	novel	
fragment	inhibitor	will	be	a	valuable	contribution	to	SR	research	and	potentially	enable	













determination.	 The	 61	 most	 potent	 hits	 (IC50	≤	1.2	mM)	 were	 advanced	 to	 biophysical	 hit	 validation.	



















Ro3	2500	Diversity	Fragment	Library	 Maybridge	 100	 1	 5	
3D	Fragment	Library	 Life	Chemicals	 100	 1	 5	
	
7.2.3 Buffers	and	solutions	






























































All	 automated	 dispensing	 steps	 were	 performed	 with	 a	 Multidrop	 Combi	 and	
compound	 addition	 steps	 with	 a	 FluidX	 Xpp-721	 liquid	 handler.	 Before	 use,	 the	
dispensing	cassette	of	the	Multidrop	Combi	was	primed	with	assay	solution	to	ensure	










50%	 inhibition	 (2	µL	 10	mM	malonate	 in	 100%	 DMSO;	 final	 concentration	 100	µM),	
and	100%	inhibition	(2	µL	100	mM	malonate	in	100%	DMSO;	final	concentration	1	mM)	





Assay	 procedure.	 The	 384-well	 assay	 plate	 was	 preloaded	 with	 the	 positive	 (plus	
enzyme;	4	µL	SR	solution	II)	and	negative	(no	enzyme;	4	µL	Tris	mix	buffer)	controls	to	
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columns	1,	2,	23,	and	24	 (Fig.	7.2B	 for	plate	map).	 SR	 solution	 II	was	dispensed	 into	
columns	3-22	(4	µL;	final	concentration	400	nM).	Samples	were	then	transferred	from	
each	of	the	four	intermediate	plates	(2	µL;	final	fragment	concentration	1	mM;	FluidX-
Xpp-721	 with	 EZ-Load	 96-well	 pipette	 tips)	 to	 the	 384-well	 assay	 plate	 using	 a	
quadrant	 layout	 (Fig.	 3.2B),	 and	 the	 plate	 was	 incubated	 for	 15	min	 at	 RT.	 L-serine	
solution	 II	 was	 dispensed	 to	 the	 entire	 plate	 to	 start	 the	 reaction	 (4	µL;	 final	
concentration	2	mM;	Multidrop	Combi),	and	then	the	plate	was	incubated	for	20	min.	
The	H2O2	produced	 in	 the	assay	was	quantified	with	 the	addition	of	30	μL	Detection	
Solution	A,	and	after	a	5	min	incubation	the	luminescence	signal	was	measured.	
	






























final	 concentration	 1%),	 50%	 inhibition	 (2	μL	 2.5mM	 sodium	 benzoate;	 final	
concentration	 25	µM),	 and	 100%	 inhibition	 (2	µL	 25mM	 sodium	 benzoate;	 final	
concentration	250	µM).		
	
Assay	procedure.	SR	was	omitted	 from	 the	 counter	 screen	and	 instead	4	μL	 Tris	mix	
buffer	was	dispensed	across	 the	entire	384-well	plate.	The	procedure	was	otherwise	
performed	as	in	section	7.3.1,	but	instead	of	L-serine	solution	II,	D-serine	solution	was	
dispensed	 into	 all	 wells	 of	 the	 384-well	 plate	 (4	µL;	 final	 concentration	 15	µM).	 The	








Preparation	 of	 stock	 and	 intermediate	 plates.	 Hits	 were	 cherry-picked	 from	 the	
fragment	 library	stock	plates	to	create	new	IC50	stock	plates.	Each	100	mM	fragment	
hit	was	used	to	perform	one	10-point	1:3	serial	dilution	 in	100%	DMSO	per	row	of	a	







(plus	 enzyme;	 4	μL	 SR	 solution	 II)	 and	 negative	 (no	 enzyme;	 4	μL	 Tris	 mix	 buffer)	
controls	to	columns	1,	2,	23,	and	24.	SR	solution	II	was	dispensed	to	columns	3-22	(4	µL;	
final	 concentration	 400	nM).	 Samples	 were	 transferred	 in	 duplicate	 from	 two	
intermediate	 plates	 to	 the	 384-well	 assay	 plate	 (2	µL;	 final	 concentrations	 0–5	mM;	










analysed	 using	 the	 Dotmatics	 Electronic	 Lab	 Notebook	 (ELN)	 server	
(http://dotmatics.chem.sussex.ac.uk)	 to	 calculate	 percentage	 inhibition.	 Plate	 data	
quality	was	 assessed	 using	 the	 Z’	 score,	 as	 described	 in	 section	 3.3.8.3.	 Plates	were	




fragments	 were	 classified	 as	 hits	 if	 they	 demonstrated	 a	 significant	 percentage	
inhibition	in	the	fragment	screen,	and	little	to	no	inhibition	in	the	counter	screen.	Such	





















(N1	and	N2).	The	Z’	scores	 for	all	 ten	plates	 for	both	N1	and	N2	are	plotted	on	the	graph.	The	Z’	was	




















reasonably	 good	 correlation	 and	 reproducibility	 between	 the	 two	 screens.	 Several	
fragments	appeared	to	inhibit	greater	than	100%	as	a	result	of	the	luminescence	signal	
being	 reduced	below	 the	background	 (no	enzyme)	 control,	which	may	be	 caused	by	
interference	with	DAO	or	the	luminol	redox	reaction	that	respectively	turn	over	basal	
levels	 of	 D-serine	 and	 H2O2.	 Numerous	 outliers	 that	 demonstrated	 over	 threefold	











the	 stringency	by	 raising	 the	 threshold	 to	50%.	The	outcome	would	be	an	 improved	
likelihood	of	the	fragments	within	the	confidence	 interval	being	genuine	hits,	as	well	
as	 reducing	 the	 initial	 hit	 number.	 A	 50%	 significance	 threshold	 reduced	 the	 hit	
number	 to	 970;	 equivalent	 to	 a	 hit	 rate	 of	 30%.	 This	 hit	 rate	was	 greater	 than	 that	
typically	 expected	 for	 a	 fragment	 screen	 (~10%),	 but	 it	was	probable	many	of	 these	
initial	hits	were	false	positives.		
	
A	 histogram	 of	 the	 hits	 (Fig.	 7.5),	 shows	 how	 the	 high	 hit	 rate	 resulted	 in	 a	 highly	
spread	normal	distribution.	The	fragments	with	50%	inhibitory	activity	or	greater	are	












Fragments	 from	 two	 libraries	 (Maybridge	 Ro3	 2500	 and	 Life	 Chemicals	 3D	 fragment	 libraries)	 were	
screened	and	the	distribution	of	their	percentage	inhibition	was	plotted	(green).	The	high	(red)	and	low	
(black)	 enzyme	 controls	 were	 normally	 distributed	 around	 0%	 and	 100%,	 as	 expected.	Malonate	 (SR	
inhibitor)	was	used	as	the	compound	control.	The	threshold	for	significant	inhibition	was	defined	as	50%,	
determined	by	3	×	σ	(positive	controls)	+	10%	to	increase	stringency,	resulting	in	970	hits.	N	=	2.			 	


















The	purpose	of	 the	DAO	counter-screen	was	 to	 try	 to	eliminate	non-specific	hits.	By	
repeating	 the	 fragment	 screen	 without	 SR,	 and	 cross-referencing	 hits	 from	 the	 SR	
screen	 and	 the	 counter	 screen	 to	 eliminate	 those	 that	 inhibited	 the	 assay	 in	 the	
absence	 of	 SR,	 it	 was	 possible	 to	 produce	 a	 final	 list	 of	 specific	 SR	 hits	 (although	
unconfirmed	binding).	The	counter	screen	was	performed	once,	and	the	threshold	for	
the	counter	screen	was	defined	as	previously:	3	×	σ,	where	σ	is	the	standard	deviation	
of	 the	positive	 (100%	SR	activity)	 controls	across	 the	entire	 screen.	The	 threshold	of	
the	 DAO	 counter	 screen	 was	 thus	 calculated	 to	 be	 25%	 inhibition.	 Therefore,	




The	 scatter	 plot	 in	 Fig.	 7.6A	 shows	 the	 average	 percentage	 inhibition	 of	 the	 970	
apparent	inhibitors	from	the	initial	fragment	screen	against	the	percentage	inhibition	
of	 those	 same	 fragments	 in	 the	 counter	 screen.	 All	 the	 fragments	 exhibited	 at	 least		
50%	inhibition	 in	the	SR	screen,	and	highlighted	 in	blue	are	those	fragments	that	fell	
within	the	0	±	25%	inhibition	range	in	the	DAO	counter	screen.	Although	there	is	not	a	






7.6B.	 As	 expected,	 the	 data	 appear	 to	 be	 largely	 normally	 distributed	 around	 0%	
inhibition	 for	 SR	 specific	hits,	 and	around	100%	 inhibition	 for	non-specific	 inhibitors.	
Those	fragments	that	fell	within	the	0	±	25%	inhibition	range	are	highlighted	in	blue;	









value	 from	two	repeats)	against	 their	percentage	 inhibition	 in	 the	DAO	counter	 screen.	 (B)	Histogram	
showing	 the	 distribution	 of	 percentage	 inhibition	 data	 of	 the	 970	 fragment	 hits	 in	 the	 DAO	 counter	





The	 inhibitory	activity	of	 the	330	SR-specific	hits	 remaining	after	elimination	of	non-




100%	 inhibition,	 creating	 a	more	 apparent	 trend.	 It	 is	 clear	 in	 both	 cases	 there	was	
often	 a	 substantial	 amount	 of	 variability	 between	 repeats,	 and	 this	 effect	 is	 more	
pronounced	 with	 the	 smaller	 activity	 range	 of	 the	 SR-specific	 hits.	 The	 percentage	







correlation	was	 found	 to	 have	 an	 r2	 value	 of	 0.3.	 F01,	 the	 fragment	with	 binding	 confirmed	 by	 X-ray	
crystallography,	is	highlighted	in	green.		
	 	




















values	 twice.	 Many	 of	 the	 hits	 inhibited	 moderately	 well	 but	 only	 at	 the	 highest	
concentrations,	giving	 IC50	values	 too	high	 to	be	considered	 for	 the	next	 stage	of	hit	
validation.	The	IC50	values	of	the	330	inhibitors	from	both	IC50	screens	are	presented	in	
Fig.	 7.8A,	 and	 the	 r2	was	 calculated	 to	be	0.7.	 This	 is	 a	 reasonably	 good	 correlation,	
affected	 in	part	by	 the	disparate	 IC50	values	observed	between	experimental	 repeats	
for	 several	 fragments.	 The	 variability	was	most	 likely	 a	 result	 of	 artefactual	 data,	 as	
malonate	 inhibition	 controls	were	 in	 place	 to	 detect	 issues	with	 the	 assay.	 F01,	 the	
crystallography	 confirmed	 SR	 inhibitor	 (highlighted	 in	 green	 in	 Fig.	 7.8A),	 also	 had	
variable	inhibition	data	(Fig.	7.8B)	with	IC50	values	of	1648	µM	and	532	µM.		
	
A	majority	 of	 the	 330	 fragments	were	 found	 to	 have	 IC50	 values	 greater	 than	 1mM,	
despite	 the	 stipulation	 that	 only	 fragments	 eliciting	 50%	 inhibition	 at	 1mM	 were	
progressed	from	the	fragment	screen.	This	would	mean,	in	theory,	that	the	fragments	
should	 demonstrate	 an	 IC50	 of	 around	 1	mM	or	 below.	 That	many	 did	 not	 could	 be	
reflective	 of	 the	 solubility	 issues	 exhibited	 by	 several	 fragments	 when	 diluted	 into	
buffer	from	DMSO,	which	would	prevent	accurate	IC50	determination.		
	
The	 variability	 of	 the	 IC50	 data	 informed	 which	 fragments	 were	 selected	 for	
progression	 to	 biophysical	 hit	 validation.	 Initially,	 hits	 were	 selected	 if	 they	 had	 an	
average	 IC50	 up	 to	 1	mM	 and	 if	 the	 two	 repeats	 were	 within	 a	 threefold	 range.	
Additional	 fragments	were	 selected	 for	 follow-up	 if	 a)	 both	 repeats	 demonstrated	 a	
considerably	low	IC50	value	but	were	not	within	a	threefold	range,	and	b)	only	one	of	
the	determined	IC50	values	was	≤	1	mM	(giving	an	average	IC50	value	above	1	mM).	The	
latter	 stipulation	 applied	 to	 F01.	 A	 total	 of	 61	 fragments	 were	 progressed	 to	

























































Following	 IC50	determination,	 all	 61	 fragments	were	 subject	 to	 thermal	denaturation	
analysis	 to	 determine	 their	 thermal	 shifts	 (Fig.	 7.9).	 The	 positive	 control,	 malonate,	
produced	 positive	 thermal	 shifts	 associated	 with	 binding	 that	 agreed	 well	 with	
previous	 data	 (approx.	 6	°C;	 section	 4.4.3).	 A	 majority	 of	 the	 fragments	 (48;	 79%)	
produced	a	negative	Tm	shift	 indicative	of	 fragments	destabilising	SR	 in	 the	unfolded	
state,	 or	 fragments	 aggregating	 and	 causing	 early	 destabilisation	 of	 the	 protein.	 In	





threshold	 value	 that	 is	 inclusive	 of	most	 of	 the	 test	 compounds.	 However,	 because	
malonate	 elicits	 a	 considerable	 thermal	 shift,	 the	 significance	 was	 determined	
empirically	 rather	 than	 using	malonate	 data	 as	 a	 reference	 point.	 The	 threshold	 for	





F02,	F09,	and	F52.	The	 remaining	 fragments	either	caused	negligible	 shifts,	or	 in	 the	










and	 is	 indicated	 by	 the	 blue	 dashed	 line.	 Most	 fragments	 cause	 negative	 shifts;	 those	 that	 caused	
significant	positive	shifts	are	signaled	by	the	red	arrows.	Error	bars	=	SD,	n	=	3.	 	
























fact	 no	 conformational	 change	 was	 observed	 in	 the	 crystal	 structure	 of	 the	 SR-F01	




Figure	 7.10.	 Thermal	 denaturation	 analysis	 and	melting	point	 shifts	 (ΔTm)	 of	 SR	with	 four	 fragment	
hits.	
Thermal	denaturation	analysis	was	performed	on	1	µM	SR	with	61	 fragment	hits.	Of	 those	hits,	 three	
produced	positive	Tm	shifts	 that	were	statistically	 significant:	F02,	F09,	and	F52.	The	Tm	shift	with	F01	
was	not	significant.	Experiments	were	performed	in	triplicate;	n	=	2.		 	

































The	 average	 of	 the	 DMSO	 controls	 was	 calculated	 from	 each	 plate	 and	 used	 to	
determine	the	standard	deviation	for	the	entire	screen.	This	resulted	in	three	values,	
for	each	repeat	of	 the	screen	 (n),	which	were	then	multiplied	by	 three	to	determine	
the	degree	Fnorm	shift	that	was	significant.	These	values	(17,	14,	15;	rounded	to	two	
s.f.)	 were	 calculated	 independently	 for	 each	 repeat	 of	 the	 screen.	 The	 overall	
downward	trend	of	Fnorm	observed	over	time	(Fig.	4.11)	meant	even	though	internal	
control	data	for	each	screen	were	in	agreement,	the	standard	deviation	of	the	DMSO	






further	 five	 fragments	 (F22,	F36,	F39,	F43,	and	F53)	were	approaching	 the	 threshold	
for	 significance,	 and	 ultimately	were	 included	 in	 the	 final	 group	 of	 13	 fragments	 to	
increase	the	likelihood	of	obtaining	a	confirmed	binder.		
	
The	 Fnorm	 shifts	 (ΔFnorm)	 of	 the	 13	 fragment	 hits	 can	 be	 seen	 in	 Fig.	 7.11.	
Interestingly,	 all	 fragments	 displayed	 positive	 thermodiffusion	 (SR-fragment	 complex	
moved	away	from	heat	source)	except	F01,	the	confirmed	binder,	and	malonate.	The	
fact	 both	 F01	 and	 malonate	 exhibited	 negative	 thermodiffusion	 suggests	 potential	








Figure	 7.11.	 SR	 inhibitor	malonate	 and	 13	 fragment	 hits	 demonstrating	 a	 significant	 Fnorm	 shift	 in	
MST.	
The	binding	of	1	mM	fragment	molecule	to	50	nM	SR	was	analysed	by	MST	for	all	61	fragment	hits.	The	






Further	 analysis	 consisted	 of	 performing	 a	 10-point	 titration	 of	 each	 compound	 to	
determine	their	binding	affinity	via	calculation	of	the	dissociation	constant	(KD).	Not	all	




behaviour	 (Fig.	 7.12A).	 Four	 of	 these	 fragments	—	F04,	 F13,	 F16,	 and	 F42	—	do	 not	
approach	a	plateau	at	 the	 top	of	 the	 curve,	which	may	be	 the	 cause	of	 the	poor	KD	














































the	 other	 fragments	 and	 suggests	 these	 fragments	might	 be	 inherently	 fluorescent.	
Exceptionally	 strong	 fluorescence	 changes	 might	 also	 indicate	 aggregation	 of	 the	
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binding	 curve,	 and	 an	 example	 reflective	 of	 the	 controls	 for	 the	 other	 fragments	 is	
given	 in	 Fig.	7.13.	 The	 aggregation	 control	 is	 a	 re-read	 of	 the	 plate	 after	 a	 45	min	











(A)	 Binding	 curve	 of	 SR	 and	 F39;	 data	 were	 collected	 immediately	 after	 sample	 preparation	 (closed	
circles)	and	again	45	min	later	(open	circles).	No	distortion	to	the	overall	shape	of	the	curve	over	time	
suggests	the	effect	of	the	test	fragment	is	not	a	result	of	causing	SR	aggregation.	(B)	Identical	samples	
were	denatured	with	 the	addition	of	5%	SDS	and	1	mM	DTT,	 followed	by	heating	at	90	°C	 for	10	min,	















































ITC	 experiments	 were	 performed	 selectively	 due	 to	 experiments	 being	 limited	 by	
protein	 consumption.	 The	 three	 fragments	with	 the	 lowest	 KD	 as	 calculated	 by	MST	










achieve	 a	 curve.	 To	 obtain	 a	 binding	 curve	 of	 a	 fragment	with	 a	 KD	 of	 500	μM,	 the	
ligand	concentration	needed	 to	be	approximately	80-fold	 the	cell	 concentration.	The	
challenge	 here	 was	 the	 difficulty	 maintaining	 ligand	 solubility,	 and	 high	 ligand	
concentrations	increased	the	DMSO	content	by	default,	causing	large	obscuring	DMSO	




Following	 direct	 titration	 with	 F01,	 F39,	 and	 F45	 (Fig.	 7.14),	 the	 quantity	 of	 heat	
measured	for	each	injection	was	roughly	equal	throughout	the	experiment.	Due	to	the	
size	of	the	peaks,	it	was	not	possible	to	ascertain	whether	the	peaks	were	equal-sized	
because	 no	 binding	 had	 occurred	 and	 therefore	 there	 was	 no	 enthalpy	 change,	 or	
whether	 the	 large	 DMSO	 peaks	 were	 obscuring	 a	 binding	 curve.	 As	 analysing	 the	






The	experiment	was	performed	with	F01	 (A),	F39	 (B)	or	F45	 (C)	and	comprised	13	 injections	of	2	mM	
fragment	into	the	sample	cell	containing	25	µM	SR.	The	raw	data	peaks	(left)	were	integrated	to	obtain	
the	enthalpy	change	(ΔH)	and	were	plotted	against	the	molar	ratio	of	inhibitor	to	SR	in	the	sample	cell	
(right).	 All	 isotherms	 exhibited	 large	 heat	 of	 dilution	 peaks	 that	 prevented	 binding	 curves	 of	 the	
inhibitors	being	established.	 	





































































































assay,	 another	 type	of	 ITC	experiment.	Here,	 two	 (or	more)	 ligands	 that	bind	 to	 the	





bind	 to	 the	 same	 target	 with	 broadly	 different	 affinities,	 which	 may	 require	
comparison	 with	 a	 well-characterised	 reference	 ligand	 (malonate,	 in	 this	 case).	 The	









performed	with	100	μM	SR	and	1	mM	fragment	 (weak	binder)	 in	 the	cell,	and	1	mM	
malonate	(‘strong’	binder)	 in	the	injection	syringe.	Fig.	7.15	shows	the	binding	curves	
of	malonate	and	SR	alone	(blue)	and	malonate	when	SR	was	present	 in	 the	cell	with	
each	 fragment	 (red).	 The	 thermodynamic	quantities	of	each	experiment,	 in	 terms	of	
Gibbs	 free	energy	 (ΔG),	 enthalpy	 (ΔH)	and	entropy	 (-TΔS)	 are	 shown	 in	 Fig.	7.16,	 for	
both	 the	 strong	binder	 and	 combined	 strong	 and	weak	binders.	 It	 is	 generally	more	
applicable	to	discuss	ΔG	and	ΔH	values	as	these	are	the	properties	determined	 in	an	








F17	 (B),	 F39	 (C),	 or	 F45	 (D)	 and	 comprised	 13	 injections	 of	 1	mM	 malonate	 into	 the	 sample	 cell	





















































































Table	 7.1.	 Thermodynamic	 parameters	 of	 SR-malonate	 binding	 in	 the	 absence	 and	 presence	 of	
fragment	inhibitors.	










-Ligand	 +Ligand	 -Ligand	 +Ligand	 -Ligand	 +Ligand	
F01	 13	 15	 -4.04	 -3.5	 -6.67	 -6.57	
F17	 15	 638	 -4.21	 -80	 -6.58	 -4.36	
F39	 25	 1380	 -4.52	 -80	 -6.29	 -3.9	
























The	 malonate-only	 binding	 isotherms	 in	 Fig.	7.15	 demonstrate	 typical	 exothermic	
binding	modes	with	KD	 constants	of	13	±	1	µM	 (A),	15	±	2	µM	 (B),	25	±	5	µM	 (C),	 and	
8.6	±	3	µM	 (D).	 The	 thermodynamic	 constants	 in	 Fig.	7.16	 indicate	 SR	 binding	 to	
malonate	was	not	dominantly	enthalpic	or	entropic,	but	was	instead	favoured	by	both.	
It	is	immediately	obvious	the	binding	isotherms	in	Fig.	7.15	become	less	defined	In	the	
presence	 of	 the	weak	 ligand	 than	with	malonate	 alone,	 suggesting	 there	was	 some	
interference	or	displacement	of	malonate	binding	by	 the	 fragment	 inhibitors.	 This	 is	
reflected	by	the	apparent	KD	of	malonate	increasing	by	approximately	50-fold	when	in	
the	 presence	 of	 the	 fragment	 molecules	 (Table	 7.1).	 The	 difference	 to	 the	 binding	
isotherms	was	not	sufficient	to	empirically	estimate	the	dissociation	constants	of	the	
fragments.	 This	 may	 be	 because	 the	 fragments	 were	 not	 tested	 at	 concentrations	
required	to	saturate	SR	(typically	tenfold	the	KD),	which	in	the	case	of	these	fragments	
would	 be	 between	 5–10	mM.	 Unfortunately,	 it	 was	 not	 possible	 to	 approach	










associated	 with	 a	 molecular	 change	 leading	 to	 more	 and/or	 tighter	 van	 der	 Waals	
contacts	and	H-bonds	between	the	ligand	and	enzyme,	which	may	be	indicative	of	the	
weak	 fragment	 contacts	 being	 displaced	 by	malonate	 interactions	 in	 the	 active	 site.	
According	 to	 the	 phenomenon	 of	 enthalpy-entropy	 compensation,	 a	 more	 negative	






by	 displacing	 tightly	 bound	 water	 molecules	 in	 its	 binding	 pocket,	 consequently	
releasing	more	water	molecules	 into	 the	 system	and	 thereby	 increasing	 entropy	 (by	
increasing	disorder).		
	
F01,	 the	 inhibitor	 subsequently	 confirmed	 to	 bind	 to	 SR	 by	 X-ray	 crystallography,	
should	 theoretically	 compete	with	malonate	because	both	 ligands	bind	 in	 the	 active	
site.	 However,	 the	 thermodynamic	 profile	 of	 F01	 (Fig.	 7.16)	 was	 not	 overly	 distinct	
from	 that	 of	 malonate,	 and	 it	 also	 did	 not	 appear	 to	 influence	 the	 KD	 of	 malonate	
(Table	7.1).	An	explanation	could	be	the	experimental	concentration	of	the	fragment	
was	not	enough	to	saturate	SR	prior	to	malonate	titration,	therefore	malonate	binding	
would	 be	 largely	 unaffected	 by	 the	 presence	 of	 a	 fragment	 inhibitor	 because	most	





based	 on	 the	 generated	 thermodynamic	 profiles,	 but	 challenges	 in	 manipulating	
concentrations	to	optimise	the	c-value,	maintaining	inhibitor	solubility,	and	designing	
experiments	 around	 the	 incredibly	 weak	 binding	 affinities	 limited	 quantitative	
conclusions.	Overall,	 the	 findings	 discussed	 here	 are	 not	 unequivocal	 and	 data	 from	
the	 displacements	 experiments	 are	 subject	 to	 interpretation.	 As	 ITC	 experiments	








In	 parallel	 to	 ITC	 studies,	 the	 four	 fragments	 (F01,	 F17,	 F39,	 F45)	 were	 subject	 to	
sitting-drop	 co-crystallisation	 trials.	 SR	was	 incubated	with	 saturating	 concentrations	
of	 each	 fragment	 (10	mM)	 prior	 to	 crystallisation	 in	 varying	 PEG	3350	 and	 MgCl2	
concentrations	around	those	determined	for	the	SR	holo	crystal	(section	5.4.3)	 in	the	

















A	 100mM	pH	6	 15%	 250mM	
B	 100mM	pH	6	 20%	 250mM	
C	 100mM	pH	6	 20%	 250mM	













A	 screen	was	performed	with	 F01	 (A–B)	 and	F39	 (C–D)	 in	 increasing	 concentrations	of	PEG	3350	and	
MgCl2	 in	Bis-Tris	pH	6.	Each	 fragment	was	 incubated	with	7.5	mg/mL	SR,	5%	seed	and	5	mM	DTT	at	a	
concentration	of	10	mM	(F01)	or	5	mM	(F39)	for	30	min	RT	prior	to	plating.	Crystal	growth	began	after	




Despite	 macroscopic	 morphology	 appearing	 well	 suited	 for	 image	 collection,	 both	
crystals	displayed	prolific	microscopic	pathology	(primarily	twinning)	upon	diffraction.	
Extensive	optimisation	would	have	been	required	to	resolve	this	problem,	so	focus	was	








A	 100mM	 19.5%	 280mM	
B	 100mM	 16.5%	 240mM	
C	 100mM	 20%	 240mM	







with	 10	mM	 of	 each	 F01,	 F16,	 F17,	 F28,	 and	 F39	 was	 performed	 according	 to	 the	
protocol	in	section	5.3.3	and	5.3.4.	After	soaking,	crystals	were	cryo-cooled	and	stored	


















The	crystal	 structure	of	 the	SR-F01	complex	 (Fig.	7.20)	 reveals	 that	F01	occupies	 the	









racemisation	 (Fig.	 1.6).	 The	 positioning	 of	 F01	 in	 close	 proximity	 to	 this	 catalytically	
important	 residue	 suggests	 it	may	 inhibit	 SR	 by	 prohibiting	 the	 Cα	 of	 L-serine	 from	
approaching	and	interacting	with	Ser84.		
	
Ordinarily,	 when	 SR	 binds	 to	 its	 substrate,	 the	 small	 domain	 undergoes	 a	 major	
structural	shift	to	place	Ser84	in	an	ideal	orientation	for	proton	donation.	This	induced	
shift	 applies	 to	both	 the	 substrate	and	orthosteric	 inhibitor	malonate,	 and	 is	 true	of	
other	 racemase	 orthologues	 such	 as	 yeast	 (Goto	 et	 al.,	 2009)	 and	 rat	 (Smith	 et	 al.,	
2010).	Yet,	an	overlay	of	the	SR	holoenzyme,	F01-bound	and	malonate-bound	crystal	





F01	 is	also	an	orthosteric	 inhibitor	by	virtue	of	 its	presence	 in	 the	active	site,	but	 its	
mechanism	 of	 action	 seems	 distinct	 from	 that	 of	 malonate.	 Instead	 of	 inducing	 a	
conformational	 shift	 between	 the	 two	 domains,	 it	 appears	 F01	 locks	 SR	 in	 its	 open	











Figure	7.20.	X-ray	 crystal	 structure	of	human	SR	bound	 to	a	novel	 fragment	 inhibitor,	3-pyridin-4-yl	
benzoic	acid	(F01).		
(A)	Secondary	structure	molecular	 image	of	SR	monomer	with	F01	 (yellow	sticks)	bound	between	the	
large	 (teal)	and	small	 (purple)	domains.	The	PLP	cofactor	 (pink	sticks)	and	Mg2+	 (blue	sphere)	are	also	
present.	 (B)	 Surface	 binding	 pocket	 where	 F01	 (yellow	 sticks)	 interacts	 with	 SR.	 Residues	 shown	 are	
His152,	His82,	Thr81,	Ser83,	and	Ser84.	(C)	Ligand	interaction	diagram	for	F01.	The	inhibitor	binds	to	SR	



























This	 chapter	 describes	 a	 drug	 discovery	 workflow	 that	 was	 successfully	 utilised	 to	
enable	 the	 identification	 of	 a	 novel	 fragment	 inhibitor	 of	 human	 SR.	 Through	 the	
optimisation	and	 implementation	of	 a	medium-throughput	biochemical	 assay,	 it	was	
possible	 to	 screen	 a	 combined	 fragment	 library	 of	 approximately	 3200	 fragments	 in	
the	search	for	viable	hit	matter.	The	SR	fragment	screen	yielded	970	 initial	hits	 (30%	
hit	 rate)	 that	demonstrated	at	 least	 50%	 inhibition,	 after	which	many	 false	positives	
were	eliminated	via	a	DAO	counter	screen,	reducing	the	hit	rate	to	330	(10%	hit	rate).	
The	most	potent	fragments	(IC50	≤	1	mM)	were	retained	following	IC50	determination,	
further	 reducing	 the	 hit	 number	 to	 a	 final	 count	 of	 61	 (2%	 hit	 rate).	 The	 three	
biophysical	 techniques	 had	 varying	 degrees	 of	 usefulness;	 thermal	 shift	 experiments	
suggested	 most	 (79%)	 of	 the	 fragments	 destabilised	 SR,	 MST	 produced	 estimated	
binding	 affinities,	 and	 ITC	 could	 not	 confirm	 fragment	 binding	 to	 SR.	 Biophysical	
analysis	of	the	novel	SR	inhibitor,	F01	(3-pyridin-4-yl	benzoic	acid),	revealed	it	caused	a	
positive,	albeit	small	Tm	shift	in	the	thermal	shift	assay	(0.5	°C)	and	demonstrated	a	KD	
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enable	the	generation	of	new	hit	matter	 for	sites	 traditionally	difficult	 to	target	with	
larger	 compounds.	 This	 especially	 applies	 to	 enzymes	 such	 as	 SR,	 which	 undergo	 a	
ligand-induced	 conformational	 change	 and	 may	 not	 be	 easily	 accessible	 to	 drug	
compounds.	Our	 collaborators	at	Evotec	have	attempted	SR	compound	screens	with	
limited	 success	 likely	 for	 this	 reason	 (personal	 correspondence).	 There	 are	 currently	
drugs	on	the	market	that	were	developed	using	structure-based	drug	design,	such	as	






higher	 (10–1000-fold)	hit	 rate	compared	 to	conventional	high-throughput	compound	
screens.	 This	 occurs	 because	 fragment	 libraries	 cover	 substantially	 more	 chemical	





Fragment	 screening	 does	 have	 its	 caveats:	 fragments	 are	 more	 likely	 to	 exhibit	
promiscuous	binding;	binding	affinities	are	likely	to	be	lower	for	fragments;	and	it	can	
be	more	difficult	 to	 identify	 false	positives	and	non-specific	binders	within	a	high	hit	
number.	 The	 purpose	 of	 the	 DAO	 counter	 screen	 was	 to	 identify	 and	 extract	 non-
specific	 inhibitors	 from	 the	 initial	 hit	 rate,	 by	 defining	 SR-specific	 hits	 as	 those	
producing	 ≥	50%	 inhibition	 in	 the	 SR	 screen	 and	 0	±	25%	 inhibition	 in	 the	 counter	
screen.	While	these	stipulations	removed	many	hits	with	moderate-to-substantial	non-
specific	activity,	it	is	possible	that	good	SR	inhibitors	were	removed	indiscriminately	for	









project.	 As	 biophysical	 analysis	 was	 not	 necessarily	 predictive	 of	 success	 in	
crystallography,	it	would	certainly	be	beneficial	to	revisit	this	group	of	61	fragment	hits	
and	characterise	them	further	with	the	aim	to	advance	a	greater	variety	of	fragments	
through	 to	 crystallography	 trials.	 This	 process	 could	 incorporate,	 firstly,	 manual	
repetition	 of	 the	 counter	 screen	 assay	 for	 the	 hits	 to	 more	 reliably	 confirm	 their	
specificity,	and	secondly,	experimentally	confirming	Ki	values	and	 ligand	efficiency	to	
better	assess	and	 rank	 the	hits.	An	additional	biophysical	 technique	 that	could	be	of	
use	 is	 nuclear	magnetic	 resonance	 (NMR),	which	 is	 sensitive	enough	 to	detect	weak	
binders	and	give	 information	on	 the	 ligand-binding	site,	as	well	as	provide	 the	KD	by	
ligand	 titration	 (Lepre,	 2011).	 Moreover,	 ligand-observed	 NMR	 experiments	 in	 the	
absence	of	protein	can	identify	false	positive	and	false	negatives	(Dalvit	et	al.,	2006)		
	
To	 summarise,	 FBDD	 is	 a	 technique	 suitable	 for	 hit	 generation	 and	 hit-to-lead	
development	 for	SR,	as	evidenced	by	 the	 identification	of	a	novel	 fragment	 inhibitor	






Thermal	 denaturation	 analysis	 of	 the	 61	 hits	 did	 not	 initially	 seem	 promising.	
Practically	 all	 fragments	 that	 caused	 a	 significant	 Tm	 shift	 did	 so	 in	 the	 negative	
direction,	 and	 those	 that	 did	 cause	 a	 positive	 shift	 exhibited	 atypical	 fluorescence	
curves.	 Negative	 shifts	 are	 usually	 indicative	 of	 protein	 destabilisation	 rather	 than	
inhibition,	 which	 does	 not	 lend	 confidence	 to	 the	 potential	 development	 of	 these	
fragments	 into	 lead	molecules.	Compounds	 that	destabilise	a	protein	usually	 lead	 to	
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more	rapid	protein	degradation	and	ultimately	protein	depletion	in	a	cellular	context,	
which	 could	 trigger	 protein	 synthesis	 to	 replenish	 depleted	 enzyme	 pools.	 Such	 a	
response	 would	 clearly	 defeat	 the	 original	 purpose	 of	 inhibiting	 a	 protein	 for	
therapeutic	 benefit.	 An	 additional	 consideration	 is	 that	 destabilising	 compounds,	 by	




recent	 study	 that	 screened	 fragments	 also	 from	 the	 Ro3	 library	 against	 7,8-
diaminopelargonic	 synthase	 (BioA),	 a	 target	 for	 tuberculosis,	 found	a	number	of	 the	
compounds	demonstrating	potent	inhibition	also	caused	a	negative	thermal	shift	(Dai,	
2014).	 The	 researchers	were	 able	 to	 identify	 the	 target	 of	 inhibition	 of	 one	 of	 their	
compounds	as	the	PLP	cofactor	of	BioA.	Their	compound,	which	contained	a	hydrazine,	
reacted	 with	 the	 aldehyde	 of	 PLP,	 and	 this	 mode	 of	 action	 was	 confirmed	 by	
crystallography.	 Although	 hydrazines	 were	 not	 identified	 as	 a	 common	 structural	
feature	among	the	61	hits	in	the	current	study,	the	Dai	study	highlights	the	possibility	a	
proportion	of	them	could	be	destabilising	SR	via	PLP.	If	so,	there	could	be	potential	to	
structurally	 optimise	 these	 fragments	 to	 improve	 their	 specificity	 for	 SR	 over	 other	
PLP-containing	enzymes.	It	is,	however,	more	likely	that	thermal	shift	assays	are	largely	
unsuitable	 for	 a	 FBDD	 strategy	with	 SR.	Although	 the	 control	 inhibitor	malonate	did	
produce	 a	 sizeable	 positive	 shift,	 this	 may	 not	 be	 possible	 for	 fragments	 that	 bind	





Unfortunately,	 these	 values	 were	 only	 an	 estimate	 because	 the	 failure	 to	 obtain	














By	 contrast,	 MST	 studies	 on	 protein	 stability	 found	 unfolding	 of	 bovine	 carbonic	
anhydrase	II	(BCAII)	elicited	an	atypical	thermophoresis	signal	with	a	peak	rather	than	
the	 typical	 gradual	 decline	 (Jerabek-Willemsen	 et	 al.,	 2011).	 The	 findings	 were	







limited	 success	 in	 that	 crystals	 grew,	 but	were	 either	 too	 small	 for	 X-ray	 analysis	 or	
diffracted	poorly	upon	preliminary	analysis.	 In	the	context	of	studies	such	as	this,	co-
crystallisation	 is	 probably	 not	 a	 suitable	 technique	 to	 process	 large	 numbers	 of	
inhibitors	 because	 several	 different	 crystallisation	 environments	 may	 require	
optimisation.	 Certainly,	 the	 small	 crystals	 obtained	 through	 co-crystallisation	 studies	
here	 could	 be	 viable	 starting	 points	 for	 the	 production	 of	 high	 quality	 crystals.	 An	
improved	 approach	 might	 be	 to	 perform	 co-crystallisation	 trials	 with	 commercial	
sparse-matrix	 screens	 for	 de	 novo	 crystal	 generation.	 Crystallisation	 of	 the	 SR-F01	
complex	was	instead	achieved	by	soaking	the	inhibitor	into	SR	holo	crystals.	The	crystal	
soaking	 technique	may	 have	 been	 successful	 because	 F01	 stabilised	 SR	 in	 the	 open	





SR	 from	 S.	 pombe	 (which	 shares	 35%	 sequence	 similarity	 with	 hSR)	 was	 solved	 in	
complex	 with	 AMP-PCP,	 an	 ATP	 analogue,	 it	 was	 found	 that	 binding	 of	 AMP-PCP	
stabilised	the	structure	of	SR	but	did	not	induce	a	subunit	conformational	change	(as	
observed	with	malonate)	or	 a	 significant	 change	 in	 subunit	or	 side	 chain	orientation	
(Goto	 et	 al.,	 2009).	 Upon	 soaking	 of	 the	 AMP-PCP-complexed	 crystals	with	 L-serine,	
the	 conformation	 of	 SR	 changed	 from	 the	 open	 form	 to	 the	 closed	 form.	 The	
stabilisation	 of	 the	 closed	 structure	was	 thought	 to	 be	 due	 to	 reorganisation	 of	 the	
hydrogen	bond	network	between	PLP	and	ATP	to	adjust	the	active	site	structure,	and	
also	 due	 to	 the	 position	 of	 ATP	 in	 between	 the	 two	domains,	which	made	 it	 ideally	
situated	 to	 affect	 the	 mode	 of	 open-closed	 conformational	 change.	 Using	 this	
information,	 it	 could	 be	 possible	 to	 stabilise	 SR	 in	 an	 open	 conformation	 by	
crystallising	 it	with	ATP	(or	an	ATP	analogue)	and	then	soaking	with	 inhibitors.	 If	any	
inhibitors	 induce	 a	 conformational	 change,	 the	 presence	 of	 ATP	 may	 encourage	
successful	 binding	 of	 ligands	 by	 stabilising	 the	 complex	 and	 maintaining	 crystal	
integrity,	thereby	facilitating	structure	solution.	
	
To	 conclude,	 the	MTS-optimised	 biochemical	 assay	 and	 fragment	 screening	 process	




determined	by	MST	are	 likely	 to	be	error-prone.	The	successful	 solution	of	a	protein	







There	 is	 little	 doubt	 that	 the	 inhibition	 of	 SR	 remains	 an	 attractive	 therapeutic	
approach	 to	 indirectly	 modulate	 NMDAR	 function	 in	 disorders	 associated	 with	
glutamatergic	 hyperfunction.	 The	 current	 deficit	 of	 safe	 pharmacological	modulators	
of	 NMDAR	 activity	makes	 the	 development	 of	 compounds	 with	 an	 improved	 safety	
profile	 an	 even	 greater	 imperative.	 The	 accomplishment	 of	 the	 aim	 of	 this	 thesis	
through	 identification	 a	 novel,	 structurally	 validated	 SR	 inhibitor	 supports	 the	
capability	 of	 SR	 to	 be	 a	 credible	 drug	 target,	 and	 has	 the	 potential	 to	 significantly	
contribute	to	SR	SAR	studies	and	drug	development.		
	
As	 seen	 in	 the	 X-ray	 crystal	 structure	 of	 the	 SR-F01	 complex,	 the	 fragment	 inhibitor	
binds	 in	 the	 active	 site	 at	 a	 position	 distinct	 from	 that	 of	 malonate,	 inhibiting	 SR	
possibly	by	acting	as	a	‘door	wedge’	that	prevents	the	ligand-induced	conformational	






of	 specificity	 and	 related	 toxicity	 associated	 with	 malonate	 alone,	 especially	 as	





Even	more	 compelling	 about	 the	 identification	 of	 F01	 is	 the	 presence	 of	 two	 of	 its	
isomers,	F02	(4-(pyridin-4-yl)benzoic	acid)	and	F09	(3-(pyridin-3-yl)benzoic	acid)	in	the	
final	 list	 of	 61	 hits	 (Appendix	 10.4).	 The	 two	 isomers	 had	 respective	 IC50	 values	 of	
536	µM	 and	 126	µM	 and	 both	 produced	 statistically	 significant	 thermal	 shifts.	
However,	 both	 were	 perhaps	 unduly	 eliminated	 from	 the	 characterisation	 process	
during	 MST	 analysis	 despite	 demonstrating	 greater	 Fnorm	 shifts	 than	 malonate,	
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highlighting	potential	 flaws	 in	adhering	 to	a	purely	 statistical	 selection	procedure	 for	
methods	wherein	the	generated	data	may	not	be	proportional	to	the	binding	intensity.	
Nonetheless,	 the	 presence	 of	 F01,	 F02,	 and	 F09	 in	 the	 final	 hit	 list	 could	 be	
demonstrative	 of	 a	 distinct	 series	 for	 which	 more	 comprehensive	 SAR	 could	 be	
determined	using	analogues	containing	a	pyridine	or	 imidazole	scaffold.	A	developed	





literature.	 Understanding	 the	 interactions	 between	 inhibitors	 and	 surrounding	
residues	can	advance	development	of	lead	compounds	into	viable	drug-like	molecules	




Fortuitously,	 a	 recently	 developed	 technique	 transcends	 the	 historic	 bottleneck	
between	 hit	 identification	 and	 crystallography,	 enabling	 an	 approach	 for	 structure-
based	 drug	 discovery.	 The	 implementation	 in	 2015	 of	 an	 open-access	 capability	 at	
Diamond	 Light	 Source	 in	 Oxford	 now	 allows	 an	 X-ray	 screening	 experiment	 of	
approximately	1000	fragments	to	be	conducted	as	a	highly	streamlined	process	in	less	
than	 a	 week.	 This	 process,	 called	 X-Chem	 screening,	 covers	 soaking,	 harvesting,	
automatic	 data	 collection,	 and	 data	 analysis.	 For	 a	 target	 such	 as	 SR,	 which	 has	
demonstrated	 here	 and	 elsewhere	 the	 ability	 to	 form	 soaking-resistant	 crystals,	 X-
Chem	 would	 be	 a	 perfect	 method	 for	 identifying	 hits	 with	 confirmed	 binding,	





To	 this	 end,	 I	 have	 recently	 applied	 for	 and	 subsequently	 been	 awarded	 an	 MRC	
Confidence-in-Concept	 grant	 for	 the	 express	 purpose	 of	 performing	 an	 X-Chem	
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fragment	 screen	with	SR.	A	proposal	 for	SR	has	already	been	submitted	 to	Diamond	








If	 the	 above	 process	 leads	 to	 the	 development	 of	 a	 novel	 selective	 and	 potent	 SR	
inhibitor,	 it	would	be	 interesting	 to	 then	measure	 its	 functional	 effects	on	NMDARs.	
This	could	encompass	the	use	of	SR-overexpressing	cell	lines	to	determine	changes	to	
SR	 activity	 in	 a	 cell	 lysate	 assay	 using	 a	 similar	 DAO	 degradation	 and	
chemiluminescence	 detection	 method	 as	 the	 SR	 biochemical	 assay.	 Moreover,	
electrophysiological	 techniques	 (such	 as	 patch-clamp)	 could	 be	 employed	 to	
investigate	if	inhibiting	the	production	of	D-serine	with	an	SR	inhibitor	alters	the	ionic	
current	through	an	NMDAR.	The	ultimate	objective	would	be	to	test	the	SR	inhibitor	in	
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T7	term	 T7	terminator	sequence	 26	 72	












LacI	 LacI	CDS	 714	 1793	
Selectable	marker	 KanR	 Kanamycin	resistance	gene	 3936	 4748	








The	 literature	 surrounding	 SR	 was	 reviewed	 for	 biochemical	 assays	 that	 might	 have	 relevance	 to	
development	 of	 the	 chemiluminescence	 assay	 used	 throughout	 this	 thesis,	 and	 an	 overview	 of	 the	
findings	is	presented	below.	
	

















































































































































































































































































Two	fragment	 libraries	 (Maybridge	Ro3	and	Life	Chemicals	3D)	were	screened	against	SR	 in	a	coupled	
biochemical	assay.	The	fragments	shown	below	demonstrated	IC50	values	around	or	below	1	mM	at	an	
SR	concentration	of	400	nM,	and	did	not	show	nonspecific	inhibitory	activity	in	the	DAO	counter	screen.	
The	SMARTs	alert	 is	 an	 internal	quality	 control	measure	 that	 flags	potentially	problematic	or	 reactive	











1648	 532	 1090	 	




803	 268	 536	 	 u u	
3	
	
701	 919	 810	 	 u	
4	
	
890	 699	 794	 Aniline	 u u	
5	
	
290	 271	 280	 	 u	
6	
	
427	 670	 549	 	 u	
7	
	
473	 805	 639	 	 u	
8	
	
248	 211	 229	 	 u	
9	
	
235	 16	 126	 	 u u	
10	
	
1306	 965	 1135	 Sulfamine	 u	
11	
	




271	 58	 165	 	 u	
13	
	
108	 77	 93	 	 u u	
14	
	
1280	 698	 989	 	 u	
15	
	
872	 666	 769	 Halo	pyridine	 u	
16	
	
1428	 668	 1048	 	




1287	 966	 1126	 Phenol	ester	




41	 31	 36	 	 u	
19	
	
52	 42	 47	 Thiocarbonyl	group	 u	
20	
	
1369	 626	 997	 Thiocarbonyl	group	 u	
21	
	
458	 199	 329	 Ester	 u	
22	
	
52	 8	 30	 Thiocarbonyl	group	 u u	
23	
	
752	 464	 608	 	 u	
24	
	
1040	 828	 934	 	 u	
25	
	
1048	 384	 716	 	 u	
26	
	




326	 870	 598	 Thiocarbonyl	group	 u	
28	
	
62	 35	 49	 	




203	 271	 237	 	 u	
30	
	
230	 189	 209	 Thiocarbonyl	group	 u	
31	
	
180	 246	 213	 Thiocarbonyl	group	 u	
32	
	
499	 1411	 955	 	 u	
33	
	
1371	 940	 1155	 	 u	
34	
	
10	 8	 9	 	 u	
35	
	
344	 407	 376	 Thiocarbonyl	group	 u	
36	
	
45	 12	 28	 	 u u	
37	
	
160	 343	 252	 	 u	
38	
	
360	 289	 324	 	 u	
39	
	
856	 726	 791	 Aniline	








933	 872	 903	 Thiocarbonyl	group	 u	
42	
	
898	 839	 868	 	 u u	
43	
	
411	 813	 612	 Thiocarbonyl	group	 u u u	
44	
	













53	 8	 30	 	 u	
47	
	
100	 28	 64	 	 u	
48	
	
95	 4	 49	 	 u	
49	
	
19	 30	 25	 Thiocarbonyl	group	 u	
50	
	
638	 313	 476	 	 u	
51	
	
25	 8	 17	 Thiocarbonyl	group	 u	
52	
	
11	 34	 22	 	 u u	
53	
	
1208	 363	 785	 Thiocarbonyl	group	 u u	
54	
	
110	 122	 116	 Sulfamine	 u	
55	
	
838	 114	 476	 	 u	
56	
	




329	 70	 199	 Sulfamine	 u	
58	
	
422	 449	 435	 Ester	 u	
59	
	
922	 376	 649	 	 u	
60	
	
1585	 389	 987	 Sulfamine	 u	
61	
	




















(Left)	 Data	 collection	 statistics	 from	 a	 single	 crystal	 obtained	 in-house.	 (Right)	 Validation	 statistics	









































































































of	 the	 polypeptide,	 indicating	 high	 quality	 structure	 solution	 for	 the	 SR-malonate	 crystal.	 Separate	Φ	
and	ψ	distributions	are	shown	for	general,	 isoleucine/valine,	pre-proline,	glycine,	and	trans/cis	proline	












Evaluation	 of	 Ramachandran	 angles	 revealed	 negligible	 steric	 hindrances	 between	 atoms	 of	 the	
polypeptide	 (Fig.	 5.6),	 with	 99.8%	 of	 residue	 angles	 falling	 within	 allowed	 regions.	 Again,	 this	
demonstrates	the	SR	unbound	crystal	structure	was	resolved	to	a	high	degree	of	quality.	Separate	Φ	and	
ψ	 distributions	 are	 shown	 for	 general,	 isoleucine/valine,	 pre-proline,	 glycine,	 and	 trans/cis	 proline	
residues.	 Areas	 encapsulated	 by	 the	 blue	 lines	 are	 the	 favourable	 regions	 (light	 blue)	 and	 limit	 for	
allowed	regions	(dark	blue).	Favoured	regions	(1186/1221	residues,	97.1%);	allowed	regions	(1219/1221	










The	OMIT	map	 (blue	mesh)	 contoured	at	3σ	was	 calculated	using	 coefficients	Fobs	−	Fcalc	using	phases	
from	 the	 final	 refined	model,	with	 the	 coordinators	 of	 F01	 (green)	 deleted	 prior	 to	 a	 further	 road	of	





mobile,	which	could	be	attributed	 to	 the	 fact	F01	 is	 linked	 to	SR	only	by	 two	H-bonds	on	 the	protein	
surface,	whereas	inhibitors	such	as	malonate	bind	deep	in	the	active	site	where	mobility	is	limited.	
	
